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The prevalence of various B-lactamase enzyme types produced by a
population of cepha1oridine resistant Gram negative aerobic
bacteria was determined. The majority of the strains (50.8%)
produced only a chromosomal B-lactamase. B-lactamases typically
associated with plasmids were found in 112 strains (47.9%), the most
common was TEM-1 (41.9% of the total population). Conjugation
experiments demonstrated that only 93 out of 112 B-lactamases,
predicted as piasmid-mediated by biochemical analysis could transfer
these B-lactamase genes.
The Escherichia col i TEM-1 B-lactamases were heterogeneous in their
levels of expression and when transferred to E. col i J6 2-2 variation
in expression was again observed; however, these variations did not
mirror those observed in the clinical strains. The TEM-1 B-
lactamase did not confer significant cephal ori di ne resistance in
E. coli K12 and it was concluded that other host factors must play a
major role in cephaloridine resistance in the clinical isolates.
Amongst the survey strains a novel piasmid-mediated B-lactamase was
identifed in a Klebsiella pneumoniae strain, carried by plasmid
pUK702. The enzyme had a unique combination of biochemical and
enzymic properties with broad-spectrum hydrolytic activity; it was
similar to the TEM-1ike enzymes in its inhibition profile and was
designated TLE-2. Two enterobacterial strains were isolated which
produced the B-lactamase PSE-4. The biochemical and biophysical
properties of the PSE-4 genes were found to be host dependent. This
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was the first isolation of this B-lactamase outwith Pseudomonas
aeruginosa.
The incP-1 plasmid, R751, which had been used to mobilise the PSE-4
gene was found to confer a degree of carbenici11 in resistance on the
E. col i K12 J62 host strain. This plasmid also had the effect of
increasing the strains" mutation rate, resulting in resistance to a
variety of antimicrobial drugs. The mutatory effect of R751
resulted in the expression of SHV-1 B-lactamase by E. col i K12 J62
when selection was made for carbenici 1 1in/ampici11in resistant
mutants.
Six strains were identified from the cephaloridine resistance survey
which transferred B-lactam resistance that was not mediated by a B-
lactamase. In three of the six strains changes in the outer
membrane proteins of the E. col i J62-2 transconjugants were
identified.
In parallel, the incidence and mechanisms of ampicillin resistance
was investigated in 105 clinical Haemophilus influenzae isolates.
Six of the 15 ampicillin resistant strains had alterations in the
penicillin binding proteins or outer membrane proteins. In one
strain no resistance mechanism could be identified.
In conclusion, although the role of B-lactamases is paramount in
resistance to B-lactam antibiotics, resistance is multifactorial and
several mechanisms, either acting alone or in combination,
contribute to the resistance of the cell.
"Scientific discovery is a private event,
and the delight that accompanies it, or
the despair of finding it illusory does not travel"
Sir Peter Medawar
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PREFACE
It is almost 60 years since Fleming described the antibacterial
properties of penicillin (Fleming 1929). Subsequently, penicillin
was successfully purified and produced in some quantity (Chain et al
1940) and the first therapeutic successes followed immediately
(Abraham et_ aA_ 1941). So began a new era of medicine and the
treatment of infectious disease is now based firmly on antimicrobial
chemotherapy.
It was prophetic that in his original paper Fleming also described
groups of bacteria resistant to the action of penicillin (Fleming
1929). In 1940 these observations were confirmed, and in a succinct
letter to "Nature" Abraham and Chain (1940) described the isolation
of an active substance with enzymic properties from Escherichia coli
resistant to penicillin : the term "penicillinase" was coined.
Antimicrobial drug resistance is now a fact of life and its
study and exploitation has led to a greater understanding of both
bacterial genetics and biochemical pathways.
The effective use and development of antimicrobials are inextricably
interwoven with the need to understand old and new bacterial defence
mechanisms which are waged against our armoury of antimicrobial
compounds. Along with other antimicrobial groups, the ^-lactams
have been developed along their present lines in order to combat
bacterial resistance.
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Research into the diversity and mechanisms of such resistance only
serves to highlight the fact that although many battles have been





1. The ft-lactam Family (design concepts)
The ever increasing number of jl-lactam antibiotics
highlights not only their great clinical importance but
also their commercial significance, ^-lactam sales (£6,000M)
in 1984 comprised 10% of total drug sales and 60% of sales
of antibacterial drugs worldwide (Bulletin - Recent Advances
in Chemotherapy 1984). The exponential use of this class of
antibiotics during the last 15 years, has resulted in a
bewildering array of preparations on the commercial market
and undergoing clinical trials (Rolinson 1986).
^-lactams (Figure 1) interact with the two main groups of
bacterial enzymes. The first group are the lethal target
site of these compounds, the cell wall synthesising enzymes
(Park and Strominger 1957, Wise and Park 1965, Tipper and
Strominger 1965, Izaki et_ aT_ 1966). The second group, in
direct contrast, inactivate ^-lactam antibiotics and protect
the cell against ^-lactam attack - they are the ^-lactamase
enzymes (Richmond and Sykes 1973; Sykes and Matthew 1976,
Medeiros 1984). In view of these observations there are
two major criteria which surround ^-lactam design. The
essential criterion is that the compound retains its ability
to acylate a susceptible bacterial target enzyme. A second,
increasingly important feature is that the structure of the
^-lactam either prevents it from acylating the ^-lactamase
4
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enzyme (so that it is not a substrate) or prevents it, once
it has been acyiated, from undergoing hydrolysis. In this
latter case, the turnover is not complete and the ^-lactamase
will be inhibited (Fisher 1984).
While the process of drug design continues, an attractive
and expedient strategy has been to protect a potent ^-lactam
(which is ^-lactamase susceptible) by the simultaneous
challenge with a ^-lactam that is a specific ^-lactamase
antagonist. However, the ultimate aspiration seems to be the
^-lactam that retains affinity for membrane peptidases while
remaining impervious to the potent hydrolytic capability of
the ^-lactamase (Fisher 1984).
This quest can be followed through the development of the
jl-lactam group to date.
1.1 The Penams
Penicillins (Figure lb) are N-acylated derivatives of
6^8-amino penicillanic acid (6-APA) a bicyclic ring system
derived from the fusion of azotidinone and thiazolidine
rings (Batchelor et al 1959).
The first penicillin introduced into therapeutic use was
benzyl penicillin (Penicillin G) as described by Abraham
and colleagues (1941), the natural fermentation product of
the mould PeniciIlium chrysogenum (Raper et jil_ 1944).
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However, Penicillin G is acid-labile and could not be
administered orally as it is degraded by hydrochloric
acid in the stomach. The incorporation of various precursors
into the fermentation mould was found to produce small
modifications in the penicillin structure. This resulted in
the production of phenoxymethylpenicillin (penicillin V)
which is much more stable at low pH and thus suitable for
oral administration (Behrens and Kingkade 1948).
These early penicillins acted primarily against Gram positive
cocci. However, they were susceptible to the action of
staphylococcal ^-lactamases and there was a need for
compounds which were effective against the increasing
number of penicillinase producing staphylococci (Ridley et
al_ 1970).
A chance observation revealed that certain bacterial amidases
were capable of splitting the side chains of various peni¬
cillins to give the penicillin nucleus, 6-amino penicillanic
acid (Batchelor et_ 1959). The addition°*synthetic side
chains to the 6-APA nucleus led to the birth of the semi¬
synthetic penicillins.
Methicillin, introduced in 1960, was the first of these
new penicillins to go into commercial production. It is
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resistant to the action of staphylococcal ^-lactamases but
it is similar to penicillin G in that it is acid labile
(Stewart 1960).
Further chemical modification gave the isoxazolyl penicillins
- cloxacillin, oxacillin, dicloxacillin and flucloxacillin
(Knudson et aj_ 1962, Naylor et_ a]_ 1962, Kirby et al_ 1962,
Gravenkemper et_ al_ 1965, Sutherland et aj[ 1970) and, since
their introduction, the clinical relevance of ^-lactamase
mediated resistance in staphylococci has largely been
eliminated (Hamilton-Miller 1979, Brown and Reading 1983).
This group of penicillins however, is less active than
penicillin G against many Gram positive cocci as a result of
the chemical modifications which confer ^-lactamase stabi¬
lity (Sutherland et aj_ 1970).
A more important chemical modification to the 6-APA nucleus
was the insertion of an amino group in the oC-position of the
benzylpenicillin side chain. The resultant structure,
ampicillin (6-D(-)c£aminophenylacetamidopenicillanic acid)
is active against many Gram negative bacteria (Rolinson and
Stevens 1961) which brought this half of the Bacterial
Kingdom into the range of the ^-lactam antibiotics. Although
suitable for oral use, it was poorly absorbed in the gut
because of its low solubility. The simple insertion of any
hydroxy! group at the para position in ampicillin's benzyl
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side-chain resulted in amoxycillin, a compound with
considerably improved gut absorption (Sutherland et al
1972). These two broad-spectrum semi-synthetic penicillins
still dominate antibacterial drug usage throughout the
world.
Pseudomonas aeruginosa remained outside the scope of the
penicillins until an oC-carboxy group was added to the
6-APA nucleus to form carbenicillin (Knudsen et _al_ 1967)
designated disodium oC-carboxybenzyl penicillin. This
compound has gained activity against P.aeruginosa and some
other Gram negative bacilli resistant to ampicillin but
these gains are at the expense of activity against almost
every ampicillin-sensitive organism.
Modifications of the ampicillin nucleus to give the
acylureidopenicillins azlocillin (Stewart and Bodey 1977),
mezlocillin (Bodey and Pan 1977) and piperacillin (Verbist
1978) and the carbenicillin nucleus to give ticarcillin
(Bodey and Deerhake 1971), did improve the anti-pseudomonal
activity of penicillins. However all these penicillins have
poor stability to Gram negative ^-lactamases (Brown and
Reading 1983).
The recently developed temocillin (BRL 17421) is an cC-carboxy
penicillin with a 6c(?methoxy substituent (Slocombe et_ _al_
1981). The design of temocillin was an attempt to produce a
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penicillin with activity against Gram negative bacteria and
(5-lactamase stability. However, it has as a consequence, no
activity against Gram positive strains. On the other hand,
alpalcillin has a broader spectrum against Gram positive
bacteria and is relatively JJ-lactamase stable. It is active
against most Gram negative bacteria including P.aeruginosa.
However it has less activity against Serratia sp. and
Enterobacter sp. (Noguchi et_ aj_ 1976, Rolinson 1986).
The penicillins have not provided a very versatile template
for the development of broad-spectrum antibacterials which
are effective against current pathogens and stable against
the action of ^-lactamase (Fisher 1984). Intrinsically,
penicillins lack sufficient flexibility because they possess
only one position available for functional group development
(C-6). It seems that it may not be possible for penicillins
to differentiate between membrane peptidases and ^-lactamase
enzymes in order to combine a broad spectrum of activity with
^-lactamase stability (Fisher 1984).
1.2 The Cephems
Cephalosporins are N-acylated derivatives of 7^-amino-
cephalosporanic acid (7-ACA) which is derived from the cephem
nucleus (Figure 1C). A cephem is the biyclic ring system
obtained by the fusion of an azetidinone ring with a
dihydrothiazine ring (Brown and Reading 1983).
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The fungus Cephalosporium acremonium which produces
cephalosporin C was isolated in Sardinia from cultures taken
at a sewer outfall (Brotzu 1946). Florey received a culture
of the fungus in Oxford in 1948 and he later fully described
the products of this "versatile fungus" from which was
isolated not one antibiotic, but seven, amongst which was
cephalosporin C (Florey 1955).
The antibacterial activity of cephalosporin C was found to be
low but this molecule had a high degree of stability to
staphylococcal ^-lactamases, which was, at that time, unique
amongst antibiotics of this general structure.
The essential difference between penicillins and
cephalosporins was that the latter possess two positions
on the nucleus (C-31 and C-7) at which function group
substitutions could be made. The cephalosporin structure was
much more versatile than that of penicillin. Modifications
at C-7 and C-3 produce dramatic changes in chemotherapeutic
properties (O'Callaghan 1975, 1979, Queener and Neuss 1982,
Brown and Reading 1983, Fisher 1984).
The first two cephalosporins introduced into clinical use
were cephalothin and cephaloridine in 1964. (Boniece et a_l_
1962, Chauvette et al_ 1962, Muggleton et_ al_ 1964).
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Cephalothin retained the 3-acetoxy group of cephalosporin C
and consequently it is hydrolysed by esterases in the body to
the 3-hydroxymethyl compound (O'Callaghan and Muggleton
1963). Cephaloridine overcame this disadvantage by replacing
the acetoxy group at C-3 with a pyridinium group, it thus has
the metabolic stability that cephalothin lacks (O'Callaghan
1975,1979). Although cephalosporins are stable at acid pH,
cephaloridine and cephalothin are not absorbed when given by
mouth and are administered by intra-muscular and intravenous
injection respectively (reviewed by O'Callaghan 1979).
These compounds are active against many Gram negative and
Gram positive species and are stable to most staphylococcal
^-lactamases. They are however susceptible to the £-
lactamases of Gram negative bacteria and are inactive against
such organisms as P.aeruginosa. Attempts to improve on these
properties led to cefazolin which has marginally better
intrinsic Gram negative activity but still little increased
resistance to ^-lactamase action (Nishida et_ aj_ 1969).
The first oral cephalosporin was cephaloglycin (Wick and
Bon iece 1965). It was soon superceded by cephalexin (Wick
1967) which has the same 7-acyl group as cephaloglycin.
Cephradine (Gadebusch et_ aj_ 1972) is structurally very
similar to cephalexin and together with other members of this
group such as cefaclor (Neu and Fu 1978a) these compounds are
thought to owe their oral absorption properties to both the
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cc-amino group in the 7-acyl substituent and a small uncharged
group at position C-3. All have similar antibacterial
properties to cefazolin and remain susceptible to the majo¬
rity of Gram negative ^-lactamases.
A clinically significant step was made with the design of
cephalosporins more resistant to the action of Gram negative
,8-lactamases. These compounds vary in structure but their
^-lactamase stability is thought to reply on the steric
hindrance conferred by bulky side chains at C-7 (O'Callaghan
1975, Fisher 1984).
Cefamandole (Wick and Preston 1972) has good stability to
Gram negative J3-1 actamases conferred by a 7-acyl side
group. Cefuroxime (O'Callaghan et_ aj_ 1976) has an oC-
methoxyimino group at C-7 which confers ^-lactamase stability
(O'Callaghan 1979). They have a different spectrum of
activity with cefuroxime being very effective against
Haemophilus influenzae and Enterobacter spp. Cefamandole and
cefuroxime heralded the second generation of cephalosporins
(Neu 1982), However their antibacterial spectra still did not
encompass such organisms as P.aeruginosa.
Recently clinical trials have been carried out with
cefuroxime axetil, the 1-acetoxyethyl ester of cefuroxime
(Williams and Harding 1984). This is an oral cephalosporin
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with ^-lactamase stability
advance over such oral
cephalexin.
and high intrinsic activity, an
compounds as cephradine and
The ^-lactamase stability conferred by the cC-methoxyimino
group in the cefuroxime side chain was exploited in the
development of further cc-methoxyimino cephalosporins which
would form the third generation of cephalosporins (Neu
1982). Cefotaxime (Heymes et_ _al_ 1977), cefmenoxime (Tsuchiya
et_ al_ 1981), and ceftizoxime (Fu and Neu 1980) are of similar
design. In these compounds, the furyl ring in the 7-
acylamino side chain of cefuroxime is replaced by the 5-
aminothiazol-3-yl group which had been shown to give good
ant i-bacteri al activity in cefotiam (Tsuchiya et_ ^1_ 1978a).
The three compounds - cefotaxime, cefmenoxime and
ceftizoxime - have a broad antibacterial spectrum and
marginal activity against P.aeruginosa.
Compounds fully active against Pseudomonas spp. have only
been developed recently. Cefsulodin (Tsuchiya ert al_ 1978b)
the extreme of the range of compounds, has antibacterial
activity which is limited almost exclusively to Pseudomonas.
Cefoperazone (Neu et_ ^1_ 1979a) was developed with similar
side-chain modification to the acylureidopenici11in,
pipericillin (the C-7 substitution of cefoperazone being the
same as the C-6 substitution in pipericillin). Although
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cefoperazone has a broad spectrum of activity which includes
Pseudomonas spp,it is moderately susceptible to ^-lactamases,
which limits its effectiveness.
Ceftazidime (O'Callaghan et_ al_ 1980) is an extended spectrum
third generation compound combining high stability to J5-
lactamases (Simpson et_ al_ 1982) with exceptionally broad
antibacterial activity which includes Pseudomonas spp. This
was achieved by replacing the methyl group of the OC-
methoxyimino substituent of cefuroxime with 2,2-dimethyl-
acetic acid. The pyridine side-chain at C-3 of the cephem
nucleus confers good pharmacokinetics on the compound and
ceftazidime is well distributed throughout the body (Neu
1982). Ceftriaxone (Neu et^ ^1_ 1981) is another extended
spectrum third generation compound. The C-7 substitution is
similar to that in ceftazidime and they have a similar
antibacterial spectrum.
The Cephamycins and Oxacephems
The insertion of a methoxy group in the C-7 position of the
7-ACA nucleus gave rise to the cephamycins (Figure Id).
Cephamycin C, a 70C-methoxycephem is stable to jl-1 actamases
by virtue of the steric hinderance provided by the 7o£methoxy
group (Daoust et_ al_ 1973). Its marketed analogue, cefoxitin
(Onishi et _al_ 1974) has a moderate antibacterial spectrum.
Cefotetan (Toda et_ aj_ 1980a, Phillips et_ aj_ 1983) and
cefmetazole (Benlloch aj_ 1982) are newer cephamycins
which have a similar stability and antibacterial spectra to
cefoxitin but they are two to four times more active.
Cefotetan has an added advantage in that it has a greatly
increased serum half life (Phillips et_ ^1_ 1983).
The oxacephems (Figure le) were made by replacing the sulphur
atom of the cephem nucleus with oxygen. The most notable
member of this group is latamoxef (moxalactam) which was
described by Neu and colleagues (1979b). Latamoxef possess a
7cc-methoxy group which confers stability to ^-lactamase
action (a design feature used in the development of the
penam, temocillin). In many respects latamoxef represents an
evolutionary endpoint in our understanding of ji-lactam
design within the cephem framework. Latamoxef contains four
regions that, it is thought, together provide an excellent
balance of ^-lactamase inhibitory properties, as well as a
broad spectrum of activity.
1. The 7a;-methoxy side group (provides ^-lactamase stability)
2. The C-7 side chain carboxylate (improves ^-lactamase
stability).
3. The ring oxygen (provides intrinsic reactivity as an
acylating agent).
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4. The C - 31 functional group (augments antibacterial
spectrum).
(Fisher 1 9 8 4 )
Despite such a logical approach to the development of these
compounds, resistance especially amongst such organisms as
P.aeruginosa, Enterobacter spp. and Citrobacter spp. has been
developing apace.
The Carbapenems
The carbapenems result from the replacement of the sulphur
atom of the penem nucleus by a (CH2) group. (Figure If).
This type of ^-lactam includes the thienamycin and olivanic
acid families. The most promising carbapenem so far
developed is N-formimidoyl thienamycin (Kropp et al 1980).
However, a unique in vivo complication of the carbopenems is
their rapid metabolism by a renal peptidase (Kim and Campbell
1982)and thus specific peptide inhibitors are coadministered
with the carbapenem (Norrby et_ al_ 1983). The 6oc-hydroxyethyl
side chain is believed to mimic the 6oc-methoxy group of
the cephamycins by sterically hindering hydrolysis by B-
lactamases. Although generally of excellent activity against
Pseudomonas spp., thienamycin is hydrolysed by the P_.
maltophi1ia B-lactamase (Saino et al 1982) and it is
consistently less active against Proteus spp (Kropp et_ al
1980).
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Although the olivanic acids have good antibacterial activity
they are generally less active than thienamycin and are not
effective against Pseudomonas spp.
1.5 The Penems
The penem nucleus (Figure lg) is the unsaturated analogue of
the penam ring system. One synthetic example is the compound
Sch 29482 (Ganguly et_ al_ 1982). This compound combines the
features of the penicillin and thienamycin families and it is
stable to ^-lactamases. It is similar to cefotaxime in
antibacterial spectrum, but it is an oral preparation. There
is a suggestion that it is unstable as indicated by the fact
that it is highly serum bound and antibacterial activity
decreases in serum (Loebenberg et _al_ 1982). A major problem
is that Sch 29482 is metabolised to ethyl mercaptan (Brown
and Reading 1983).
1.6 The Monobactams (Azetidinone Derivatives)
The existence of azetidinone derivatives has been realised
and
since before the discovery of penicillin (Sykes/Bonner 1985).
Naturally occurring azetidinones with potentially useful
properties have been recently isolated from bacterial species
and Nocardia. The monobactams (Sykes gt g[ 1981a) and the
nocardicins (Hashimoto et_ jal_ 1976 , Imada et_ _al_ 1981) are
acylated derivatives of the 3-amino-monobactamic acid (3-AMA)
(Figure lh) and 3 amino nocardicinic acid (3-ANA) respec¬
tively (Figure li).
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Antibiotic activity demands an acylation reactivity not
attainable in simple monocyclic ^-lactams. The unusual
reactivity of bicyclic ^-lactams is attributed to the
unfavourable geometry which makes the molecule susceptible to
nucleophile attack and acylation (Fisher 1984). An electron-
withdrawing moiety, the sulphonate, brings this activity to
the monobactams. It also provides the negative charge,
proximal to the nitrogen, for membrane peptidase (and /B-
lactamase) recognition (Gordon et_ _al_ 1982).
A semi-synthetic monobactam-aztreonam (Sykes et_ _al_ 1982) ^
was chosen following evaluation of structure-activity
relationships, for further development and clinical trial
evaluation. The antibacterial spectrum of aztreonam is
restricted to Gram negative aerobes and its activity against
these organisms is similar to that of ceftazidime. Aztreonam
is also resistant to hydrolysis by most ^-lactamases (Sykes
et al_ 1982).
fi-lactamase Inhibitors (ff-lactam Class)
Inhibitors of ^B-lactamase enzymes fall into the following
broad catagories (Wise 1982).
Competitive Inhibitors
(a) Reversible - inhibitor and substrate compete for the
active site of the enzyme. No chemical inactivation of
the enzyme takes place.
(b) Irreversible - interaction between enzyme and inhibitor
is irreversible. The enzyme is inactivated, the
reaction is usually progressive as the inhibitor is
destroyed - "suicide inhibitors".
Non Competitive Inhibitors
The inhibitor does not comp ete for the active site of the
enzyme but binds at another site, inducing a distortion of
the molecule which is then incapable of enzymic hydrolysis of
susceptible substrates.
Alkoxy Penicillins
Methicillin (Rolinson et aj_ 1960) is a reversible competitive
inhibitor for several Gram negative ^-lactamases. It can
potentiate the effect of benzylpenici11 in against P.
aeruginosa due to the inhibition of the P.aeruginosa J3-
lactamase in vivo (Sabath and Abraham 1964).
Isoxazolyl Penicillins
Isoxazolyl penicillins are reversible competitive inhibitors
of ^-lactamase enzymes (Sutherland and Batchelor 1964)
Cloxacillin inhibits enterobacterial ^-lactamases (Cole 1979)
and it has been used in combination with ampicillin against
Haemophilus influenzae present in mixed infections (May and
Ingold 1971).
Other penicillins have been shown to have inhibitor
properties. Carbenicillin has an inhibitory spectrum similar
to cloxacillin (Cole 1979). There have been reports that
ampicillin also has inhibitory activity (Hamilton-Miller and
Smith 1964) however it was found by other workers to be
relatively inert (Cole 1979).
Cephalosporins
It was realised as early as 1956 that cephalosporin C
possessed ^-lactamase inhibitory properties (Abraham and
Newton 1956).
The nature of the side-chain attached to the 7-amino group
and the C-3 substituent are thought to affect the j3-
lactamase inhibitory properties of cephalosporins. The
effect of the substitutions depends on the ^-lactamase
enzyme under consideration (O'Callaghan and Morris 1972).
Cephaloglycin and cefamandole are non-competitive inhibitors
of the E_;_ cloacae jS-lactamase enzyme (Mahoney et_ al_ 1976)
whereas the other cephalosporins examined, cephaloridine
and cefoxitin, are competitive inhibitors (Cole 1979).
Carbapenems
The carbapenems as well as being potent antibacterials
have ^-lactamase inhibitory properties. Thienamycin is an
irreversible inactivator of ^-lactamases from Gram negative
bacteria (Toda et_ _al_ 1980b). Olivanic acids are also
progressive and irreversible inhibitors of various J3-




Clavulanic acid is a potent jB-lactamase inhibitor with little
antibacterial activity (Reading and Cole 1977). It was
isolated from Streptomyces clavuliqerus, and has a bycyclic
ring nucleus (clavam-Figure lj). Clavulanic acid resists
deacylation and is an irreversible suicide inhibitor of many
^-lactamases (Neu and Fu 1978b). The kinetics of clavulanic
acid/^-1actamase interaction are progressive and the
inhibition is greater with higher concentrations of
clavulanate. Irreversible inhibition is thought not to occur
during the initial turnover events (Bush and Sykes 1983).
Fisher and colleagues (1978) reported on the kinetics of
clavulanate's interaction with TEM ^-lactamase and found that
the response depended on the ratio of inhibitor to enzyme.
Sulbactam, a desaminopenicillin sulphone, resembles
clavulanic acid (English et_ a_l 1978) and is also a suicide
inhibitor with a mechanism of action similar to that of
clavulanic acid (Sykes and Bush 1982).
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Permeabi1ity
The Gram Negative Cell Wall as a Permeability Barrier
From the early days of penicillin therapy it had been thought
that the resistance of Gram negative organisms may be
attributable to the inability of the compound to penetrate
the cell. It was established by Izaki and colleagues (1966)
that the Gram negative target site was as sensitive to
penicillin as that of the Gram positive. The existence of a
barrier to penetration was further demonstrated by the fact
that disrupted cell preparations of Gram negative cells
hydrolysed ^-lactams much faster than intact cells (Smith
1963, Hamilton-Miller 1963). It was also shown that making
the cells permeable with ethylenediaminetetraacetic acid
(EDTA) increased the hydrolytic activity although no ]}-
lactamase was released into the surrounding medium (Hamilton-
Miller 1965). Gram negative ^B-lactamase enzymes were shown
to be predominately located in the periplasmic space (Neu
1968).
It was concluded that Gram negative bacteria are surrounded
by an additional membrane layer, not found in Gram positive
bacteria (Glaurt and Thornley 1969) which prevented the
penetration of ^-lactams.
The Gram negative outer membrane is complex. It surrounds a
thin layer of peptidoglycan, which imparts rigidity and
structure to the cell, which surrounds in its turn, the
cytoplasmic membrane (Figure 2). The outer membrane is
Figure 2 The Gram negative Cell Wall
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covalently linked to the peptidoglycan by low molecular
weight lipoproteins described as Braun proteins in E.coli
(Braun 1975). Several other types of outer membrane proteins
(OMPs) have been shown to be non-covalently linked with
peptidoglycan (Lugtenberg and van Alphen 1983).
Almost half of the mass of the outer membrane is protein
(Osborn et al_ 1972) although some transverse the-outer and
cytoplasmic membranes, most is thought to be restricted to
the outer membrane.
2.1 Major Outer Membrane Proteins
Permeability is governed by the presence of a group of major
outer membrane proteins known as the porins (Nikaido 1979,
Nikaido and Nakae 1979). Other major proteins include OmpA
protein and the murein lipoprotein (Nikaido and Vaara 1985).
Neither OmpA nor the murein lipoprotein appear to have pore
functions (Nikaido et_ _al_ 1977, Suzuki et_ a_l_ 1978).
Porin Proteins
The proteins coded for by ompF ompC and phoE genes in
Escherichia coli K12 are known as porins (OmpF, OmpC and
PhoE). They produce water-filled pores or channels that
allow the passage of small hydrophilic molecules across the
outer membrane (Nikaido and Nakae 1979).
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The role of porins in penetration across the outer membrane
has been established by the use of porin mutants (Bavoil et
al 1977, Beacham £t aj_ 1977, Lutkenhaus 1977). Recon-
stitution experiments, where purified porins have been
incorporated into proteoliposomes, have resulted in a versa¬
tile j_n vitro model of porin function (Nakae 1976a, b).
Bacteria occasionally produce additional porins for example
the OmpD porin of Salmonella typhimurium LT2 (Nurminem et al
1976), the prophage coded protein 2 or Lc of E.coli (Pugsley
and Schnaitman 1978) and protein K, found amongst
unencapsul ated strains of E. col i (Paakkanen et aj_ 1979,
Sutcliffe et al_ 1983, Whitfield et al 1983). Several other
proteins function as more specific diffusion channels.
Porins from both E.coli and S.typhimurium were found to exist
as undenatured trimer proteins when extracted with sodium
dodecyl sulphate (SDS) (Rosenbusch 1974, Palva and Randall
1978, Nakae et ^1_ 1979, Tokunagay et aj_ 1979). The estimated
diameters of the OmpF and OmpC channels of E.coli are 1.16
and 1.04nm respectively (Nikaido and Rosenberg 1983). The
reconstitution studies carried out on isolated porin proteins
suggest that porin channels in E.coli and S.typhimurium are
non-specific, allowing the passage of any solute provided
it is small (less than 600 daltons) and hydrophilic (Nakae
and Nikaido 1975, Decad and Nikaido 1976).
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Diffusion through pores is a passive process. It can be
assumed that if there are no removal or inactiv ation
processes taking place, equal concentrations of solutes such
as ^-lactams will be found inside and outside the cell after
equilibrium is reached (Nikaido 1985). Most Gram negative
bacteria possess a ^-lactamase enzyme (Matthew and Harris
1976) which may destroy a significant proportion of incoming
^-lactam molecules. Any assessment of permeability of the
outer membrane to ^-lactam compounds must take these possible
influences into account.
Alternative g-lactam Uptake Pathways
Some ^-lactams are lipophilic and may diffuse through the
lipid bilayer of the outer membrane. The 1ipopolysaccharide-
protein complexes on the outer membrane however, normally
present a hydrophobic barrier (Nikaido 1985). It is
possible that such a pathway may become significant in non
enteric organisms with significant amounts of phospholipid eg
Neisseria gonorrhoeae (Lysko and Morse 1981).
2.2 Assessing Permeability
Crypticity
Hamilton Miller (1963) called the ratio between hydrolysis of
B-lactams by intact and disrupted cells the "permeability
index" and used this as a measure of permeability. This was
later used by Richmond and Curtis (1974) who called the
index "crypticity".
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The crypticity index is only a valid parameter when different
bacterial strains are used containing equal amounts of an
identical ^-lactamase and they are challenged with a given
^-lactam at the same external concentration (Nikaido 1985).
Modifications have been made to the crypticity index in
order to make it more quantitative (Sawai et_ aj_ 1977,
Zimmerman and Rosselet 1977). Nikaido et al ( 1977) have
expanded this work to produce a value for ^-lactam compounds
termed the "permeability coefficient" which is independent of
external concentration of j3-lactam and the Km and Vmax of the
^-lactam hydrolysis.
Use of Mutants in Assessing Permeability
Richmond et _al_ (1976) isolated mutants of E.coli K12 (DC2,
DC3) which have been used in permeability studies. Both
mutants are more sensitive to the action of j3-lactam
antibiotics than the parent strain (DCO). The DC2 strain
does not appear to be a porin mutant (Unpublished results
quoted in Nikaido and Vaara 1985), but it does have changes
in 1 ipopolysaccharide (LPS), although it is not clear how
these affect permeability (Clark 1984).
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The EDTA treatment of Gram negative bacteria produces cells
which are similar to the DC mutants (Scudamore et_ ^1_ 1979).
Neither mutation in strains DC2 or DC3 nor EDTA treatment of
wild type strains produces uniform changes, increasing
permeability to all agents. Removal of LPS enhances
diffusion of hydrophobic agents (Leive 1974) and data from
Scudamore and colleagues (1979) confirm that misleading
results are obtained for hydrophilic agents.
Binding to Penicillin Binding Proteins as a Measure of
Permeabi1ity
The labelling of penicillin binding proteins (PBPs) in intact
and disrupted cells can be compared to evaluate permeability.
If the unlabelled ^-lactam inhibits well in disrupted cells
but poorly in intact cells it is assumed it penetrates poorly
(Zimmerman 1980, Rodriguez-Tebar et_ al_ 1982). This technique
is useful for ^-lactamase stable compounds unsuitable for
conventional crypticity assays.
Measuring Permeability with Reconstituted Liposome Vesicles
Reconstituted liposomes containing only a few porin channels
were first used to assess permeability by Nakae (1976b). The
liposome swelling assay has been used widely to assess influx
of solutes. The swelling rate of the liposome is limited by
the rate of influx of the solute, rather than by the rate of
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diffusion of water. It is presumed that the solute is
crossing the lipsome membrane through the porin channels
(Nikaido and Rosenberg 1981, 1983).
2.3 Diffusion of ^-lactams Through the Outer Membrane
The physicochemical properties of the solute determines its
rate of diffusion. These are hydrophobicity, size and
charge, all of which interact with each other.
Hydrophobicity
The efficacy of a J3-lactam is thought to be reduced if the
compound is hydrophobic (Biagi et al 1970).
Zimmerman and Rosselet (1977) demonstrated that hydro¬
phobicity resulted in a slowing down, of diffusion of j3-
lactams. There was also a direct correlation between
hydrophilicity and penetration rate. Hydrophobicity has a
similar effect on penetration through OmpF and OmpC porins in
intact cells. However using proteoliposomes, hydrophobicity
affects penetration through the narrow channel of OmpC more
severely than the wider OmpF porin (Nikaido et_ £l_ 1983).
Most penicillins are too hydrophobic to be tested with
a proteoliposome system; therefore direct comparison is
difficult and analogues have been used (Yoshimura and Nikaido
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1984). These results have shown that the ^-lactam nucleus
affects penetration to a greater extent that the hydro-
phobicity of peripheral substituents.
Effect of J3-lactam Size
Liposome swelling assays have shown that ^-lactam size plays
an important role in determining penetration through porins
(Nikaido and Rosenberg 1981). ^-lactams penetrate faster
through the larger OmpF channel of E.coli (Nikaido and
Rosenberg 1983). There are exceptions, and a few ^-lactams
penetrate very well in spite of their size (Nikaido and
Rosenberg 1983).
Effect of Charge
Net negative charges severely impede penetration of a
^-lactam through the outer membrane eg cephacetrile and
cefsulodin. This phenomenon may relate to the presence of a
Donnan potentional across the outer membrane (negative
inside) (Stock £t aj_ 1977). Diffusion of zwitterionic
compounds such as imipenem, cefaclor, ampicillin and cephalo-
ridine is mainly affected by their size. However they
penetrate much more rapidly than compounds carrying a net
negative charge, as zwitterionic compounds are probably
surrounded by hydration shells which impart hydrophilicity to
the molecule (Nikaido 1985).
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2.4 Other Bacterial Porins
Most porins share the properties of the OmpF channel of
E.coli (Hancock 1984, Nikaido and Vaara 1985, Nikaido 1985).
Generally porins favour cations over anions, the exception
being N.gonorrhoeae which was reported to be anion-selective
(Greco et_ aj_ 1980). However Young et _al_ (1983) showed that
the porin was cation-selective and not anion-selective as
previously reported.
The large porin channels of P.aeruginosa and N.gonorrhoeae
are less affected by the solute's size, charge or hydro-
phobicity state. Haemophilus influenzae has been shown to
produce a porin with a molecular weight exclusion limit which
lies between the value for the Enterobacteriaceae and the
pseudomonads (Vachon et aj_ 1985). H. influenzae porin
protein I has been shown not to act as a barrier to diffusion
and the organism has no effective permeability barrier
(Coulton et_ ^1_ 1983, Vachon et_ ^1_ 1985). P.aeruginosa on the
other hand produces large porins (Hancock et_ _al_ 1979) but is
well documented as being impermeable to many solutes (Brown
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1975, Bryan 1979). It is thought that only a small fraction
of porin molecules in P.aeruginosa produce open channels at
any one time (Benz and Hancock 1981, Yoshimura et_ al_ 1983).
This phenomenon combines with the organism's inducible
chromosomal ^-lactamase to make it resistant to most fi-
lactams.
Cefsulodin is active against P.aeruginosa, despite its large
size and two negative, one positive charge differential. It
probably achieves its affect by its relative stability to
^-lactamase enzymes and its affinity for sensitive target
enzymes in Pseudomonas (Tsuchiya et_ 1978b). Cefsulodin is
however, inactive against E.coli probably because of these
very features.
2.5 Opening and Closing Porins
Porin channels may be opened and closed in response to
stimuli and in adverse conditions, perhaps to stop uptake
of antibiotics. An electrical potential can close porin
channels (Schindler and Rosenbusch 1978, 1981), However,
Nikaido and coworkers (reviewed by Nikaido and Vaara
1985) feel that the electrical potentials present under
physiological conditions would be insufficient to regulate
porin channels.
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The ^-lactam Target Sites
3. Cell Wall Synthesis - The Target Site of ff-lactam Antibiotics
Gardner (1940) was the first to observe the physiological
effects of penicillin on growing cell cultures. He observed
that at low concentrations of penicillin the cells did not
lyse but were converted to filaments. Duguid (1946)
indicated that penicillin may interfere with the synthesis of
an unknown structure of bacterial cell surfaces. The first
biochemical clue was provided by Park and Johnson (1949)
and Park (1952) who discovered that several novel uridine
nucleotides accumulate in the cytoplasm of penicillin treated
Staphylococcus aureus. It was not until 1957 that Park and
Strominger observed the composition of these nucleotides was
similar to those of the recently discovered cell wall, this
suggested that they may be cell wall precursors. It was
demonstrated that in a hypertonic medium penicillin produces
viable spheroplasts of E.coli and not lysis (Lederberg 1956,
1957, Hahn and Ciak 1957). Penicillin was thus shown to
interfere with cell wall biosynthesis.
Since the 1950s the complex mechanism of cell wall synthesis
has been elucidated (reviewed by Rogers 1970, Waxman and
Strominger 1982).
3.1 The Target Site
From the early studies, it was recognised that radioactive
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penicillin was bound to a (protein) target in membranes of
bacterial cells (reviewed by Cooper 1956). The primary
target was the terminal step in cell wall biosynthesis,
catalysed by an enzyme (peptidoglycan transpeptidase*) (Wise
and Park 1965, Tipper and Strominger 1965, Izaki et al
1966). Subsequently it was found that several proteins in
the membrane bound penicillin specifically. Another enzyme,
D,D-alanine carboxypeptidase* was shown to be inhibited by
penicillins but it was not regarded as a lethal target
site (Blumberg and Strominger 1971, 1972, Suginaka et_ al
1972).
The existence of multiple penicillin binding proteins (PBPs)
in the membrane of all bacteria studied so far, suggests that
there are multiple targets of penicillin action. It is now
clear that different ^-lactams exert their bactericidal
effects by interacting with different subsets of PBPs (Spratt
1975, 1977, 1983, Spratt and Pardee 1975).
3.2 Peptidoglycan Biosynthesis
Peptidoglycan biosynthesis has been extensively reviewed
(for example see Ghuysen 1977, Rogers et_ al_ 1980).
During the final stage of biosynthesis, a free amino group on
the N-acetylmuramyl pentapeptide of one glycan stand,
displaces the terminal D-alanine from a pentapeptide of the
* E.C. number not available.
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second glycan stand in a transpeptidation reaction. It is
this cross-linking step which is the penicillin-sensitive
reaction of cell wall biosynthesis (Wise and Park 1965,
Tipper and Strominger 1965).
In addition to the transpeptidase reactions, two other
related penicillin sensitive reactions have been described
(Figure 3). D,D-alanine carboxypeptidase effects cleavage of
the terminal D-alanine from pentapeptide side chains of cell
wall precursors (Izaki et al_ 1966, 1968, Araki et_ al_ 1966).
The D,D-alanine carboxypeptidase activity in E.coli membranes
is significantly more sensitive to penicillin than is the
transpeptidase activity (Blumberg and Strominger 1974). The
other penicillin sensitive reaction is endopeptidase*
catalysis which leads to hydrolysis of the interpeptide
cross-link formed in a transpeptidation reaction. The
sequence of transpeptidase followed by endopeptidase
reactions produces a product indistinguishable from that of
the D,D-alanine carboxypeptidase reaction (Figure 3) (Waxman
and Strominger 1982).
3.3 The Properties of the Penicillin-Sensitive Enzymes
Penicillin binding proteins are numbered in order of
decreasing molecular size which ranges from 120,000 to around
* E.C. Number not Available
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Figure 3 Penicillin Sensitive transpeptidase
(TPase), D-alanine carboxypeptidase
(CPase), and endopeptidase reactions.




























































27,000 daltons (Makover et_ ^1_ 1981, Waxman and Strominger
1982). They vary in relative abundance, for instance, PBP2,
in E.coli binds only around 1% of available radiolabeled
penicillin (Spratt 1977). It is estimated this corresponds
to between 15 and 20 molecules of PBP2 per cell.
The PBPs themselves can be divided into two categories, high
molecular weight PBPs (60-92,000 in E.coli) and low molecular
weight PBPs (40-49,000 in E.coli). Their role in E.coli has
been elucidated in two main ways (Spratt 1980a). B-lactams
have at least three morphological effects on E. c o 1 i
(filimentation, rapid cell lysis and growth into spherical
cells), | he degree of response can be correlated with binding
to particular PBPs (Spratt and Pardee 1975, Spratt 1975).
The consequences of PBP inactivations has been determined by
the use of mutants which lack PBPs or produce only thermolabile
Jobanputra
forms (Spratt 1975, 1980b, Spratt and/ 1977, Suzuki et al
1978, Broome-Smith and Spratt 1982).
Studies have shown that high molecular weight PBPs are
essential for cell viability (PBPs 1, 2 and 3 in E.coli). In
contrast, mutants that lack low molecular weight PBPs (4,5
and 6 in E.coli) are viable and do not show significant
morphological abnormalties (Spratt 1977, 1983).
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The High Molecular Weight PBPs
Spratt (1975) was the first to deduce a likely physiological
role for each high molecular weight PBP of E.coli (Table 1)
(PBPslA, IB. 2 and 3). Generally the high molecular
weight PBPs are more sensitive to the action of ^-lactams,
especially the cephalosporins (Waxman and Strominger 1982).
In E.coli, PBPslA and IB are enzymes of cell elongation.
Rapid lysis of E. col i occurs when both 1A and IB are
inhibited (Spratt 1975, 1977, Tamaki et_ al_ 1977, Suzuki et al
1978). ^-lactams such as cephaloridine have a high affinity
for PBPslA and IB (Spratt 1975). Mutants which lack either
Jobanputra
PBP1A or IB are viable (Spratt and / 1977, Suzuki et al
1978). PBP 1A mutants have a much slower rate of lysis and
PBP1A is thought to have a role in peptidoglycan metabolism.
Mutants of PBP1B have decreased peptidoglycan biosynthetic
activity and they over-produce PBPslA and 2 to compensate
(Tamaki et_ aj_ 1977). The mutants are extremely susceptible
to the action of cephalosporins (Suzuki et_ ^1_ 1978) owing to
the high sensitivity of PBP 1A which becomes indispensible.
Mutation in both PBPslA and IB is lethal to the cell (Spratt
and Jobanputra 1977)
E.coli PBP2 has a role in cell shape. Mecillinam is highly
selective for PBP2 and produces large osmotically stable
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Table 1. Properties of the Penicillin Binding Proteins of Escherichia
coli (taken from Spratt 1983).
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round cells which eventually lyse after several hours of
growth (Tybring and Melchior 1975). The PBP3 of E.col i is
important in cell division. Cephalexin, ampicillin and
cefuroxime bind to this PBP and induce fi1amentat ion of
E.co1i by specifically inhibiting cell division without
affecting cell lysis (Spratt 1975, 1980a). It is thought
that PBP3 may be synthesised or inactivated upon completion
of DNA replication (Spratt 1977).
Enzymic Activity of High Molecular Weight PBPs
Difficulties have been encountered in detection of the
enzymic activity of purified high molecular weight PBPs
(Table 1) and most progress has been made with PBP1B of
E.coli. It appears to perform a coupled transpeptidase/
transglycosylation reaction in vitro with a lipid inter¬
mediate (Tamura ^t aj_ 1980, Suzuki et_ aj_ 1980). As the
synthesis and cross linking of peptidoglycan needs to be
strictly controlled, it makes sense to combine transglycosy-
lase and transpeptidase activities in a single enzyme (Spratt
1983).
There is preliminary evidence that PBP2 is a peptidoglycan
transpeptidase but it is not known if it also has trans-
glycosylase activity (Ishino et _al_ 1982). PBPslA and PBP3
have also been reported to be bifunctional transglycosylase/
transpeptidases (Ishino et al 1980, Ishino and Matsuhashi
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1981). These high molecular weight PBPs do not appear to act
as D,D-alanine carboxypeptidases (Matsuhashi et_ ^1_ 1982).
However, each presumably has a specific function: PBP1B and
possibly 1A may be involved in cell elongation peptidoglycan
biosynthesis; PBP3 may synthesise the peptidoglycan of the
septum at cell division and PBP2 may be responsible for the
initiation of synthesis at new sites of cell wall growth
(Spratt 1983).
The Low Molecular Weight PBPs
The low molecular weight PBPs in E.coli (PBPs4,5 and 6)
are generally less sensitive to jl-lactams, especially
cephalosporins. They are the major PBPs in the inner
membrane and comprise 50 to 90% of the total (Waxman and
Strominger 1982). Strains with deletions of the PBP5 and
PBP6 gene have been engineered and have shown that these PBPs
are non-essential and their loss has no effect on cell
morphology (Spratt 1980b, Broome-Smith and Spratt 1982).
Only point mutants of PBP4 have been described and the effect
of total loss of PBP4 has not been established. Loss of PBPs
4,5 and 6 in one strain has not been examined and the effect
is unknown (Spratt 1983). The properties of these PBPs are
summarised in Table 1.
Enzymic Activity of Low Molecular Weight PBPs
PBPs4,5 and 6 of E.coli all catalyse D,D-alanine car-
boxypeptidase reactions. Under appropriate conditions the
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low molecular weight PBPs will also catalyse a model trans¬
peptidase reaction, and PBP4 has been shown to have endo-
peptidase activity (Tamura et_ £l_ 1976, Spratt and Strominger
1976, Amanuma and Strominger 1980).
PBP4 is thought to catalyse the secondary transpeptidation
which produces the characteristic mature cell wall, (de Pedro
Schwarz 1981). Mutants that are deficient in this enzyme
are unable to carry out this secondary phase of crosslinking
but show no obvious morphological defects (Spratt 1983).
3.4 Relationships Amongst PBPs
There is good evidence that the PBPs of a given organism are
independent proteins and are not related by a preproduct.
Each of the PBPs of E.coli has been mapped to a different
position on the bacterial chromosome (Suziki et a]_ 1978).
There is also comparatively little amino acid homology among
the different PBPs of E.coli (Broome-Smith et £]_ 1985). Such
results do not preclude evolutionary relationships or any
structural similarity between PBPs.
3.5 Is Lysis the Direct Result of Inactivation of Essential PBPs?
There is now substantial evidence that induction of cell
death and lysis are both secondary responses to inhibition of
cell wall assembly. This evidence has been reviewed by
Shockman et al (1979) and Tomasz (1979a, 1979b).
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In several organisms, the lytic effects of ^-lactams can be
eliminated by the inactivation of peptidoglycan hydrolases
also know as autolysins*. This effect is described as
"tolerance" and it is not accompanied by a change in growth
sensitivity to ^-lactams which indicates that the primary
targets (the PBPs) remain unaltered.
3.6 The Action of Carboxypeptidase and Transpeptidase in Vitro
The activity of carboxypeptidase in vitro is monitored by the
release of free D-alanine which results from nucleophile
attack at the carbonyl carbon of the penultimate D-alanine of
a cell wall pentapeptide. The nucleophile may be from water
(OH). However if it is an amino compound (R-NH2) a transpep-
tidation reaction takes place, i.e. transpeptidase activity
(Tamura et aj_ 1976, Waxman et _al_ 1980).
H20_
Kl






Figure 4 Schematic Presentation of PBP Action
(Taken from Waxman and Strominger (1982))
There is competition between the pathways leading to
carboxypeptidase and transpeptidase products. Endopeptidases






hydrolyse the D-alanine, D-alanine peptide dimers formed via
transpeptidase reactions (Tamura et_ ^1_ 1976).
Penicillin Binding to PBPs
The kinetics of binding ^-lactam antibiotics is similar to








E.I, Non covalent, reversible complex
E-I, Covalent penicilloyl PBP
Figure 5 Inhibition of PBPs by ^-lactam Antibiotics
(Taken from Blumberg and Strominger (1971),
Frere et_ _al_ 1975a)
The K3 (E-I ) E + degraded ^-lactam) is low and
therefore there is an accumulation of stable penicilloyl
enzyme complex (E-I). Binding of ^-lactams is characterised
by first order kinetics (Frere et_ aj_ 1975al Once bound to
the active site a suitable ^-lactam side chain may interact
with a specific enzyme grouping so as to correctly position
and/or catalytically inactivate the ^-lactam for subsequent
enzyme acylation (Ghuysen et^ aj_ 1980). The kinetics of
^-lactams suggest a classic competitive inhibition (Umbreit
and Strominger 1973, Yocum et_ ^1_ 1974, Frere et^ aj_ 1975b).
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In the absence of added nucleophiles, degradation of
erf
penicilloyl-PBP complexes can occur by either^two pathways.
The bound penicilloyl moiety can be enzymically hydrolysed to
yield penicilloic acid eg PBPs 5 and 6 of E.coli. (Tamura et
al 1976). The second possibility is fragmentation of the
bound penicilloyl moiety at a very slow rate (Marquet et al
1979). The choice of pathways between hydrolysis and
fragmentation depends on the ^-lactam in question, the
reaction conditions and the nature of any exogenous
nucleophi le (Ghuysen et_ _al_ 1980).
3.7 The Action of jl-lactams - The Substrate Analogue Hypothesis
Tipper and Strominger (1965) proposed that penicillin acts
as a structural analogue of the acyl-D-alanyl-D-alanine
terminus of nascent polypeptide strands (Figure 6).
Penicillin was predicted to bind to and acylate the enzyme
with its highly reactive ^-lactam bond positioned at the
active site (Yocum et_ al_ 1979). In order to be effective as
a substrate analogue, jS-lactams must be sufficiently similar
to the natural substrate to permit recognition by cell
wall enzymes and inhibit their enzymic action (Waxman and
Strominger 1982, 1983).
There are contradictions to the substrate analogue theory
when the ^-lactam structure is examined closely and compared
to that of acyl-D-alanine (reviewed by Waxman and Strominger
1983).
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Figure 6 Stereomodels illustrating the proposed similarity
between acyl-D-alanine (lower structure) and
penicillin (upper structure).
Arrows indicate bonds cleaved during substrate
catalysis or during the reaction leading to
inactivation by penicillin.
(Taken from Waxman and Strominger 1983)
o
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Lee (1971) has argued that several anomalies can be explained
by the possible structural analogy of penicillin and a
transition state structure formed during cleavage of the
D-Alanine D-Alanine peptide bond.
It is believed that a transition state enzyme bound substrate
has a compressed and twisted peptide dihedral angle. There
is concomitant loss of double bond character and weakening of
the peptide bond. ^-lactams have a bicyclic ring system
which imparts significant single bond character to the
corresponding ^-lactam bond which favours ,8-lactam binding to
the enzyme (Waxman and Strominger 1982, 1983). Other
features, including side-chain substitutions and portions of
the ^-lactam nucleus with no analogy in the dipeptide
probably decrease enzyme recognition. Overall, substrate and
^-lactam are thought to bind with similar affinity (Ghuysen
et al_ 1979).
3.8 Homology to jl-lactamase Enzymes
It has been suggested that ^-lactamase enzymes may have
evolved from the penicillin sensitive enzymes of cell wall
synthesis (Tipper and Strominger 1965). Several PBPs have
been found to have ^-lactamase activity (Spratt 1980b, Waxman
and Strominger 1983). Several ^-lactamases and PBPs have
been shown to use an acyl-enzyme reaction mechanism via an
active site serine residue (Frere et_ £l_ 1976, Knott-Hunziger
et_ ^1_ 1979, Waxman and Strominger 1980).
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Some homology between the low molecular weight PBPs of
bacilli and ^-lactamases has been determined (Knott-Hunziger
et al 1979, Waxman and Strominger 1983). If PBPs and fi-
lactamases have a common evolutionary history, this should
emerge from further comparison of their amino acid sequences.
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Resistance to g-lactam Antibiotics
4. Genetics of Resistance to ft-lactam Antibiotics
4.1 Chromosomal Resistance
Chromosomal mutants can be obtained with relative ease by
sub-culture in the presence of an antimicrobial agent.
Spontaneous mutants arise at a frequency between one in 1C)6
and one in 10^ per cell division (Lederberg and Lederberg
1952).
Step-wise mutations can lead to antibiotic resistance and the
strain retains its apparent virulence. In N.gonorrohoeae
chromosomal resistance to penicillin can result from the
acquisition by transformants of the pen A locus which
alters the affinity of PBP2. Further transformation of mtr
and pen B loci alter the outer membrane permeability of the
organism and further contribute to penicillin resistance
(Guymon et_ al_ 1978). Alterations of other genes, perhaps pern
and tern, have resulted in reduced affinity of PBP1 for
penicillin and highly penicillin resistant gonococci (Barbour
1981, Dougherty et_ _al_ 1980). Single-step chromosomal mutants
can occur, such as the carbenicillin-resistant mutants in
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P.aeruginosa, which have reduced affinity of all PBPs
(Godfrey and Bryan 1982).
A degree of intrinsic ^-lactam resistance in some bacteria
can be attributed to the presence of a basal level of
chromosomal ,8-1actamase. The enzyme may be inducible (Sykes
and Matthew 1976) and mutations in the induction regulatory
system in organisms such as Pseudomonas, Enterobacter,
Serratia and Citrobacter can lead to high levels of
constitutive 8-lactamase production (Gootz et_ aj_ 1982).
Hyperproduction of chromosomal £-1actamase has been observed
in E.coli. Expression of the E.coli K12 amp C, structural
gene is normally low which is thought to result from the
presence of a weak promoter and a transcriptional attenuator
in the ampC leader (Jaurin et_ aj_ 1981). E.coli mutants have
been isolated which hyperproduce chromosomal ^-lactamase.
Up-promoter mutations have been shown to increase expression
seven to 21 fold (Jaurin et_ al_ 1981). Expression could also
be increased up to 21 fold in one-step by (1) the insertion
of an insertion sequence (IS) into the ampC promotor (Jaurin
and Normark 1983) (2) ampC attenuator mutation (Jaurin et_ al_
1981) (3) gene amplification (Edlund et al 1979).
Naturally occuring ampC hyperproducing strains have been
found with 24 to 48 fold increases in level of production
(Bergstrom and Normark 1979). They all had an identical
449 base pair sequence which encodes a very strong B-
lactamase promotor. This promotor is identical to that
found in Shigella sonnei except for a single base pair
change. It appears that naturally occuring chromosomal
jl-lactam resistance may have evolved by horizontal transfer
of ampC DNA from Shi gel! a species (Olsson et_ aj_ 1983).
4.2 Plasmid - Determined Resistance
Transferable resistance to antimicrobial agents was first
discovered amongst strains of S.flexneri isolated in Japan
by Akiba et al_ 1959 and Ochai et al_ 1960), who recognised
the R (resistance) factor as being analogous to the F
(fertility) factor of E.coli K12 (Cava!1i-Sforza et al 1953,
Hayes 1953).
It has been generally observed that the introduction of a
new antimicrobial agent is generally (although not always)
followed by the identification of plasmid - mediated
resistance mechanisms (Anderson 1968, Datta 1984).
Ampicillin (Rolinson and Stevens 1961) was introduced into
clinical use in 1962 and the first R plasmids encoding
resistance to this compound were detected soon after
(Anderson and Datta 1965).
It has been established that conjugative plasmids were
present in enteric bacteria isolated from the "pre-
antibiotic" era (1917-1954). The plasmids are similar to
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the R plasmids of today except for the lack of antibiotic
resistance determinants (Hughes and Datta 1983, Datta and
Hughes 1983). There was therefore, a reservoir of
transferable plasmids present before the advent of anti¬
microbial selection pressure.
Plasmids, and other resistance genes can be transferred
between bacteria by conjugation, transformation and
transduction (reviewed by Broda 1979 and Saunders 1984).
All plasmids are dependent on host replication functions,
although different plasmids vary in individual respects
(Norstrom et £l_ 1984). Plasmids replicate independently of
the chromosome.
Those of more than 35 kilobases tend to maintain low numbers
per cell (one to four copies), whereas smaller plasmids are
usually present in high copy number (Broda 1979, Nordstrom et
al_ 1984).
Replication is governed by regulating the number of
initiation events at the origin. Mutations in the regulatory
genes can result in runaway, uncontrolled plasmid replication
(Tomizawa et_ al_ 1981, Light and Molin 1981).
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Plasmid Classification
Plasmids can be classified into incompatibility (Inc) groups.
Plasmids of the same Inc group fail to coexist stably in the
same host cell, -V* have closely related replication
regulation systems and have a large degree of DNA homology
(Grindley et_ aj_ 1973, Falkow et_ a]_ 1974, Smith et_ ^1_ 1974,
Roussel and Chabbert 1978).
Incompatibility grouping is generally impractical for large
surveys of resistance plasmids. Difficulties may also be
encountered with natural plasmids which carry two or more
different Inc group determinants (Grant et al_ 1980, Taylor et_
al 1981, Nugent et_ £l_ 1982, Bird and Pittard 1983).
Plasmids have been classified by size, the resistance markers
present and their individual restriction endonuclease digest
pattern (O'Brien et_ aj_ 1982, Tietze and Tschape 1983).
4.3 Transposons
Transposons are units of DNA capable of transferring
(transposing) themselves from one replicon to another. They
are unable to replicate independently and must be maintained
as part of a functional replicon (Figure 7) (reviewed by
Kleckner 1981). Transposition itself occurs independently of
the normal host homologous recombination mechanism i.e. the




FormationandResolutionfPlasmidCoin egratesDuringTranspositionofn3 (TakenfromS unders1984)
There are three types of transposon. The first group are the
composite transposons which consist of one or more resistance
genes bounded by IS sequences 700 to 1500 base pairs in
length, usually in reverse orientation (Ross et_ jil_ 1979
Rosner and Guyer 1980,). The second group of transposons are
the Tn3-like group. They have three sites and two functional
groups essential for transposition?, tnpA determines
transposase and tnpR a bifunctional protein which regulates
the expression of transposase and resolves intermediate
cointegrate formations in the transposition process (Chou et_
al 1979, Gill et_ al_ 1979). The three essential sites are the
two inverted repeat sequences (38 base pairs long) at the
ends of the unit and the internal site (res or IRS - the
internal resolution site) necessary for cointegrate
resolution (reviewed by Kleckner 1981).
The third class of transposon is exemplied by Tn916. This
group are collectively termed the conjugative transposons,
units which apparently transfer by a conjugation process in
the absence of detectable plasmid DNA (Franke and Clewell
1981).
The Transposition Event
Much of the work on the mechanism of transposition has been
carried out with Tn3. The inverted repeat sequences are
thought to act as recognition sequences for the transposase.
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This enzyme cuts the target DNA molecules and joins
them to form a cointegrate. In Tn3, the enzyme resolvase,
resolves the cointegrate at a specific site {res), it also
regulates its own synthesis and the synthesis of the
transposase (reviewed by Kleckner 1981, Saunders 1984).
Transposition cointegrates are resolved by host resolvases in
some cases.
The phenomenon of transposition immunity (Robinson et_ _al_
1977) prevents intermolecular transposition into a replicon
which already contains a copy of the transposon. Clustering
of resistance determinants, perhaps in non-essential sites,
is also observed. Transposons may thus show a regional
specificity for insertion into DNA molecules. Transposon 3
inserts into regions rich in AT base pairs (Heffron et_ jal_
1975a) whereas Tn7 inserts into many plasmid sites but into a
single chromosomal site in E.coli and many other bacteria
(Lichtenstein and Brenner 1982).
Transcription of bla encoded by Transposons
Differences in the absolute levels of ^-lactamase produced by
various transposons has been explained by the efficiency of
the transcription of the bla gene itself. This is a similar
phenomenon to that described with E.coli amp C chromosomal
mutations (Olson et_ ^1_ 1983) described earlier. Some bla
genes have more efficient promoters and the evolutionary
success of certain ^-lactamases such as TEM-1 may have
resulted from mutations of a promoter region, resulting
57
in enzyme hyperproduction rather than mutations in the
structural region which would produce a qualitative
alteration (Yamamoto et al 1982).
4.4 Gene Amplification
Amplification by Tandem Duplication
Tandem duplication is a method of elevating the numbers of
gene copies - the gene dosage effect (Anderson and Roth
1977). Both chromosomal (Edlund et _al_ 1979) and plasmid -
borne determinants (Yagi and Clewell 1976, Schmitt et_ al_
1979, Schoffl and Puhler 1979, Wiebauer et_ 1981) can be
amplified in this way.
Increased Plasmid Copy Number
Mutations in plasmid replication control genes can result in
a large number of resistance plasmid (Nordstrom et al_ 1972,
Tomizawa et aj_ 1981, Light and Molin 1981). Plasmid copy
mutants have been used to relate gene dosage effects to
antimicrobial drug susceptibility (Uhlin and Nordstrom
1977).
4.5 Acquisition of Multiple Copies of a Transposon
Multiple transposition is distinct from tandem duplication
and it has been observed for such transposons as TnA (Tn2660)
in the R6K plasmid (Holmans and Clowes 1979). Transposition
immunity (Robinson et_ aj_ 1977) seems to apply to inter-
molecular transposition and has little effect on intra¬




The promiscuity of transferable resistance genes has led to
wide spread antimicrobial drug resistance. The clonal
expansion of a bacterium carrying a resistance plasmid
when selection pressure is applied has also made a large
epidemiological impact (Rowe et_ al_ 1980, Hughes et_ aj_ 1980).
"Endemic plasmids" have also spread widely within bacterial
populations and carried drug resistance into many bacterial
genera (Ingram et_ al_ 1973, Witchitz and Chabbert 1972, Datta
1984).
Transposons have complicated and magnified the problems of
the 1960s. About half of the transferable ^-lactamases have
been found to be mediated by transposons (table 2) (Yamamoto
et_ al_ 1981, Medeiros et_ al_ 1982, Sinclair and Holloway 1982,
Phillipon et_ al_ 1983, Yamamoto et_ aH_ 1983, Kratz et a]_ 1983,
Jacoby personal communication). The evolutionary success of
TnA encoding the TEM ^-lactamase is well documented and is
due to the promiscuity of the TEM transposons (Tn 1, 2, 3,
401, 801, 802, 901, 902, 1701, 2601, 2602, 2660) (Kleckner
1981). The spread of TEM-1 through the bacterial population
will be discussed in a later section.
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5. ff-lactam prUg Resistance
There are at least eight possible biochemical mechanisms of
drug resistance (Goldstein et_ a]_ 1974).
1 - decreased intracellular drug level i.e. impermeability
2 - the destruction of the drug
3 - the decreased conversion of a drug to a more active form
4 - the increased concentration of a metabolite antagonising the
drug action
5 - an increase in the level of target enzyme
6 - decreased requirements for the product of the drug sensitive
reaction (hypothetical)
7 - a mechanism for by-passing or repairing the drug sensitive
reaction
8 - decreased affinity of the receptor for the drug
Five of these mechanisms (1, 2, 5, 7, 8) are probably
involved in ^-lactam resistance and can be broadly divided
into enzymic detoxification/destruction mechanisms (2) and
mechanisms which do not involve enzymic destruction (1, 5, 7,
8).
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5.1 Enzymic Destruction of ^-lactam Antibiotics
J3 -1 act am antibiotics are substrates for a number of
hydrolytic enzymes. The enzyme described originally by
Abraham and Chain (1940) as a "penicillinase" was isolated
from E.co 1 i a type of strain subsequently found to
produce the enzyme penicillin amidase (penicillin amido
hydrolase, E.C. 3.5.1.11.) (Batchelor et_ ^1_ 1961).. This
enzyme has also been called an amino acid acylase and is
quite distinct from the enzyme classically associated with
the name penicillinase (Pollock 1971). Bacterial amidase
enzymes act principally against penicillins, removing the
acyl side chain to form aminopenicillanic acid (Batchelor et_
al 1961, Hamilton-Miller 1966). Although their contribution
to bacterial resistance is unclear, their enzymic action
has been exploited in the production of semi-synthetic
penicillins (Batchelor et al 1959).
A second type of enzymic degradation involves the removal by
acyl esterases* of the acetyl group attached at C-3 on the
cephalosporin C nucleus. Certain semi-syntheti c
cephalosporins with an acetoxy methyl function at C-3, ie
cephalothin and cefotaxime are also susceptible (Sykes and
Smith 1979, Sykes 1982). The product of the reaction is a
compound of reduced antibacterial activity.
* E.C. number not available
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^-lactamases are the most important enzymic resistance
mechanism, although not the only ^-lactam degrQdative enzymes
(Pollock 1971, Sykes and Matthew 1976, Sykes and Smith 1979,
Sykes 1982). Originally they had been called penicillinases
and they were given the name "penicillin amido ^-lactam
hydrolase" E.C. 3.5.2.6. (Pollock 1971). However, with
the advent of new substrates such as the broad spectrum
penicillins and the cephalosporins, enzyme characterisation
improved and the cephalosporinase enzymes were recognised
(Jago et_ al_ 1963, Fleming et_ al_ 1963, Ayliffe 1964, Hamilton-
Miller et_ a]_ 1965). In 1972, the enzyme commission included
cephalosporinase (E.C. 3.4.2.8) as official nomenclature,
describing penicillinase as ^-lactamase I and cephalospori¬
nase as ^-lactamase II (Hamilton-Miller 1979). Recently
however, these enzymes have been grouped under one heading
(E.C. 3.5.2.6) as the "J3-1 actamase enzymes" (Enzyme
Nomenclature 1984).
5.1.1 Classification of ft-lactamase Enzymes Produced by Gram
Negative Bacteria
Gram negative bacteria produce a wide variety of ^-lactamase
enzymes (Richmond and Sykes 1973, Sykes and Matthew
1976, Medeiros 1984). The enzymes may be inducible or
constitutively produced and they are generally periplasmic
or cell bound (Richmond and Sykes 1973). There are many
classification schemes for jl-lactamase enzymes. The earliest
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relied on the substrate profile or specificity of the enzyme
as the primary parameter and included additional factors such
as enzyme inhibition profiles and cross-reaction to antisera
for finer discrimination (Jack and Richmond 1970).
Richmond and Sykes (1973) elaborated this technique and
described five broad enzyme classes based on substrate
profile and inhibition studies.
Class I enzymes are the chromosomal cephalosporinases of
Gram-negative bacteria which are competitively inhibited by
cloxacillin and carbenicillin.
Class II enzymes are broad spectrum penicillinases which are
competitively inhibited by cloxacillin but not carbenicillin.
Class III enzymes are broad spectrum and are competitively
inhibited by cloxacillin but not carbenicillin or para-
chloromecuribenzoic acid (|)CMB). They comprise the plasmid-
mediated TEM-type ^-lactamases.
Class IV enzymes are broad spectrum chromosomal enzymes and
are sensitive to jdCMB.
Class V is a heterogenous grouping of penicillinase enzymes
which are resistant to inhibition of jdCMB and cloxacillin.
They include the oxacillin and carbenicillin hydrolysing
plasmid mediated ^B-lactamase enzymes.
(Richmond and Sykes 1973)
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Sykes and Matthew (1976) later described how enzyme substrate
profile, inhibitor studies, immunological studies, molecular
weight determination and the genetic location of ^-lactamase
genes could all be used as a means of classification. These
c
parameters were combined with the isoeletric point (pi) of
the ^-lactamase enzyme to create a classification index.
The use of analytical isoelectric focusing (IEF) developed
by Matthew et_ aj[ ( 1975 ) enables the identification and
classification of ^-lactamases in large numbers of clinical
bacteria (Simpson et_ aj_ 1980, Roy et_ aj_ 1983). Each
transferable ^-lactamase has a unique pi and characteristic
banding pattern on IEF (Matthew and Harris 1976). IEF
however, does not reveal any similarities between ^-lactamase
enzymes.
The use of substrate profile for enzyme classification has
been criticised as collecting information about the Vmax of
the enzyme for the substrate but little about the affinity
(Km). In the classification of new ^-lactamase enzymes a
direct comparison of hydrolysis of substrates is probably
best made using relative efficiency of hydrolysis as
described by Sykes et_ al_ (1981b).
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The efficiency of hydrolysis = Vmax per unit enzyme
Km
The relative efficiency may be normalised with respect to
that of penicillin G (Sykes et al_ 1981b).
The most recent classification system has evolved from the
methodologies of amino acid and nucleotide sequencing. Three
evolutionary distinct classes of ^-lactamase enzyme have been
recognised (Ambler 1980, Bergstrom et_ al_ 1982): Class A have
an active site serine residue and are around 29,000 daltons
in size. They are principally penicillinase enzymes with
significant amino acid sequence homology. The group includes
the TEM-type ^-lactamases and the penicillinases of S.aureus
and B.licheniformis. Class B is restricted to the 23,000
dalton metallo-thio cephalosporinase of B.cereus type II.
Class C ,3-lactamase enzymes are large proteins (around 39,000
daltons) and they include the chromosomal cephalosporinases
of Gram negative bacteria. They show little sequence homology
with Class A enzymes although they both have an active site
serine residue (Bergstrom et_ al_ 1982, Jaurin and Grundstrom
1981, Knott-Hunziger et_ _al_ 1982). It is thought that the
similarity of the active sites of class A and class C enzymes
may result from convergent solution (Knott-Hunziger et_ al
1982).
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5.1.2 ^-lactamase Enzymes Mediated By Chromosomal Genes
Chromosomal ^-lactamase enzymes are generally specific for
species and, sometimes, for subspecies (Matthew and Harris
1976). The chromosomal enzymes of Richmond and Sykes (1973)
class I are often inducible.
Recent studies have shown that many of the newly introduced
^-lactams are capable of inducing high levels of ^-lactamase
production in a variety of Enterobacteriacae (Minami et_ _al_
1980, Sanders et _al_ 1982, Sykes and Bush 1982, Gootz and
Sanders 1983). There have also been reports of induction by
penicillins (Minami et a]_ 1983). Occasionally, new forms of
the ^-lactamase enzyme are seen after induction and it is
unclear whether these are new enzymes or a modified form of
the native enzyme (Sanders et_ al_ 1982).
Chromosomal ^-lactamase enzymes have now been found which
hydrolyse most classes of ^-lactam antibiotic. Even the
extremely stable carbapenem thienamycin is hydrolysed by
an enzyme produced by P .mal toph i 1 i a (Saino et a_l_ 1982).
5.1.3 ft-lactamase Enzymes Mediated By Plasmids and Transposons
The transferable ^-lactamase enzymes are produced
constitutively and generally in greater quantities than the
chromosomal ^-lactamases (Matthew 1979).
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Twenty eight plasmid mediated ^-lactamases have been
described so far (Table 2). They can be broadly sub¬
divided into four classes, the broad spectrum enzymes, the
oxacillinases, the carbenici11inases and the cephalosporinase
enzymes (Matthew 1979, Medeiros 1984). Within the classes
there can be a degree of immunological cross-reactivity
(Matthew 1979, Holland and Dale 1985).
Some transferable ^-lactamase enzymes hydrolyse the newer
^-lactam antibiotics. Several of the OXA and PSE enzymes
have been shown to have hydrolytic activity against "jl-
lactamase stable" compounds, albeit small (Simpson et a]_
1982, Medeiros 1984).
Knothe et_ a_l_ ( 1983 ) have reported a transferable
lactamase which conferred resistance to second generation
cephalosporins and cefotaxime. The enzyme, named SHV-2, is
thought to have evolved from SHV-1 by mutations in at least
two base pairs, subtly cha nging the ,8-lactamase enzyme's
hydrolytic properties (Kliebe et _al_ 1985).
5.1.4 Distribution of PIasmid-Mediated ^-lactamase Enzymes in
Clinical Bacteria
The location of ^-lactamase genes on transferable elements
has led to ubiquitous spread of some types of ^-lactamases
throughout the world. This has been particularly evident
with the TEM-1 and TEM-2 ^-lactamase enzymes.
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Table 2 The Transferable j3-1actamase Enzymes
Relative Rates of Hydrolysis* Inhibitors
AMP CARB OXA METH CLOX CER CTX CLOX pCMB CLAV
Broad spectrum
Enzymes
76 <1TEM-1" 106 10 5 0 0 + - +
TEM-2 107 10 5 0 0 74 0 + - +
SHV-1 212 8 0 <2 <2 56 0 + +/- +
SHV-2 145 ND 0 ND ND 32 4 + +/- +
HMS-1 253 14 <2 <2 <2 183 ND + + -
TLE-1 67 13 4 5 6 52 6 + ND +
TLE-2 140 13 ND <0.1 <0.1 NM ND + + +
ROB-1 186 25 6 ND ND 24 ND ND ND ND
LCR-1 145 4 ND 20 3 55 ND + - +
NPS-1 223 18 40 <0.1 ND 3 <1 - - ND
BRO-1 103 78 ND 131 5 23 ND + ND +
Oxaci11inases
+/- NDOXA-1 382 30 197 332 190 30 22 +
OXA-2 179 15 646 23 200 37 1 - - -
OXA-3 178 10 336 29 350 44 0 ■ - - ND
OXA-4 438 39 220 711 64 194 63 +/- ND -
OXA-5 188 40 210 109 258 89 49 - ND -
OXA-6 596 46 1048 585 301 149 28 + ND -
OXA-7 545 48 702 424 494 136 31 - ND -
Carbenici11inases •
PSE-1 90 97 <2 <2 <2 18 27 - + -
PSE-2 267 121 317 803 371 32 16 .ND + -
PSE-3 101 253 ND ND 3 10 <1 ND - -
PSE-4 88 150 8 16 <2 40 1 ND - -
CARB-4 130 79 1 <1 <1 18 ND - + -
SAR-1 63 122 <0.1 <0.1 <0.1 21 <0.1 + - +
AER-1 38 98 0.9 0.3 0 26 20 ND ND ND
N-3 113 113 ND ND <2 12 ND + ND ND
N-29 124 128 ND ND <2 6 ND + ND ND
Cephalosporinase
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This enzyme which is common amongst the Enterobacteri aceae,
has been found on plasmids from most incompatibility groups
thus facilitating its spread (Hedges et aj_ 1974, Heffron
et_ aj_ 1975b). Ampicillin is widely used in the treatment
of H. inf1uenzae infections and in 1974 ampicillin
resistant H.influenzae were identified (Thomas et _al_ 1974).
The strains produced TEM-1 pi asmid-borne ^-lactamase
(Elwe 11 et_ _al_ 1975). One H.influenzae strain was found to
carry one-third of the Tn3 sequence on a plasmid (DeGraaff
et_ aj_ 1976). It has been proposed that this transposon (Tn2)
may have evolved from Tn3 by deletion and subsequent
acquisition by cryptic plasmids indigenous to H.influenzae
(Laufs and Kaulfers 1977, Kaulfers et _al_ 1978).
Treatment of gonococcal infections also relied heavily on
penicillin and TEM-1 producing N.gonorrhoeae were isolated in
1976 (Percival et al_ 1976, Ashford et aj[ 1976). Here too,
all or part of Tn3 is found in TEM-1 producing strains. It
has been shown that two ^-lactamase plasmids from gonococci
show homology with an R factor from H,influenzae (Elwell et_
al 1977. It is possible that ampicillin resistance plasmids
were acquired by gonococci from H.influenzae or that both
acquired similar plasmids from an enterobacterial source.
More recently there has been a report that a strain of
N.meningitidis has been isolated which produces the TEM-1
^-lactamases However this claim is unsubstantiated (Dillon
et al_ 1983).
Transferable ampicillin resistance in Vibrio cholerae emerged
in the 1970s (Rahal et al_ 1973, Hedges et_ _al_ 1977, Threlfall
et al 1980) and the TEM-1 ^-lactamase enzyme was identified
(Hedges et_ _al_ 1977). A novel ^-lactamase has since been
identified in V.cholerae (SAR-1) (Reid and Amyes 1986) a
parallel to the discovery of R0B-1 in H.influenzae (Rubin et
al 1981). These two genera only produce TEM-1 and their
respective novel ^-lactamase.
The remaining plasmid encoded ^-lactamase enzymes have
different distributions amongst the bacterial genera (Matthew
1979, Simpson et_ ^1_ 1980, Roy et £l_ 1983). In contrast to
TEM-1 another broad spectrum enzyme, HMS-1, is extremely rare
having been found only once in an isolate of P.mirabi 1 is
(Matthew et ^1_ 1979). The distribution of the enzymes within
bacterial genera also differs. In E.coli TEM-1 is the most
prevalent in the United Kingdom and Spain (Simpson et afl_
1980, Roy et _al_ 1983), whilst in P.aeruginosa in France,
PSE-1 occurs most frequently (Phil 1 ipon et aj_, personal
communication in Medeiros 1984). In the United Kingdom PSE-4
is the most common transferable ^-lactamase found in
P.aeruginosa (Williams et al 1984).
70
5.1.5 Mode of Action of ^-lactamase Enzymes
The TEM-1 ^-lactamase is the best studied enzyme in
mechanistic terms and a general reaction scheme has been
outlined:
Kl





Figure 8 Action of ^-lactamase Enzymes
(Taken from Bush and Sykes 1984)
For the ^-lactamase enzymes examined so far the first step
has been found to equilibrate rapidly (Bush and Sykes 1984).
The formation of a covalent acyl enzyme intermediate from the
E.S. complex has been shown for the TEM ^-lactamase (Fisher
et al 1980) and some chromosomal ^-lactamases (Knott-
Hunzi ger et al 1980, Anderson and Pratt 1981, Cartwright and
Fink 1982). The deacylation of E-S yields free enzyme and a
^-lactam with an open ^-lactam ring. For most substrates for
the deacylation step is rate determining (Frere 1981).
After the opening of the ^-lactam ring, the penicillins
further break down to penicillanic acid (Newton et al_ 1967).
The cephalosporins may also undergo spontaneous degradation
and fragmentation because of the conjugated ring system and
the substituent at the C-3 position of the dihydrothiazine
71
ring renders the hydrolysed molecule unstable (Hamilton-
Miller et_ aj_ 1970, Sykes and Smith 1979).
^-lactamase enzymes are "floppy" enzymes and lack rigid
tertiary structure. They satisfy the requirements of the
induced fit model of enzyme action (Koshland 1970).
Acyl intermediates of class C enzymes have also been found
with P.aeruginosa and E.coli K12 (Knott-Hunziger et^ al_ 1980,
1982). The labelled serine residues from these ^-lactamase
enzymes were found in peptides which differed from those of
the class A series (Knott-Hunziger et_ £l_ 1982).
5.1.6 Contribution of the ^-lactamase Enzyme to ^-lactam Resistance
The extrapolation of jS-lactamase enzyme in vitro properties
to the in vivo function of the enzyme is difficult. The
in vitro testing of antimicrobial susceptibility and the
measurement of the enzyme activity all require careful
standardisation (Pollock 1971).
The levels of ,8-lactam resistance of Gram negative bacilli
often do not correlate with the rates at which these
antibiotics are hydrolysed by the cell-free ^-lactamase
enzyme (Percival et_ aj_ 1963, Richmond and Sykes 1973,
Medeiros et_ a]_ 1974). The permeability of a cell and the
susceptibility of its target site(s) both interact with the
^-lactamase to determine the cell's resistance to ^-lactam
antibiotics. If a ^-lactamase is to compete successfully
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with the PBP target site for the incoming ^-lactam antibiotic
then it should have a higher affinity for the ^-lactam (Bush
and Sykes 1984). Many PBPs however are extremely susceptible
to ^-lactams at levels of 0.5juM or less (Curtis et al_ 1979,
Georgopapadakou and Liu 1980) and thus the ^-lactamase would
not be effective as the sole resistance mechanism.
5.1.7 Non-Hydrolytic "Trapping" of j3-lactam Antibiotics By J3-
lactamase Enzymes
Treatment failures have occurred during therapy with a
variety of ^-lactamase stable ^-lactam antibiotics. These
failures result from the emergence of resistant strains
including E .cloacae, Citrobacter sp., P. aeruginosa and
S.marcescens (Sugarman and Pesanti 1980, Preheim et a]_ 1982,
Q
Ols'on et_ aj_ 1983). All the strains had a derepressed
constitutive chromosomal ^-lactamase enzyme which result from
mutations in the regulatory genes controlling ^-lactamase
expression (Gootz et al 1982). The strains were also found
to be resistant to a variety of third generation ^-lactam
antibiotics (Nikaido 1985).
Class I enzymes (Richmond and Sykes 1973) were found to have
a high affinity for virtually all the newer cephalosporins
and it was suggested that the ,B-lactamase enzyme was unable
to hydrolyse the ^-lactam but bound to it and "trapped" the
compound thereby preventing it from reaching its target site
(Yokota and Azuma 1980, Then and Angehrn 1982, Sanders
1983).
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This argument has been opposed in the belief that the amount
of enzyme needed to trap the incoming ^-lactam would
necessarily be large (Seeberg et_ al_ 1983). However, most of
the ^-lactams penetrate the outer membrane slowly and the
amount of enzyme present in constitutively derepressed cells
is relatively high (Nikaido 1985). The bacteria remained
sensitive to thienamycin probably because it penetrates the
Gram negative outer membrane very efficiently and has high
affinity for PBP2 which is present in small numbers in the
cell (Spratt 1975, MSD Product Monograph 1985).
The most stable ^-lactams may, in fact.be slowly hydrolysed
by some ^-lactamase enzymes (Livermore 1985). Changes in the
methods of assay have reduced the amount of substrate present
and increased the amount of enzyme. Therefore it is possible
that "periplasmic detoxification" is efficient in vivo (Bush
et al 1985, Livermore 1985, Sanders and Sanders 1986).
Transfer of the E.cloacae ^-lactamase (b 1 a) genes into
the standard genetic background of E.coli K12 resulted
in the strain becoming resistant to ^-lactamase stable
cephalosporins and demonstrated that resistance was not a
strain property because E.coli K12 is permeable to third
generation cephalosporins (Seeberg et_ al_ 1983). This result
supported the "trapping" theory.
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Livermore (1985) contests this theory and cites the covalent
linkage of clavulanic acid with the TEM ^-lactamase (Charnas
et al 1978). The minimum inhibitory concentrations of
clavulanate are not changed with the introduction of plasmids
coding for TEM into the E.coli strain, as would be expected
if "trapping" were taking place. Livermore (1985) argues
that the results of Seeberg et aj[ (1983) could be explained
if slow hydrolysis of the incoming ^-lactam antibiotics were
taking place, and thus "trapping" is not a valid hypothesis.
It is possible that both trapping and slow hydrolysis occur
in vivo and their roles may be complementary as derepression
of the ^-lactamase results in large amounts of the enzyme in
the periplasmic space.
The mechanics of ^-1 actamase/^-1 actam interaction are
summarised in Figure 8.
Good substrates will be found as products of the reaction
(P). Slowly hydrolysed substrates will remain primarily in
the E.S complex, the condition postulated by the "trapping"
theory. Some non-substrate drugs such as moxalactam may
fulfill the trapping conditions entirely by remaining as
E.S (Bush et_ al_ 1982, Gwynn and Rolinson 1983 and Sanders and
Sanders 1986).
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^-lactamase stability which once seemed an important
attribute for ^-lactam antibiotics is perhaps now less
clear-cut. Future drug design rationale appears to require a
compound which is stable to ^-lactamase enzymes, but which is
smaller in size and penetrates the cell wall rapidly eg
thienamycin (Kropp et_ aj_, 1980 Nikaido 1985).
5.2 Resistance Mechanisms to ^-lactam Antibiotics Which Do Not
Involve Enzymic Destruction
There are a variety of possible resistance mechanisms
to ^-lactam antibiotics which do not involve enzymic
degradation. These include permeability changes, altering
the amount of target enzyme, and decreasing the affinity
of the target for the j3-lactam (Goldstein et_ a_l_ 1974).
5.2.1 Reductions in Outer Membrane Permeability
It has been demonstrated that the loss of porin proteins
results in ^B-lactam resistance in E.col i (Bavoil et_ _al_
1977, Harder et_ _al_ 1981), in Salmonel 1 a (Nikaido et_ ^1_
1977) P.aeruginosa (Nicas and Hancock 1983), P.mirabilis
fa
and E.cloacae (Sawai et_ aj_ 1982). Changes in outer mejbrane
proteins can also result in resistance to other types of
antimicrobial agent eg tetracyclines (Foulds 1976) and
chloramphenicol (Burns et aj_ 1985).
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The genetic basis of permeability resistance in E.coli K12 is
the alteration in production of OmpF and/or OmpC porin at the
OmpB regulatory gene locus (Jaffe et al 1982). Mutants
lacking more permeable OmpF porin are more resistant to
hydrophobic or dianionic compounds which have difficulty in
penetrating the narrower OmpC Channel (Harder et_ _al_ 1981).
Resistance to latamoxef has also been shown to result from
changes in E.coli outer membrane proteins (Komatsu et_ aj_
1981). It appears retrospectively, that the observed change
was a decrease in the amount of OmpF protein specifically.
Porin protein production may be repressed or induced by
varying salt or sucrose concentrations in growth medium (van
Alphen and Lugtenberg 1977). Resistance in clinical isolates
may therefore result from phenotypic rather than mutational
alterations in porin composition.
^-lactam resistance resulting from permeability changes has
been regarded as generally being chromosomally mediated.
Curtis and colleagues however described a mutant of the
RP1 plasmid (RP1 amp-1) which specified ampicillin resistance
in the apparent absence of detectable ^-lactamase activity
(Curtis et_ _al. 1973, Curtis and Richmond 1974) The locus
determining the resistance was called irp (intrinsic
resistance to penicillins). The RP1 plasmid was found to
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protect P.aeruginosa from the lytic action of EDTA and
polymyxin B, as well as from the effects of cold shock
(Kenward et_ al_ 1978). Shipley and Olsen (1974) had described
how the tetracycline resistance loci of RP1 may change
the permeability of bacteria carrying the plasmid. They
postulated that a product of RP1 may insert into the cell
membrane blocking the normal channels or altering the elec¬
trostatic properties of the cell surface (Shipley and Olsen
1974). Such a mechanism may affect the penetration of
^-lactams as well as tetracyclines. Other plasmids - R1818
and RTEM were also found to affect the gross physical
properties of the P.mirabilis cell envelope. In this case
increasing the sensitivity of the cells to deoxycholate
(Hesslewood and Smith 1974).
The RP1 amp-1 description was picked up by some workers as a
plasmid-encoded permeability barrier to ^-lactams (Ikeuchi
and Osada 1981). It is believed however that Curtis and
colleagues (1973, 1974) overlooked a basal level of fi-
lactamase production by RP1 amp-1 which was responsble for
the residual ampicillin resistance (Crowlesmith and Howe
1980a,b).
Other resistance plasmids have also been reported to have an
effect on the outer membrane of E. coli and produce ^-lactam
resistance (Iyer et^ ^1_ 1978, Rossouw and Rowbury 1984). In
one study, the plasmid only produced resistance in one type
of strain - E. coli B/r and not in the E. coli K12 strains
(Iyer et^ aj_ 1978).
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Irvine et ^1_ (1981) have also reported that hypersensitivity
to ^-lactam antibiotics can also result from changes in
outer membrane proteins.
5.2.2 Lipopolysaccharide Changes Associated with Resistance to
^-lactams
Changes in lipopolysaccharide (LPS) have been most fully
studied in S. typhi murium (Sanderson et_ jal_ 1974, Koplow and
Goldfine 1974, Ames et_ _al_ 1974, Nikaido 1976, Prehm et_ _al_
1976, Janzer et_ aj_ 1981). Alterations in the LPS could
potentially produce changes in sensitivity to antibiotics.
Although LPS mutants show increased susceptibility (Tamaki et
al 1971 Coleman and Leive 1979), mutations correlating with
^-lactam resistance have been reported in P.aeruginosa
(Godfrey et ^1_ 1984). Two of the mutants differentiated
between ^-lactams on the basis of relative hydrophobicity
(hydrophilic ^-lactams were less effective). As no outer
membrane protein changes were seen in these two strains,
it was postulated that LPS may have an interaction with the
porin channels themselves and it is therefore difficult to
separate changes in LPS from the possible affects on the
porins (Angus et ^1_ 1982).
Changes in whole cell lipid content may also alter ^-lactam
susceptibility (Dunnick and O'Leary 1970, Legaskis et ^1_
1978, Lysko and Morse 1981). Increases in the relative
concentrations of lipid have been reported to produce
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resistance to methicillin, cloxacillin and penicillin G
in S.aureus, S.faecal is and B.subtilis (Hugo and Stetton
1966). ^-lactam resistance in S.marsescens was also
attributed to an increase in extractable lipid and
phospholipid (MiHer et al 1973).
5.2.3 Alterations in Penicillin Binding Proteins
Decrease in the amount of PBP or the affinity of PBP(s) for
^-lactam antibiotics can result in a significant degree
of resistance to these compounds (Park et aj_ 1971). Spratt
(1978) isolated E.coli mutants with reduced binding to PBP2.
Such strains are resistant to mecillinam and thienamycin
which have been shown to have a high affinity for PBP2.
(Spratt 1978, M.S.D. Product Monograph 1985). PBP mutants
have also been isolated from other species (Curtis et al
1978, Barbour 1981, Hartman and Tomasz 1981, Kleppe et al
1982).
Such mutants have also been found amongst clinical strains.
In cystic fibrosis patients ^B-lactam resistant P.aeruginosa
emerged with modified PBPs (Godfrey et aj_ 1981). Changes in
PBPs associated with ampicillin resistance have also been
reported in H.influenzae (Parr and Bryan 1984, Mendelman et_
al 1984). PBP alterations have also been reported in Gram
positive cocci (Hakenbeck et a1_ 1980, Georgepapadakou et_ al
1982).
80
^-lactam resistance resulting from alterations in PBPs are
most common in bacteria which produce 1ittle ^-lactamase, or
have only recently acquired piasmid-mediated ^-lactamases
e.g. S.pneumoni ae (Hakenbeck et_ ^1_ 1980, Fontana et_ £l_
1983), N.gonorrhoeae (Dougherty et_ ^1_ 1980) and H.inf 1 uenzae
(Parr and Bryan 1984, Mendelman et_ _al_ 1984). ^B-lactamase
stable antibiotics have been used to treat S.aureus infections
for some time and alterations in PBPs are an important
resistance mechanism (Georgopapadokou et_ £]_ 1982, Hartman and
Tomasz 1984). The use of ^-lactamase stable jl-lactams in the
treatment of Gram negative bacterial infections may result in
a concomitant increase in PBP mutants amongst this population.
Many of the newer compounds show a high affinity for PBP3 in
E. coli and therefore low level resistance could arise by
mutation in this one PBP (Spratt 1983). However, other
^-lactams bind to more than one essential PBP and, therefore,
resistance would require a decrease in the affinity of each
of thfcst essential PBPs. Such mutations, which produce a
generalised reduction in PBP binding have been reported
(Mackenzie et al_ 1980, Godfrey and Bryan 1982). In S.aureus
it is thought that further mutations must occur to allow the
organism to survive with only one enzymically active PBP
(Spratt 1983).
Multiple mutational events can confer higher levels of
B-lactam resistance eg N.gonorrhoeae (Dougherty et_ al_ 1980).
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Hyperproduction of the susceptible PBP target site may also
be a B-lactam resistance mechanism. High level resistance in
P.aeruginosa has been reported associated with an increase
in the levels of production of PBP6, a non-essential PBP
(Godfrey et_ 1981).
As with permeability mutations, PBP alterations may also
result in increased susceptibility to ^-lactam antibiotics.
The mutation in this case results in an enzyme with increased
binding affinity for the ^-lactam (Rodriguez and Saz 1975,
Noguchi et_ al_ 1980).
5.2.4 Appearance of Novel PBPs (A New Insusceptible Target Site)
Enterococci and S.aureus may synthesize a new PBP which can
take . over the functions of all the other PBPs. this novel
PBP then becomes essential for growth. The enzyme has a
lower affinity for B-lactams, especially methicillin and the
cephalosporins, and the cell becomes ^-lactam resistance by
virtue of this insusceptible target site (Fontana 1985).
This low affinity PBP (PBP21) is inducible and an increase
in the amount of protein correlates with an increase in
resistance in S.pneumoniae (Fontana et_ jil_ 1983) and 5.aureus
(Hartman and Tomasz 1984). In S.aureus the expression of
methicillin resistance in influenced greatly by growth
conditions. The low-affinity PBP being best expressed at
30°C and low pH (Sabath 1977). ^-lactam susceptible cells do
not have any detectable low-affinity PBP even under the above
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conditions (Brown and Reynolds 1980, Hartman and Tomasz
1984).
This inducible low-affinity PBP is not essential for normal
growth and therefore a new approach may be required in order
to direct ^-lactams at non-essential low-affinity targets.
It is thought that PBP2' may be a detour enzyme of PBP2
and/or PBP3 (Ubukata et_ _aj_ 1985) such a resistance mechanism
may also develop in Gram negative bacteria.
Transferable PBP resistance mutations have not been reported
however it is possible that the flanking of a chromosomal
gene by insertion sequences may result in such an event
(Spratt 1983).
5.2.5 Tolerance to ff-lactam Antibiotics
Tolerant organisms appear to be "defective" in their
production or the action of cellular autolytic enzymes (Home
and Tomasz 1977, Kitano and Tomasz 1979a,b Bergeron and
Lavoie 1985). E.coli PBP1, has been implicated in triggering
the autolytic system (Kitano and Tomasz 1979b) and therefore
changes in PBPs may affect tolerance as well as direct
susceptibi1ity.
There have been reports of treatment failures, resulting,
from tolerant organisms, which support the clinical
significance of this resistance mechanism (Broughton et_ aj_
1976, Feldman 1976, Walker et_ al_ 1976, Brennan and Durack
1983).
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The Aims of This Thesis
1. To identify the principal resistance mechanisms to B-lactam
antibiotics in a population of aerobic, clinical, Gram
negative bacteria.
2. To identify the B-lactamases present within this population.
3. The characterization of novel, transferable S-lactam
resistance mechanisms.
4. To establish the principal mechanisms of resistance in an
ampici11 in resistant H. influenzae population.
5. To determine the role of the pi asmid-mediated B-lactamases in
B-lactam resistance.
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II. MATERIALS AND METHODS
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1. Bacterial Strains
The Gram negative aerobic clinical strains used in this
thesis were all collected during the period 1983/84. All
strains were maintained at -70°C in nutrient broth with 10%
glycol v/v. Details of the individual strains are given in
the appendix.
The standard bacterial strains used in this thesis are
listed in Table 3, and standard bacterial plasmids and
bacteriophages are detailed in Table 4. The standard B-
lactamase producing strains are listed in Table 5.
2. Information Storage and Retrieval
Information concerning each bacterial strain was recorded on
a computer data form and stored on the database program
dBASE III (Ashton-Tate, Milton Keynes). The database system
was used for the identification and removal from the
survey of repeat isolates from individual patients.
3. Materials
3.1 Antimicrobial Agents
The antimicrobial agents and their suppliers are listed in
Table 6. Nitrocefin (87/312) was provided by Glaxo Group
Research Ltd. All were supplied sterile. B-lactams were
prepared by aseptically adding sterile sodium phosphate
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Table3 StandardBacterialrains BacterialStrainMa kersRefer nce E.coliK12J6 E.coliK12J6 -x K12J6 -2K12J53 114 K12PB 150 NCTC10418 P.aeruginosaA08 P.aeruginosaA0381 P.aeruginosaA01670 P.aeruginosau21E.coli E.coli E.coli E.coli E.coli P.aeruginosaNCTC10662 H.influenzae1184Epro"his~trp"lac~ pro"his"trp~Tac-NaR pro'his"trp"lac~RfR pro'met" prototroph his'recASmRNa prototroph met'i1v" leu"SmR ade'leu"RfR i1v"leu~RfRSmR prototroph prototroph
Bachmann(1972) Bachmann(1972) Bachmann(1972) Bachmann(1972) Amyes(1974) GivenbyProfessorN.Datta IsaacandHolloway(1968) StanisichndHolloway(1969) MillsandHolloway(1976) Jacoby(1974) GlaxoroupResearchCulture
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Hedgestal(1974) HedgestaT(1974) Petrocheilout£ _(1977) Medeirostal(1985) MattheweT~aT~(1979) Simpsonetal(1983) LivermoreancTJo es(1986) Hedgesta^(1985) EliassonndKamme(1985) Rubineta]_(1981) Takahashietl_(1983) Takahashietl(1983) DaleandSmitTT"(1974) DaleandSmith(1974) Medeirostaj_(1985) Medeirostal(1985) MedeirostaT(1985) Medeiros(?taT(1985) Medeirostal(1985)
P.aeruginosa/...
Table5(continu d) Standard(^-l ctamaseProducingStr in Plasmidor(3-l cta ase BacterialStrains _transposonproducedReferen e P.aeruginosau21 P.aeruginosau21 P.aeruginosau21 P.aeruginosaDalgle sh E.coliD31 A1caligenessp. K.pneumoniae1 K.pneumoniae14 E.cloacaeHennessey C.diversus2046E E.cloacaeP99RPL11PSE-1 R151PSE-2 Rmsl49PSE-3 pMG19PSE-4 R22KaCEP-1 PLQ3CEP-2 K1 K14 EnzymeA 2064E P99
MatthewndSykes(1977) Matthew(1978) Sawadaetl(1974) Furth(TWIT)" Bobrowski£tal(1976) LevesquetaT~(1982) MarshalletT(1972) MatthewTv?H rris(1976) Hennessey(1967) SimpsonandPleste(1983) Flemingtal(1963)
aA=eromonas
13B=ranhamella
Table6 Antimicrobialgents Compound ChemotherapeuticAgents Ampicillin Aztreonam Benzylpenicillin Carbenicil1in Cefamandole Cefazolin Cefotaxime Cefotetan Cefoxitin Cefsulodin Ceftazidime Ceftriaxone Cefuroxime Cephaloridine Cephradine Chioramphenicol ClavulanicAcid CIoxacil1in Colistin/...
Supplier
BeechamR searchLabor tories,Middlesex E.R.Squibbando s,Middlesex GlaxoLaboratoriestd.,reenf rd,Middlesex BeechamR searchLabor tories,Middlesex DistaProductsLtd.,Basings oke EliLi lyandCo.td ,Basingstoke RousselLaboratoriestd.,Middle x I.C.I.Ltd ,Macclesfield Merck,SharpandDohmeLtd.,H rts Ciba-GeigyLa oratories,Horsham GlaxoLaboratoriestd.,reenf rd,Middlesex RochePr ductsLtd.,Herts GlaxoLaboratoriestd.,reenf rd,Middlesex GlaxoLaboratoriestd.,reenf rd,Middlesex E.R.Squibbando s,Middlesex Parke-Davis,ontypoolGw nt GlaxoroupResearchLtd.,re nf rd,Middlesex BeechamR searchLabor tories,Middlesex
Table6(continu d) AntimicrobialAgents CompoundSupplier ChemotherapeuticAgents Colistin Gentamicin Kanamycin Methicil1in Moxalactam NalidixicAcid Norfloxacin Oxytetracyclinehydrochloride Piperacil1in Rifampicin Spectinomycin Streptomycin Sulphamethoxazole Trimethoprim NonChemotherapeuticAgents NitrocefinGlaxoroupResearchLtd.,Gr enf rdMiddlesex MercuricchlorideSigmaChemicalo.,Ltdondon Allantimicrobialconcentrati nsarexpressedintermofhbas .PharmaxLtd.,Bexley,K nt RousselLab ratori std.,Middlesex BristolLaboratories,Middle ex BeechamRes archLaboratories,Middl sex EliLi lyandCo.td ,Basingstoke SterlingWinthropLaboratories,Su rey Merck,SharpandDo meLtd.,Herts GlaxoLabor toriesLtd.,Greenf rdMiddl se LederleLaboratoriesDivision,H n s LePetite,Milan,Italy UpjohnLtd.,CrawleySussex GlaxoLabor toriestd.,Greenford,Middl se WellcomeFoundationLt .,K nt WellcomeFoundationLt .,K nt
buffer (pH 7.0, 50mM). Preparations of sulphamethoxazol e,
nalidixic acid and norfloxacin were made by dissolving the
compound in N/10 NaOH and then the solution was made up
aseptically with sterile distilled water. Solutions of
rifampicin and chloramphenicol were made by first dissolving
these drugs in a minimum volume of absolute ethanol and then
the solution was made up with distilled water. Nitrocefin
was dissolved with the aid of dimethyl sulphoxide (DMSO)
(Anal aR, BDH Chemicals Ltd., Poole) and made up in sodium
phosphate buffer (pH 7.0, 50mM). All other compounds listed
were dissolved directly in sterile distilled water.
Compounds, with the exception of nitrocefin were made up
freshly as required; nitrocefin stock solution (500mgL~l)
could be stored for up to one week at 4°C in the dark.
3.2 Buffers
Sodium phosphate, sodium acetate and Tris-HCl buffers were
prepared as described in Data for Biochemical Research
(Oxford University Press, 1974). Other specialist buffers
are described in the appropriate methods section.
4. Media
4.1 Complex Media
The complex media used were as follows. Nutrient Broth No.
2 (CM67), Isosensitest Broth (CM473), Brain Heart Infusion
Broth (CM225), Diagnostic Sensitivity Test Agar (CM216),
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Columbia agar base (CM331), MacConkey agar (CM76), all
Oxoid, Basingstoke, Hants; Pseudomonas isolation agar
(Difco, Detroit, Michigan), 20mls of glycerol per litre was
added to this agar before autoclaving.
Minimal Medium
Double strength minimal salts medium (DM) was prepared as
described by Davis and Mingioli (1950) (Table 7).
Table 7







The compounds were dissolved in 1 litre of distilled water
in the order given and then 50ml quantities of base were
distributed and autoclaved at 15psi for 15 minutes.
Media was diluted to single strength before use. Supplement












D-glucose BDH 200mgml-1 2.8mgml Autoclaving
L-adenine BDH 5mgml-1 50mgL~l Steaming
L-histidine BDH 5mgml"1 50mgL*l Steaming
L-isoleucine BDH 5mgml 50mgL"l Steaming
L-leucine BDH 5mgml-1 50mgL-l Steaming
L-methionine Si gma 5mgml-1 50mgL~l Steaming
L-proline BDH 5mgml-1 50mgL"l Steaming
l-tryptophan Si gma 2.5mgml-1 50mgL"l Steaming
L-valine BDH 5mgml~1 50mgL~l Steaming
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4.3 Preparation of Plates
DM minimal medium plates
Minimal plates were prepared by adding appropriate
supplements (Table 8) aseptically to 50mls double-strength
DM base. Antimicrobial drugs were added aseptically where
necessary to give the required concentration. Finally,
1.4ml s of a 20% glucose solution were added and the volume
made up to 60ml s by the addition of sterile distilled water.
This was mixed and added to 40mls of molten bacteriological
agar no. 1 (3.75g) (Oxoid). After rolling gently to mix,
the plates were poured and once set, dried inverted at 55°C
for 20 minutes. All plates were used within one week of
manufacture.
Plates containing complex media
Complex media were made up according to the manufacturer's
instruction and were autoclaved at 15psi for 15 minutes
before the plates were poured. Plates containing
antimicrobial agents were made by adding the required
concentration of drug solution to molten Oxoid Diagnostic
Sensitivity Test Agar (DSTA) cooled to 55°C. Plates
contained approximately 15mls of agar, after setting, all
the plates were dried, inverted at 55°C for 20-30 minutes.
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Preparation of chocolate blood agar plates
Chocolate blood agar plates were prepared by adding
defibrinated horse blood (SR50; Oxoid, Basingstoke, Hants.)
to molten Columbia agar base to a final concentration of 5%
v/v and maintaining at 95°C for 5 minutes until the medium
assumed a uniform "chocolate" colour.
Preparation of lysed blood DSTA plates
Lysed horse blood DSTA plates (LBD) were prepared as
follows. Molten DSTA was made up according to the
manufacturer's instructions, autoclaving as before, and
cooling to 55°c. Saponin (1%, v/v, BDH) was added to lyse
the defibrinated horse blood (SR50, Oxoid) the lysed horse
t
blood was added to the agar to a final concentration of
0.25% and B-nicotinamide adenine dinucleotide (B-NAD)
(Sigma) was added at a concentration of lOmgL-1. Solutions
of antimicrobial agents were added to the appropriate
concentrations, as required, before plates were poured.
5. Methods
5.1 Identification of Bacterial Species
The API 20E microtube system (API System, S.A., France) was
used for the identification of all strains except
H. inf1uenzae. Pseudomonas isolation agar (PIA) was used to
confirm the identification of Pseudomonas species.
H. i nf 1 uenzae were defined as Gram negative bacilli
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requiring both haemin (factor X) (Sigma) and B-NAD (factor
V) (Sigma) for growth. These growth requirements were
confirmed by disk testing (Mast Laboratories, Liverpool) on
Nutrient agar plates (Columbia agar base) with disks
containing either factor X or V or both.
5.2 Biotyping and Serotyping of H. influenza Strains
Biotyping (Kilian 1976, Gratten 1983) and serotyping (Ingram
et_ aj_ 1979) were kindly carried out by Mr M. Croughan of
Edinburgh's City Hospital.
5.3 Viable Counts
Serial dilutions of bacterial cultures were made using 1 in
10 and 1 in 100 dilutions in DM base. Suspensions,
appropriately diluted were vortexed (Rotary Mixer,
Gallenkamp) and 0.1ml amounts spread with a sterile glass
spreader on to solid medium.
All plates were incubated inverted at 37°C for 18 hours or
in the case of DM medium, for 66 hours.
5.4 Selection of Cephaloridine Resistant and Ampicillin
Resistant Strains
A 10~4 dilution of an overnight, shaken, nutrient broth
culture of each organism was made by serial dilution in
single strength DM base with no supplements. A Denley A400
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Multipoint inoculator was then used to deliver a 2pl amount
of this suspension on to the surface of DSTA plates
containing either ampicillin or cepha1oridine at 8mgL~l
(Garrod et aj_ 1981). The inoculum suspension contained
approximately 106CFU ml~l.
5.5 Sensitivity Testing Against Antimicrobial Agents
Sensitivity to compounds, other than cephaloridine and
ampicillin, were determined. The compounds in Table 6 were
incorporated into the agar at a concentration of 10mgL-l.
The exceptions were sul phamethoxazole and spectinomycin used
at 100mgL*l; mercuric chloride used at 10"^M; norfloxacin
used at O.lmgL*! and rifampicin used at 20mgL_l.
Each plate was inoculated with the two control organisms
E. col i NCTC 10418 and P. aeruginosa 10662. A DSTA plate
containing no antimicrobial agents was also inoculated as a
positive control. Plates were incubated, inverted for 18
hours at 37°C. Growth at the point of inoculation defined
resistance to the included compound.
Ampicillin resistant H. inf 1 uenzae were selected by a
modification of the above method. Cultures were grown on
chocolate blood agar plates which were incubated for 18
hours at 37°c in 5% CC>2* Two colonies from this plate were
inoculated into 4.5mls of BHI broth supplemented with 8-NAD
(10mgl_-l) and 10mgl_-l haemin (Sigma) and incubated with
shaking for 18 hours at 37°C. Broth cultures were diluted
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10-4 by serial dilution in DM base providing a suspension of
approximately lOSCFU ml_l.
This suspension was inoculated on to the surface of LBD
plates containing the appropriate antimicrobial agent.
H. i nf 1 uenzae were screened for resistance to lmgL"l
ampicillin, other compounds were used at the same
concentrations as before. The control organism was used as
H. inf1uenzae 1184E. Plates were incubated for 18 hours at
37°C in 5%C02; resistance was defined as before.
5.6 Minimum Inhibitory Concentration (MIC) Determination on
Sol id Media
A 10-4 serial dilution of an overnight, nutrient broth
culture was made in single strength DM (approximately 106CFU
ml-1) and 2pl of this was inoculated as before on to the
surface of DSTA plates containing anti microbial agents.
Drugs were incorporated into the plates in two-fold serial
dilutions and the MIC was expressed as the first
concentration permitting no visible growth. Controls were
included as before to ensure the reproducibility of
sensitivity testing results.
MICs for H. inf1uenzae strains were determined similarly
with the modifications given in the previous section. The
MICs of ampicillin for the H. inf1uenzae strains were also




Overnight nutrient broth cultures were serially diluted 1 in
107 in DM base lacking glucose. 0.1ml aliquots of this
suspension were spread with a sterile glass spreader on
nutrient agar plates (or DSTA plates containing an
antimicrobial agent where appropriate) and incubated
inverted for 12 hours at 37°C. These plates, containing
around 150 colonies, were then replica plated (Lederberg and
Lederberg 1952).. The plates were inverted over a square of
sterile velvet held on a cylindrical rubber block (8cm
diameter) by a perspex collar. The agar surface was pressed
gently against the pile and then removed. Replica plates,
marked for subsequent orientation, were inverted in turn
over the fabric and pressed against it so as to pick up a
sample of each colony adhering to the pile. Plates were
then incubated for 12 hours at 37°C.
5.8 Testing for Loss of Resistance Markers
i
Single colon^s were streaked on to DSTA plates containing
one of each of the original strains' antimicrobial drug
resistance markers, and a DSTA plate without antimicrobial
drugs as a positive control. Plates were incubated at 37°C
overnight. No growth along the streak line on any of the
selective plates indicated loss of that particular marker.
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5.9 Plasmid Transfer
Plasmid transfer experiments were performed by inoculating
donor cells from a fresh MacConkey agar plate into 4.5mls of
Nutrient broth no. 2 (Oxoid) and recipient cells similarly
from a single colony into another 4.5ml s of nutrient broth.
Cultures were incubated shaking (Gal 1enkamp Orbital Shaker)
at 37°C overnight. After a viable count of a 10-7 dilution
on MacConkey agar was performed, 0.1ml of the donor culture
and 1ml of the recipient culture were mixed in 4.5mls of
fresh pre-warmed nutrient broth. The mating mixture was
incubated statically at 370C for the required time which
varied from 1 to 18 hours (Smith 1969) as specified. At the
end of this time the mixture was mixed on a Whi rl emixer to
separate donor and recipient cells which were then collected
by centrifugation at 4,000rpm for 20 minutes (Heraeus Christ
Bactifuge). The pellet was resuspended in 5.6ml s of DM base
without supplements (equivalent to the volume of the
original mating mixture) and further serially diluted to
10-4 in dm base. A 0.1ml amount of each dilution was spread
on the surface of selective DM agar plates which would allow
only for the growth of a piasmid-containing recipient
strain. Controls were made by spreading 0.1ml amounts of
washed donor and recipient cells on to the same sel ective
plates. The plates were incubated for between 48 - 66
hours. Resultant transconjugant colonies were purified by
streaking out on identical DM selective plates. Frequency
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of plasmid transfer was expressed per viable donor cell as
described by Amyes (1974).
5.10 Plasmid Mobilisation
A 0.1ml amount of an overnight nutrient broth culture of the
donor strain containing a standard R plasmid was added to
lml of recipient culture in 4.5mls of pre-warmed nutrient
broth. The recipient strains possessed plasmids or
chromosomal genes which were not able to promote their own
transfer. The mating mixture was incubated statical ly at
37°C overnight. The mixture was then spread on to DM agar
plates selective for R plasmid containing recipients.
Plates were incubated for 48 hours at 37°C and the resultant
colonies purified on the same selective plates. R plasmid
transfer from one of these transconjugants to E. col i J62~2
was performed as described above. The resultant
transconjugants were tested for possession of the gene from
the original culture by plasmid isolation and testing for
markers present in the original recipient.
Mobilisation experiments were also carried out with the
transfer factor X+ (Sharma et a_l_ 1984) as described by Young
et al (1986).
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5.11 Creating a Carbenicillin/Ampicillin Sensitive Derivative of
R18 by Mutagenesis and Replica Plating
A 0.5ml amount of an overnight nutrient broth culture of
P. aeruginosa PA01670 containing the plasmid R18 was taken
and added to 4.5mls of pre-warmed nutrient broth and shaken
at 370C for 1.5 hours to get the culture into logarithmic
(log) growth. A 100jj 1 amount of methane sulfonic acid,
ethyl ester (EMS) (Sigma) was added to the culture, which
was then vortexed. The culture was incubated at 37°C for 1
hour statically. The culture was then serially diluted to
10-2 in warm nutrient broth and the diluted culture was
shaken overnight at 37°C. A 10-6 dilution of this culture
was plated on to DSTA plates containing kanamycin (20mgL"l)
(an R18 selectable marker). The plates were incubated
overnight and the resultant colonies were replica plated as
previously described, on to DSTA plates containing
kanamycin, tetracycline (20mgL-l), or carbenici 1 1in
(200mgL-l) and a DSTA plate. All carbenici11 in sensitive,
and kanamycin, tetracycline resistant colonies were isolated
and purified on tetracycline (20mgL-l). The loss of
carbenici11 i n resistance (TEM-2) was confirmed by
isoelectric focusing of a B-lactamase extract and resistance
testing on carben i ci11in (60mgL-l). The resultant
carbenici 11 in sensitive plasmid was designated -R18-18.
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5.12 Isolation of Plasmid DNA
Three small scale methods were used for the isolation of
plasmid DNA.
5.12.1 The method of Birnboim and Doly (1979).
Without modification.
5.12.2 The method of Kado and Lui (1981).
Cells were grown shaking in 4.5mls of nutrient broth
overnight and pelleted by centrifugation (4,500rpm, 20
minutes, Christ Bactifuge). Optimum lysis was obtained by
holding cells at 60°C for 20 minutes. No further
modifications were made.
5.12.3 The method of Takahashi and Nagano (1984).
Cells were grown shaking in 4.5mls nutrient broth overnight
at 37°C and harvested by centrifugation (4,000rpm, 15
minutes, Christ Bactifuge). The method suggested by the
authors was then followed exactly.
All solutions of plasmid DNA not analysed directly by
agarose gel electrophoresis were stored at -20°C until
required.
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5.13 Preparation of DNA for Restriction Endonuclease Digest
Plasmid DNA for restriction endonuclease digest was
extracted as described by Takahashi and Nagano (1984).
To lOOpl of plasmid DNA solution were added a further 350pl
of TE (lOmM Tris-acetate, 2mM disodium EDTA, pH 8.0) buffer
and 50n1 of acetate buffer (1M sodium acetate, lOmM Tris-
acetate, 2mM disodium EDTA, pH 8.0), and this solution was
mixed. The DNA solution was ethanol precipitated with 2
volumes of cold (-20°C) 95% ethanol for 5 minutes and
collected by centrifugation (2874g, 5 minutes, 4°C, MSE
Microcentaur) then the pellet was dried in a vacuum
dessicator (60 minutes). The pellet was dissolved in 60pl
of a DNAse free RNAse solution (50mgL~l) (Sigma) and
incubated at 370C for 30 minutes.
Ten microlitres of the plasmid DNA solution was removed to a
sterile Eppendorf tube. To this was added 2pl of the
appropriate restriction enzyme buffer (10 times strength,
supplied by NBL Enzymes Ltd., Northumberland), 7pi 1 of
sterile distilled water and 5-10U of the required
restriction endonuclease. The tube was incubated at 37°c
for 3 hours and the reaction was terminated by cooling to
40C and adding 10pi 1 of loading buffer (0.1% SDS, 0.05%
bromophenol blue, 25% sucrose and 5mM sodium acetate
(Sigma)). The sample was analysed by agarose gel
electrophoresis using as molecular weight markers, DNA
digested with HindIII (Murray and Murray 1975).
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5.14 Agarose Gel Electrophoresis
Horizontal slab gel el ectrophoresis was performed by the
method of Meyers et aj_ (1976). A 30pl volume of plasmid DNA
was mixed with lOpl of loading buffer and placed into the
wells of a horizontal slab gel (14 by 25 x 0.5cm) consisting
of 0.5% agarose (Sigma) in Tris-acetate buffer (40mM Tris-
acetate, 2mM disodium EDTA, pH 7.9). Similarly, the 30pl of
restricted DNA samples (which included loading buffer, see
above) were loaded into a gel of 0.7% agarose.
The samples were el ectrophoresed initially at 200V to allow
the DNA to enter the gel and then plasmid DNA was
electrophoresed overnight at 70V and restricted DNA at 40V
overnight. The gels were run submerged in Tris-acetate
buffer (40mM Tris-acetate, 2mM di sodium EDTA, pH 7.9). The
gels were stained with a 0.75mgL_l solution of ethidium
bromide in the Tris-acetate buffer for 30 minutes. DNA was
visualised over a long-wave ultra-violet light source
(Ultra-violet Products Inc., Cambridge). The distance
travelled by DNA through the gel is inversely proportional
to the logarithm of its molecular size.
Photographic negatives of DNA agarose gels were prepared on
Kodak Plus-X pan film using a 5 x 4 inch plate camera fitted
with a Wratten 22 orange filter.
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5.15 Incompatibility Group Testing Using Phage PR4
Phage PR4 specifically lyses bacterial cells containing
plasmids of inc P , N or W. To determine whether a plasmid
of these inc groups was present in a strain, 0.1ml log phase
culture was spread on to the surface of a nutrient agar
plate and allowed to dry. A phage suspension (lO^pfu ml-1)
was spotted on to the surface of the plate and the plate was
incubated overnight at 37°C. Lysis indicated that the
strain contained a plasmid of inc P, N or W.
5.16 Enrichment of a Bacterial Culture for Strains Which Had
Lost an incP Plasmid
Phage PRR1 specifically lyses bacterial eel 1 s containing
i ncP plasmids. The phage (lOOpl of a lO^pfu ml
suspension) was added to a log phase nutrient broth culture
of the i ncP plasmid containing strain, and gently mixed.
The culture was then incubated statically overnight at 37°C.
The presence of the phage PRR1 enriches the culture for
strains which have spontaneously lost the incP plasmid.
The culture was serially diluted to 10-6 -jn dm base and
0.1ml was plated on to MacConkey agar plates. Individual
colonies were then tested for the loss of a selectable
plasmid marker as previously described. Loss of the plasmid
was confirmed by DNA agarose gel electrophoresis.
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5.17 Nitrocefin Spot Test for B-lactamase Activity
Single colonies of bacteria were spotted with a 50mgL~*
solution of nitrocefin (O'Cal 1aghan _et a_l_ 1972) for B-
lactamase activity. The intact substrate is yellow but
becomes red when the B-lactam bond is broken. A colour
change of the nitrocefin from yellow to red within 5 minutes
was taken as positive reaction.
5.18 B-lactamase Preparation
5.18.1 Large scale preparation of crude cell extracts
B-lactamase extracts were prepared as described by Simpson
et_ aj_ (1980). Overnight cultures were made in 1 litre
volumes of nutrient broth, incubating overnight with
shaking. Cells were harvested at 5,000g for 15 minutes at
4°C (Sorval1 RC-5B Refrigerated Superspeed Centrifuge, Du
Pont Instruments). The pellet was resuspended in 15ml s of
20mM, pH 7.0 sodium phosphate buffer. Cells were then
disrupted by ultrasonication with constant cooling (8pm, 1
minute x 3, MSE Soniprep 150, MSE Instruments, Crawley).
Cell debris was removed by centrifugation at 38,000g for 15
at 4°C (Sorval 1). The supernatant crude enzyme preparation
could then be stored at -20°C until required.
In order to prepare a store of standard B-lactamase enzymes
100ml cultures were used, resuspending cells in 5mls of
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phosphate buffer. Crude standard enzymes were stored in lml
aliquots for sequential use.
5.18.2 Small-scale preparation of crude cell extracts
Small amounts of B-lactamase enzyme were prepared according
to the method of Livermore and colleagues (1984). Cell
cultures were grown on 2ml nutrient agar slopes, these were
incubated for 18 hours at 37°C. Cells were removed from the
surface of the agar slope by addition of 1ml of sodium
phosphate buffer (20mM, pH 7.0) and thoroughly resuspended.
The cells were then disrupted at 4°C by u 1 trasonication
(8pm, 30 seconds, Soniprep). Cell lysate was cleared using
an MSE Microcentaur centrifuge (ll,500g, 10 minutes, 4°C).
Cleared lysate was stored at -20°C until required.
5.19 B-lactamase Enzyme Induction
A single colony from a fresh agar plate was inoculated into
4.5mls of nutrient broth and incubated shaking overnight at
37°C. One ml of this culture was added to 100ml s of pre-
warmed nutrient broth and shaken for 2 hours at 37oc.
Cefoxitin, a well documented inducer of B-lactamase
production (Minami et a_l_ 1980) was then added to the growing
culture at one-quarter of the MIC value for that particular
strain and incubation was continued for a further 16 hours.
B-lactamase enzymes were extracted as previously described
for large-scale preparation of crude enzyme extracts.
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5.20 Assessment of B-lactamase Activity of Crude Enzyme
Preparations
Samples of 25pl of crude B-lactamase extract were added to
75pl of nitrocefin solution (50mgL-!) in a microtitre tray
(Cooke Microtitre System, Sterilin). The reaction time,
defined as a colour change from yellow to red, was taken as
an indication of the B-lactamase activity of the enzyme
preparation (Simpson et al 1980).
5.21 Preparative Isoelectric Focusing (IEF)
B-lactamase crude extracts were purified by preparative IEF.
The procedure and apparatus is fully described by Winter et
al (1975).
A gel slurry was prepared consisting of crude enzyme and
5mls of ampholines (LKB, Bromma, Sweden, various pH ranges),
made up to 100ml s with distilled water. Five grams of
Ultradex (LKB, Bromma, Sweden) was slowly dissolved in this
enzyme/ampholine solution which was then weighed and poured
into the flat bed electrofocusing tray. Wicks, soaked in
ampholines (pH 3.5-10.0), were first placed at either end of
the tray and the gel tray was placed on a level surface and
25% of the initial gel slurry weight was evaporated off by
placing the gel next to an electric fan.
The prepared gel was then el ectrofocused at 8 watts, 1500V
for 18 hours (LKB, 10-2000V Power Pack). After focusing,
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two strips of paper soaked in nitrocefin solution (50mgL-l)
were placed at either side of the gel to visualise the
focused S-lactamase activity. The gel was then fractionated
with a 20 zone grid (LKB) and the fractions collected with a
spatula. Each was transferred to a small column (LKB) and 2
mis of sodium phosphate (20mM, pH 7.0) buffer was applied to
each, enough to resuspend the gel bed and el ute the enzyme
fraction.
The enzyme fractions could be stored at -20°C until required
and their purity confirmed by analytical IEF (see over).
Often a second round of preparative IEF was carried out on a
set of pooled fractions using an appropriate narrow pH
ampholine range.
5.22 Analytical Isoelectric Focusing
The method used for analytical isoelectric focusing (IEF) of
B-lactamases is described by Matthew £t a_l_ (1975). The
crude B-lactamase extracts were focussed on a glass plate
supporting a thin layer of polyacry1 amide gel containing
carrier ampholines. The composition of the gel mixture is
described in Table 9.
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Table 9







(TEMED) in distilled water
Si gma 0.2 ml 0.25mgL-1
40% ampholines w/v (various
pH ranges)
LKB 2.0 ml 2% w/v
Acrylamide (lOOg) plus
methylene bisacrylamide
(2.7g) in water (300mls)
BDH 9 ml acrylamide 70mgL*l
bisacrylamide 2gL"
Distilled water 25 ml
Riboflavin (20mgL"l) Si gma 4 ml 2mgL-1
Details of the preparation of the IEF gels are given in
Matthew et aj_ (1975).
Samples of the B-lactamase enzymes (up to 100jj 1) were
applied near the anode on the surface of the gel. The
loading of B-lactamase on each track was equalised with
respect to enzyme activity (see previously). Isoelectric
focusing was carried out at 4°C at 1 watt (maximum voltage
500V) for around 18 hours (LKB 10-2000V Power Pack). The pH
of the gel was read at the end of each run using a miniature
flat-ended combined glass electrode (Pye-Unicam 403,
30M8E07) at 0.5cm interval s from the cathode to the anode.
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After pH measurements, the gel was stained for B-lactamase
activity and photographed.
5.22.1 Staining polyacrylamide gels for B-lactamase activity
B-lactamase enzyme activity was detected with nitrocefin. A
sheet of Whatman No. 54 paper which had been dipped in a
solution of nitrocefin (500mgL~l) was laid over the surface
of the gel, taking care to avoid trapping air bubbles. The
focused bands of B-lactamase activity appear red on a yellow
background.
5.22.2 Photography of Analytical IEF Gels
When a focused gel was treated with nitrocefin the B-
1actamase bands appeared gradually and by the time the
weakest bands were visible, the strongest bands had
diffused. Serial photographs were taken to obtain a
complete record. Kodak Ortholith film (35mm) was used with
transmitted light and a Wratten 58 green filter.
5.22.3 Identification of B-lactamase enzymes using analytical IEF
Twelve samples of B-lactamase enzyme could be loaded on each
plate. To give a visual check on focusing lOpl of myoglobin
(lOmg ml -1) (Sigma) was 1 oaded at the edge of each gel . On
primary identification runs all the available tracks were
occupied by test B-lactamase extracts. Subsequently, B-
1 actamases with similar isoelectric points (pi's) and
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patterns of satellite bands were checked for identity with
standard enzymes (Table 5) being run in adjacent tracks.
5.23 Assays of |3-lactamase Activity
5.23.1 Macroiodometric Assay System
The macroiodometric assay system was first described by
Perret (1954) and the revised method (Sykes and Matthew
1979) was followed during this thesis.
5.23.2 Spectrophotometric Assay of B-lactamase Activity
A detectable shift in the ultraviolet absorption spectrum of
penicillins and cephalosporins occurs upon hydrolysis of the
cyclic amide bond in the (3-lactam ring. The wavelength at
which maximum decrease in absorption occurs following
hydrolysis is termed X max. This is determined by
comparing spectra of intact and fully hydro!ysed substrate.
The rate of substrate hydrolysis is assessed by measuring
the rate of decrease in optical density (OD) at \max.
The basic method employed for spectrophotometric assay was
that of O'Callaghan and colleagues (1969). A Pye-Unicam
SP1800 uv/vis spectrophotometer with a thermostatically
controlled cell carrier was used to measure OD. Penicillin
and cephalosporin substrates were prepared at 10"2m and
10-3m respectively in 20mM sodium phosphate buffer (pH 7.0).
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Test and blank cuvettes were prepared and equilibrated at
37°C. The test cuvette contained 0.3ml substrate and 2.6mls
sodium phosphate buffer (20mM, pH 7.0); the blank cuvette
contained 2.9mls buffer. B-lactamase enzyme preparation
(0.1ml) was added to each cuvette and monitoring of the
decrease in 00 at /\max was begun immediately. The initial
linear part of the reaction curve was used to obtain a value
for change in 0D minute-1.
calculation: R = A OP x N x enzyme dilution
ODi x time
where R = pmoles of substrate hydro!ysed minute*^-ml "^enzyme
A0D = change in optical density
N = pmoles substrate in cuvette
(0.3 for cephalosporins, 3.0 for penicillins)
ODj = optical density of intact substrate
Protein concentrations of crude 13-lactamase extracts were
determined as described in a further section and the
specific activity of each enzyme preparation was expressed
per mg protein.
5.23.3 Determination of Michael is Menton kinetics
The Km and Vmax values were obtained by measuring the rate
of hydrolysis at limiting substrate concentrations and
plotting the reciprocal of the substrate concentration
against the reciprocal of the rate by the Lineweaver-Burk
method.
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The Vmax values were normalised with respect to benzyl
penicillin, i.e.:
relative Vmax = (Vmax per pi of enzyme) of substrate x 100
(vmax per pi ot enzyme) of benzyl
penicillin
The efficiency of hydrolysis of the enzyme was obtained by
the same parameter as Pollock's "physiological efficiency"
as outlined by Sykes et aj. (1981b) where efficiency of
hydrolysis = Vmax per pi of enzyme
Km
The relative efficiency of hydrolysis was also normalised
with respect to benzyl penicillin, i.e.:
Relative _ Efficiency of hydrolysis of substrate x 100
efficiency trnciency or hydrolysis or Denzyl
penicillin
5.24 Inhibition of 13-lactamase Activity
The effect of 13-lactamase inhibitors was examined by the
spectrophotometry assay system described above (O'Callaghan
^t a_l_ 1969). Inhibitor studies were performed with
nitrocefin (O.lmM) or benzyl penicillin (ImM) as substrate.
The potential inhibitor was added at the start of the assay
at various concentrations ranging from lOmM to 10~2m in the
case of the cephalosporins. The effect of the inhibitors
was expressed as the concentration required for 50%
inhibition (ID^q) of enzyme activity.
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5.25 Relative Substrate Affinity Index Values
The relative substrate affinity index (RSAI) values of B-
lactamase enzymes against a range of B-lactams were
determined (James 1983). The RSAI value is the ratio of the
ID50 of nitrocefin cleavage to the nitrocefin concentration
used in the assay (50mgL~l). This technique was semi-
automated using a Tikertek Multiscan (Flow Laboratories,
Middlesex). Ten test B-lactams could be simultaneously
assayed against each enzyme as potential inhibitors of
nitrocefin hydrolysis. The adaptations were described by
Eliasson and Kamme (1985). Each assay was carried out in
duplicate.
5.26 Gel Filtration
A Sephadex G75 col umn was prepared as fol1 ows. Sephadex G75
t
(Pharmacia, Uppsala, Sweden) was swollen in a 90°c water
bath for 3 hours in sodium phosphate buffer (20mM, pH 7.0).
The slurry was allowed to cool and then poured carefully
into an LKB (Bromma, Sweden) gel filtration column (50 x
1.5cm2). When the column was full, the top was connected
and the flow started in a downward direction using an LKB
peristaltic pump. The flow rate was adjusted to between 6
and 8mls per hour and the column was washed with sodium
phosphate buffer (20mM, pH 7.0) for 48 hours. The samples
for separation, usually 1ml were applied slowly through the
sample applicator (LKB) and el uted with phosphate buffer.
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Fractions were collected using an LKB ultrorac fraction
collector. Elution was continued until a volume of buffer
equivalent to the total column volume had passed through
(75mls). The column was washed with sodium phosphate buffer
for 12 hours between each run. The fractions containing the
B-lactamase activity were determined by testing samples with
a nitrocefin solution (50mgL-l).
5.27 B-lactamase Enzyme Molecular Weight Determinations
(by the method of Andrews 1964)
The proteins bovine serum albumin (BSA), ovalbumin, B-
1 actogl obul in.oC-chymotrypsinogen and cytochrome C (all
Sigma) were all dissolved at 5mgml-1 and 2ml s were applied
to the Sephadex G-75 column. The position of the peaks of
the protein markers was established by measuring the OD of
the fractions by the method of Waddel1 (1956)0 the position
of cytochrome C was confirmed by measuring the absorbance at
410nm. B-lactamase samples could then be applied to the
calibrated column and its molecular size determined from the
standard curve.
5.28 Protein Estimations
Protein estimations were carried out according to the method
of Waddel 1 (1956) except for penicillin binding proteins
(PBPs) where the Lowry assay system was used (Lowry et al
1951). Both methods have been fully described and compared
by Hesslewood (1973).
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5.29 Raising Antisera to B-lactamase Enzymes
Antisera to the purified 6-lactamases TEM-1, SHV-1, N-29 and
TLE-2 were raised in female New Zealand White rabbits. Dr
A. McColm kindly carried out the animal experiments and the
preparation of the antisera. Three rabbits were immunised
with each B-lactamase and sera from unimmunised animals was
used as a control.
5.30 Auchterlony Gel Diffusion Tests
Auchterl ony gel diffusion tests were carried out with (2.0%)
agarose gels (LKB, Agarose-M), made in 0.05M barbitol buffer
(Sigma) containing 0.2% sodium azide. Ten microlitre
volumes of reactants were allowed to diffuse against each
other for 24 hours in a damp atmosphere (37°c). Gel s were
washed for 72 hours at 4°C in 0.85% saline and then stained
for 1 hour in naphthol blue black (Sigma) solution (0.5%
w/v, 5% glacial acetic acid) before destaining with
methanol :water:acetic acid (45%, 45%, 10% v/v). Precipitin
arcs could then be visualised.
5.31 Immuno Analytical Isoelectric Focusing
Immuno-IEF was carried out according to the method of
Matthew _et _al_ (1975). Pol yacryl amide gels were prepared as
for analytical IEF but cast with 1 ongditudinal slots to allow
the application of antisera (Figure 9). B-lactamase was
applied to the gel which was then focused as before.
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Figure 9
Polyacrylamide gels used for immuno analytical isoelectric focusing.
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Antisera was applied to fill the slots (around lOOpl) and
the gel was incubated at 37°C for 2-3 days to allow for the
formation of precipitin arcs next to the focused 13-
lactamase. The gel was stained with nitrocefin solution
(50mgL*l) which revealed the position of the [3-lactamase and
the precipitin arcs.
5.32 Preparation of Outer Membrane Proteins
Outer membrane proteins were prepared by harvesting (6,000g,
10 minutes, Sorvall) cells from 100ml s of an overnight
culture. This was a nutrient broth culture except in the
case of H. infl uenzae where it was BHI supplemented with 13-
NAD (10mgL-l) and haemin (10mgL-l) as before. The cells
were washed once in sodium phosphate buffer (50mM, pH 7.0)
and the pellet was resuspended in 10mls of the same buffer.
The cells were then disrupted by sonication (8pm, 2 minutes,
Soniprep), and large cell debris was removed from the lysate
by centrifugation (2,500g, 10 minutes, 4°C, Sorval 1 ). The
supernatant containing the OMPs was decanted, n-lauryl
sarcosine (Sigma) was added to give a final concentration of
2% w/v and this was incubated at room temperature for 30
minutes. Sarcosyl-insol uble OMPs were sedimented by
centrifugation (40,000g, 60 minutes, 4°C, Sorvall). The
clear 0MP pellet was then resuspended in 1ml of sodium
phosphate buffer (20mM, pH 7.0) and the protein
concentration was measured and adjusted to 5mgml-l in the
same buffer. Samples (50pl) were subjected to SDS-
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polyacrylamide gel electrophoresi s (PAGE). MoTecular weight
markers (BDH) were included on each gel (range 12,300-
78,000).
5.33 Preparation of Penicillin Binding Proteins (PBPs)
The preparation and assays of PBPs were carried out as
described by Spratt (1977) with the following modifications.
Cells were routinely grown in 500ml batch cultures in
nutrient broth (or supplemented BHI for H. inf1uenzae).
Each flask was inoculated with 5mls of an overnight culture
and shaken at 37°C until the culture was in late log phase
(3.5-4 hours). Cells were harvested (10,000g, 5 minutes,
4°c, Sorval 1) and resuspended in 40mls of cold sodium
phosphate buffer (20mM, pH 7.0) and then ultrasonicated
(8pm, 3 minutes, Soniprep). Unbroken bacteria were removed
by centrifugation (8,000g, 10 minutes, 4°C, Sorval 1)
resuspended in 20mls sodium phosphate buffer (20mM, pH 7.0)
and sonicated and centrifuged as before. The cell envelopes
contained in the combined supernatants were pelleted by
ul tracentrifugation (100,000g, 30 minutes, 4°C, MSE Europa)
and washed by resuspension in 10mls of phosphate buffer and
recentrifuged.
The membrane pellet was resuspended in 4mls of sodium
phosphate buffer (20mM, pH 7.0) and adjusted to give a final
protein concentration of 10mgml-l). Membranes were stored
at -70OC until required.
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5.33.1 Penicillin Binding Protein Assay
(l^c) Benzyl penicillin was purchased from Amersham
International Ltd. For the standard assay of H. influenzae
PBPs the procedure followed was that described by Spratt
(1977). The final concentration of radiol abel 1 ed benzyl
penicillin used in the assay was 35mgL-l to ensure
saturation of all PBPs. The binding of non-radioactive 13-
1actams was studied by measuring their competition for the
binding of (14c) benzyl penicillin to each of the proteins.
Eleven serial dilutions of the test antibiotic were prepared
in sodium phosphate buffer (20mM, pH 7.0) at 20 times the
final concentration required in the assay, and lOpl of each
dilution was added to a separate Eppendorf tube, and
equilibrated at 30°C. Two tubes containing lOpl of buffer
were used as control s. The assay was started by the
addition of 200pls of pre-warmed membrane and each tube was
vortexed and then incubated for 10 minutes. After this time
20pl of (14c) benzyl penicillin (50pCi ml-1; 54mCi mM-1) was
added to each tube which was vortexed and incubated for a
further 10 minutes. The reaction was terminated by the
addition of 5jj 1 of non-radioactive benzyl penicillin
(120mgL~l) followed by 20pl of 20% (w/v) sarcosyl , the tubes
vortexed and allowed to stand at room temperature for 20
minutes.
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The sarcosyl-insoluble outer membrane and peptidoglyean were
sedimented by ultracentrifugation (100,000g, 30 minutes,
10°C, MSE Europa). The sarcosyl soluble supernatants are
carefully removed from the tubes and either prepared for SDS
PAGE electrophoresis as detailed later, or stored at -20°C
until required. High molecular weight standards were used
(Biorad, Watford, range 45,000-200,000). F1uorography was
carried out as described by Spratt (1977).
5.34 SDS PAGE of Outer Membrane Proteins and Penicillin Binding
Proteins
The apparatus and discontinous buffer system used for the
vertical slab gel SDS PAGE was essentially that of Laemmli
and Favre (1973). The slab gel el ectrophoresis equipment
used was supplied by Raven Scientific, Suffolk.
The pol yacrylamide gel solutions were as fol 1ows. Stock
solution I contained 30g Acrylamide plus 3g methylene
bi sacryl amide. This was adjusted to 100ml s with distilled
water and kept in the dark at 4°C. Running gel comprised
stock solution I (16.6ml s), 12.5ml s Tris H-Cl (1.5M, pH
8.8), 0.5mls SDS (10% w/v), 0.5ml s ammonium persulphate
(lOmg ml-1) and distilled water (19.8ml s). Stacking gel
solution contained stock solution I (2.0ml s), 0.1ml of 10%
(w/v) SDS, 2.5mls Tris H-Cl (0.5M, pH 6.8), 50pl ammonium
persulphate (lOmg ml~l) and distilled water (5.3ml s).
Polymerisation was started by the addition of N,N,N",N"-
tetramethylenediamine to a final concentration of 0.2%
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(v/v). The electrode buffer contained 0.025M Tris, 0.19M
glycine and 0.1% SDS (pH 8.3).
The 50pl protein samples were prepared in 0.0625M Tris-HCl
(pH 6.8) containing SDS (2% w/v), glycerol (10%),
bromophenol blue (0.001% w/v) and 2-mercaptoethanol (5%)
(Sigma) final concentrations. Samples were boiled for 5
minutes before application to the polyacrylamide gel.
El ectrophoresis was performed at constant current, 40mA
through the stacking gel , 60-70mA through the separating
gel. Gels were immersed in stain for 1 hour (Coomassie Blue
R (Sigma), 0.1% (w/v), methanol 50% (v/v), glacial acetic
acid 10% (v/v)) and then destained (methanol 5% (v/v),
glacial acetic acid 10% (v/v)).
5.35 Densitometry
A scanning microdensitometer (Joyce Loebbel , Sweden) with




SURVEY AND COLLECTION OF CEPHALORIDINE RESISTANT STRAINS
1. A Survey of Cephaloridine Resistance Amongst Gram Negative
Bacteria from Clinical Isolates
A population of Gram negative bacteria was isolated from
clinical specimens in Dundee, Edinburgh and Glasgow during
the period January to March 1984. This population was
examined to determine the extent of resistance to
cephaloridine and ampicillin.
The 549 clinical strains collected were a random population,
the majority (441) being isolated from urinary tract
infections (UTI). Three hundred and 74 strains were
obtained from Edinburgh hospitals, 93 from Dundee hospitals
and 82 from Glasgow hospitals.
A minimum inhibitory concentration (MIC) value of greater
than 8mgL~l of cephaloridine and ampicillin was used to
select resistant strains. With these breakpoints, 164
cephaloridine resistant strains and 282 ampicillin resistant
strains were isolated from the total population of 549
(29.9% and 51.4% respectively). In order to determine the
levels of resistance to ampicillin and cephaloridine in each
centre (Edinburgh, Dundee, Glasgow), the sensitivity data
were compared (Table 10).
The data indicate that a high proportion of Gram negative
bacteria isolated in Glasgow were resistant to ampicillin
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Table 10
Resistance to Cephaloridine and Ampicillin Amongst Clinical Isolates








CERS AMPS* 51 186 23 260
(54.8) (49.7) (28.0) (47.4)
CERR amps 0 7 0 7
(0) (1.9) (0) (1.3)
cerR ampR+ 21 99 37 157
(22.6) (26.5) (45.1) (28.6)
cers ampR 21 82 22 125
(22.6) (21.9) (26.8) (22.8)
All Strains 93 374 82 549
* CERS AMPS MIC of cephaloridine (CER) or ampicillin (AMP) of
8mgl_-l or 1 ess
+ CERR AMPR MIC of cephaloridine (CER) or ampicillin (AMP) of
greater than 8mgL
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and cephal oridine (45.1%). A smaller proportion of strains
from Dundee (22.6%) and Edinburgh (26.5%) were resistant to
both B-lactams. Ampicillin resistance amongst Glasgow
isolates was very common, 71.9% of strains isolated were
resistant to 8mgL-l. In Dundee and Edinburgh, 45.2% and
48.4% of strains were resistant to ampicillin. When strains
resistant to ampicillin, but sensitive to cephaloridine were
examined, similar proportions were found in all three
centres.
A high proportion of strains from Glasgow were resistant to
cephaloridine (45.1%), while a smaller proportion of strains
from Dundee and Edinburgh (22.6% and 28.4% respectively)
were cephaloridine resistant. The majority of cephaloridine
resistant strains were also ampicillin resistant, however
seven Edinburgh strains (1.9%) were cephaloridine resistant
but ampicillin sensitive. It was apparent from this survey
that a resistance mechanism(s) to cephaloridine does not
necessarily confer resistance to ampicillin and vice versa.
Strains from urinary tract infections (UTI) were examined to
determine the degree of resistance to ampicillin and
cephaloridine amongst one type of isolate (Table 11).
Only the Edinburgh strains in Table 10 comprised UTI and
non-UTI isolates. A slightly higher proportion of the UTI
isolates from Edinburgh (25.2%) were resistant to ampicillin
but sensitive to cephaloridine than had been found amongst
all types of isolate from this centre (21.9%). This
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Table 11









CERS AMPS* 51 130 23 204
(54.8) (48.9) (28.0) (46.2)
CERR AMPS 0 7 0 7
(0) (2.6) (0) (1.6)
CERR AMPR+ 21 62 37 120
(22.6) (23.3) (45.1) (27.2)
CERS AMPR 21 67 22 110
(22.6) (25.2) (26.8) (24.9)
All Strains 93 266 82 441
* CERS^AMPS MIC of cephaloridine (CER) or ampicillin (AMP) of
8mgL_l or less
+ CERR,AMPR MIC of cephaloridine (CER) or ampicillin (AMP) of
greater than 8mgL
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however, did not affect the percentage of ampicillin
resistant strains found amongst UTI isolates from Edinburgh
as there was a corresponding slight decrease in the number
of cephaloridine and ampicillin resistant strains found.
When UTI isolates were compared, Edinburgh and Dundee had
similar proportions of ampicillin resistant organisms (48.5%
and 45.2% respectively), whereas a significantly larger
proportion of strains isolated in Glasgow (71.9%) were
resistant to ampicillin (P<0.001,\2 = 16.3), 2 degrees of
freedom). Glasgow was also found to have a larger
proportion of UTI strains which were resistant to
cephaloridine (45.1%), significantly greater than the
numbers in Dundee (22.6%) and Edinburgh (25.9%) (P<0.01,"X.2
= 13.76, 2 degrees of freedom).
Thus it appears from this survey that resistance to
ampicillin and cephaloridine is a greater problem in Glasgow
than in either Edinburgh or Dundee.
In total, from all types of isolate, 164 cephaloridine
resistant strains were collected from initial sensitivity
studies (106 from Edinburgh, 21 from Dundee and 37 from
Glasgow). A further 70 Gram negative bacterial strains
resistant to cephaloridine were collected from the three
centres in April 1983 on the same criteria as previously
described (eight from Edinburgh, 38 from Dundee and 24 from
Glasgow). All but one was al so ampi ci 1 1 i n resi stant. In
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total the number of cephal oridine resistant strains under
examination was 234. These strains are detailed in the
appendix. The 70 isolates collected separately are given
the prefix "A".
1.1 Identification of Cephaloridine Resistant Bacterial Strains
The genus and species of the 234 cephaloridine resistant
strains were confirmed by identification with the API 20E
system. A total of 10 genera were identified comprising 20
species (Tabl e 12). In al 1 three centres E. col i was the
prevalent species (37.3%, Dundee; 41.2%, Edinburgh; 57.4%,
Glasgow). Amongst cepha 1 ori di ne resistant UTI strains
E. col i were found in a higher proportion of isolates
(41.9%, Dundee; 58.3%, Edinburgh; 59.3%, Glasgow).
1.2 Sensitivity Testing of Cephal oridine Resistant Bacteria
The cepha1oridine resistant strains were tested for
sensiti vity to a selection of antimicrobial agents. Data
for each of the individual strains are presented in the
appendix.
To summarise these data, sensitivity to a B-lactam was
expressed as the MIC of a B-lactam for 90% of the bacterial
population under study, the MIC90 (Figures 10 a, and b,
and Table 13). Pseudomonas spp. (26 strains) were not
included in the cumulative figures, however the MlCgg of
cefsulodin, a narrow spectrum anti-pseudomonal compound, for
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Table 12






Acinetobacter calco. 0 1 1 2
Citrobacter freundii 3 3 1 7
Enterobacter aerogenes 0 2 0 2
E. agglomerans 1 0 0 1
E. cloacae 9 12 4 25
E. sakazakii 0 1 0 1
Escherichia coli 22 47 35 104
Hafnia alvei 0 1 0 1
Klebsiella oxytoca 7 2 3 12
K. ozaenae 1 2 0 3
K. pneumoniae 3 5 0 8
Proteus mirabilis 2 10 0 12
P. morganii 4 1 4 9
P. vulgaris 2 7 1 10
Providencia stuartii 0 0 1 1
Pseudomonas aeruginosa 3 14 5 22
Ps. fluorescens group 0 2 1 3
Ps. maltophilia 0 1 0 1
Serratia marcescens 2 1 5 8
S. odorifera 0 2 0 2
TOTAL 59 114 61 234
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Figure 10a
Cumulative minimum inhibitory concentrations of cephaloridine,
cephradine, cefazolin, ampiciTlin, cefuroxime and cefamandole for
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Figure 10b
Cumulative minimum inhibitory concentrations of cefoxitin,
cefotetan, cefotaxime, ceftazidime and ceftriaxone for cephaloridine
resistant clinical strains.
O Dundaa A Edinburgh X Slaagou O Dundaa A Edinburgh X SLaagou
0 Dundaa A Edinburgh X Slaagou 0 Dundaa A Edlnburgn X Glaagow
0.125 0.2S 9.3 I 2 ♦ ■ 8 IS 32
niniaua Inhibitory Concantration jjg/al.
O Dundaa A Edlnburgn X Glaagou
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Table 13
Cumulative MIC90 Values for Clinical Strains (excluding Pseudomonas)
Resistant to 8mql_-l Cephaloridine
MICgo Values (mgL"1)
B-lactam Dundee Edinburgh Glasgow
Cephaloridine 64 16 64
Cephradine 64 16 125
Cefazolin 8 8 32
Ampicill in 500 500 2000
Cefuroxime 2 4 16
Cefamandole 4 8 16
Cefoxitin 4 8 32
Cefotetan 0.5 0.5 0.5
Cefotaxime 0.25 0.25 0.25
Ceftazidime 0.25 0.25 0.5
Ceftriaxone 0.25 0.25 0.25
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these Pseudomonas strains was shown to be 32mgL-l (Figure
10c).
Although the population was selected on cephaloridine
resistance, the MIC90 values of ampicillin were higher than
those of cephaloridine in all three centres. Cephaloridine
and cephradine had similar MIC90 va^ues f°r eac^ centre with
strains from Glasgow and Dundee having higher MICgg values
than strains from Edinburgh. Cefazolin, another first
generation cephalosporin, was more active with MlCgg values
of 8mgL~l in Dundee and Edinburgh and 32mgL_l in Glasgow.
The second generation cephalosporins, cefuroxime,
cefamandole and cefoxitin, were similarly active against
strains from each centre, with the MlCgg values for Glasgow
isolates being slightly higher than those for strains from
Dundee and Edinburgh. Cefotetan, a cephamycin (like
cefoxitin) is a very active compound and this is reflected
in the low MlCgg values for strains from all three centres.
Third generation cephalosporins were also tested. These
included cefotaxime, one of the earliest extended spectrum
cephalosporins, ceftazidime and ceftriaxone. All were
extremely active against this cephaloridine resistant
population with 90% of the strains from all three centres
being inhibited by 0.25mgL-l of cefotaxime and ceftriaxone.
Ceftazidime inhibited 90% of strains from Dundee and






















Other resistance markers associated with cephaloridine
resistance were also examined during the survey (Table 14).
Streptomycin resistance was associated with cephaloridine
resistance in 46.2% of the 234 strains.
Also commonly associated with cephaloridine resistance were
chloramphenicol (42.3% of strains), tetracycline (41.0%) and
sulphamethoxazol e resistances (39.7% of strains). This
association changes when Pseudomonas strains, which are
intrinsically resistant to many drugs, are excluded.
Streptomycin resistance is still most commonly found
associated with cephal oridine resistance (45.7% of strains).
Next most common are tetracycline (42.8%), sul phamethoxazole
(39.9%) and chloramphenicol (36.0%) resistances. The 26
Pseudomonas strains were almost uniformly resistant to
nalidixic acid (96.2%), trimethoprim and chloramphenicol
(92.3%), and kanamycin (88.5%) at the concentrations tested.
Norfloxacin, streptomycin and sulphamethoxazol e resistances
were also commonly found amongst the Pseudomonas strains.
1.3 B-lactamase Enzymes Produced by the Cephaloridine Resistant
Population
The B-lactamase enzymes produced by the 234 strains were
identified by analytical isoelectric focusing (IEF) of
small-scale crude enzyme extracts. Resistant strains which
did not appear to produce a B-lactamase enzyme were induced
with cefoxitin (materials and methods). Comparison with
11+0
Table 14
Other Resistance Markers Associated with Cephaloridine Resistance
Percentage Number of Strains
Antimicrobial Non-Pseudomonas Pseudomonas All Strains
Agent+ Species Species
Chioramphenicol 36.0 92.3 42.3
Colistin 25.5 3.8 23.1
Gentamicin 8.6 3.8 8.1
Kanamycin 16.3 88.5 24.4
Nalidixic Acid 7.2 96.2 17.1
Norfloxacin 8.2 53.8 13.2
Rifampicin 10.1 19.2 11.1
Streptomycin 45.7 50.0 46.2
Sulphamethoxazol e . 39.9 38.5 39.7
Tetracycl ine 42.8 26.9 41.0
Trimethoprim 23.1 92.3 30.8
+ Antimicrobial sensitivities were tested at the concentrations
given in the materials and methods section.
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standard marker enzymes enabled preliminary identification
of the B-lactamases as to whether they may be plasmid-
mediated or of probable chromosomal origin. Later these
affiliations were confirmed by genetic experiments (Section
1.3.4).
Certain types of chromosomal enzymes are well characterised
and standard marker enzymes were used for specific
identifications, otherwise typing of chromosomal enzymes
was by bacterial species (Simpson j?t aj_ 1980).
1.3.1 Distribution of B-lactamase enzymes
Only three enterobacterial strains did not produce a
detectable 6-lactamase enzyme, all were Proteus mirabilis.
One hundred and nineteen strains produced only a typically
chromosomally-mediated B-lactamase and no plasmid enzyme.
One hundred and twelve strains produced an enzyme which is
typically piasmid-mediated, in addition to the chromosomal
B-lactamase (Table 15).
In almost all cases, the B-lactamase predicted plasmid-
mediated was produced in greater quantities than the
chromosomal B-lactamase in cultures which had not been
induced with cefoxitin. This was determined from the
intensity of the focus ed bands in IEF gels, after overlay
with nitrocefin solution. This result strongly suggested
that the predicted piasmid-mediated B-lactamase was the
12+2
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principal enzyme in the majority of the cephal oridine
resistant strains.
o
1.3.2 Chromsomally-mediated B-lactamase enzymes
Thirty six (61%) of bacterial strains from Dundee resistant
to cephaloridine produced one B-lactamase with an
isoelectric point which was al ways typical of the species
concerned. This compared with 52 strains isolated in
Edinburgh (46%) and 31 strains isolated in Glasgow (51%).
There are two major groups of Gram negative chromosomal B-
lactamase enzymes. The broad spectrum enzymes hydrolyse
benzyl penicillin and carbenici11 i n as well as
cephalosporins, and the cephalosporinase enzymes which have
little or no activity against the penicillins. It was
possible to establish what proportion of the chromosomal
enzymes produced by the 119 strains were "typical cephal o-
sporinases" and what proportion could be described as "broad
spectrum" enzymes on the basis of published data for the
bacterial species involved.
The majority of chromosomal B-lactamases produced by this
group were cephalosporinases - 93 strains, 21 strains
produced broad spectrum enzymes (Table 16).
The overall incidence of each type of chromosomal B-
lactamase enzyme produced by strains which did not have a
typica1 1 y piasmid-mediated enzyme was 39.7% for cephalo-
sporinase enzymes and 11.1% for broad spectrum enzymes.
lhh































































































1.3.3 Typically piasmid-mediated B-lactamase enzymes
The proportion of 6-lactamase enzymes which could be
piasmid-mediated on the basis of IEF results is detailed in
Table 16. Of the 59 Dundee strains, 22 produced B-
lactamases that could be pi asmid-mediated. Amongst the
Edinburgh strains such enzymes were found on 61 occasions.
In addition, one strain K. pneumoniae 175, produced an
unclassified B-lactamase (Results section 2). The B-
1 actamase SHV-1 which may be chromosomal or pi asmid-mediated
was found in two K1ebsiel1 a strains which also produced the
TEM-1 B-lactamase. Twenty nine strains from Glasgow
produced the TEM-1 or TEM-2 B-lactamase enzymes.
A large proportion of cephaloridine resistant strains from
Edinburgh and Glasgow (53.5% and 47.5% respectively)
produced B-lactamase which can be piasmid-mediated. A lower
percentage (37.3%) of strains isolated in Dundee produced
such B-lactamases.
Seven wel 1 -characterised B-lactamase enzymes were identified
amongst the survey strains (Tables 15 and 16). These were
the TEM-1, TEM-2, OXA-1, OXA-2, OXA-3, PSE-4 and SHV-1 B-
1actamases (Figure 11). The most commonly found B-lactamase
was TEM-1 found in 98 of the 234 cepha1oridine resistant
strains - 41.9%). The incidence of TEM-1 amongst Dundee
strains was 33.9%, in Edinburgh it was 47.4% and in Glasgow
TEM-1 was found in 39.3% of strains.
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Figure 11_
Isoelectric focusing patterns of standard piasmid-mediated
[5-lactamase enzymes identified amongst survey strains.
Track A - PSE-4 (Pi 5.3) Track B - TEM-1 (Pi 5.4)
T rack C - TEM-2 (Pi 5.6) T rack 0 - OXA-3 (Pi 7.1)
Track E - OXA-1 (pi 7.4) Track F - SHV-1 (Pi 7.6)







The TEM-2 B-lactamase was produced by eight strains and was
the second most commonly found B-lactamase. None of the
strains isolated in Dundee produced TEM-2. Two strains
produced the OXA-3 B-lactamase, whilst OXA-1 and OXA-2 were
each found in single isolates. The SHV-1 B-lactamase was
produced by two Klebsiel1 a strains. The carbenici 11inase,
PSE-4, was identified in a K. pneumoniae isolate and an
E. cloacae isolate. This B-lactamase was previously
believed to be confined to P. aeruginosa due to the transfer
deficient nature of the PSE-4 element (Results section 3).
1.3.4 Establishing the genetic location of B-lactamase enzymes
predicted as being plasmid-mediated
Isoelectric focusing identified piasmid-1 ike B-lactamase
enzymes in 112 strains. Conjugation and mobilisation
experiments were carried out to confirm the genetic location
of the B-lactamases in these strains.
Conjugation experiments were performed as described in the
materials and methods. Matings were carried out overnight
into E. col i J62~2 R-jfR pro~his~trp~ with selection made for
transfer of ampicillin resistance, the principle substrate
of the B-lactamases in question. Any clinical strains
resistant to rifampicin were conjugated with E. col i J62-1
Nal R pro~his~trp~ with appropriate selection.
Seventy eight strains transferred the marker B-lactamase by
simple conjugation as demonstrated by IEF of crude enzyme
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extracts of transconjugants. Mobilisation experiments were
carried out (materials and methods) with the plasmids X+, Sa
or R751 with appropriate selection and then mating from the
clinical strains into E. col i J62-? as before. In total 15
mobilisations were successful, 10 with X+, four with Sa and
one involving R751 (Results sections 3 and 4).
Thus in a total of 93 strains the B-lactamase predicted as
being pi asmid-mediated by IEF was confirmed as being
transferable by genetic experiments. Nineteen strains did
not transfer their B-lactamase enzymes to an E. coli
recipient (Table 17).
The 19 strains may be capable of transferring these B-
lactamases under different conditions but they are not
freely transferable.
1.3.5 The specific enzyme activity of B-lactamase producing
strains
The specific enzyme activities of cell extract preparations
from the cephaloridine resistant strains were calculated as
described in the materials and methods with cephal oridine as
substrate. Strains producing a B-lactamase which had
required induction in order to visualise the enzyme on IEF
gels were assayed as uninduced and induced preparations.
The uninduced value was used in any comparative studies with
other strains. The values obtained were expressed per mg
li+9
Table 17
Cephaloridine Resistant Strains which did not Transfer a B-lactamase
which is Normally Plasmid-mediated
Strain Species Number of Strains B-lactamase
E. coli 14 TEM-1
C. freundii 1 TEM-1
K. oxytoca 1 TEM-2
E. coli 1 TEM-2
H. alvei 1 OXA-1
S. marcescens 1 OXA-3
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protein and details for each strain are presented in the
appendix.
1.4 A Study of the TEM-1 [3-1 actatnase in the Clinical E. col i
Population
The largest single population of strains found in the survey
were E. coli producing the TEM-1 B-lactamase (76 strains).
These strains were examined initially in order to determine
the variation in enzyme activity within a single species
producing the same B-lactamase. The variation was
considerable. Figure 12 illustrates as a histogram the
specific enzyme activity of individual clinical E. coli TEM-
1 strains. The majority of strains (85%) had a specific
enzyme activity value of between 1 and 35nM cephal oridine
hydrolysed minute-! mg protein-!.
It was apparent that high levels of TEM-1 B-lactamase
production as measured by j_n vitro hydrolysis of
cephaloridine, did not necessarily confer high levels of
resistance to cephaloridine. For instance, strain E. coli
374 possessed the highest specific enzyme activity value of
208.4nM cephaloridine hydrolysed minute"! mg protein"! and
yet MIC values of B-lactam antibiotics were surprisingly low
with cephaloridine inhibiting the growth of this strain at
64mgL-l. One of the strains with a very low specific enzyme
activity (0.32nM cephaloridine hydrolysed minute"! mg
protein-1) E. coli 135 had very high MIC values, being
inhibited only by 2000mgL"l cephaloridine.
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Figure12 Histogramfthespecificactiv t esfindividualcl n alE. oli TEM-1producingstrains.
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The TEM-1 enzymes were transferred to E. col i J62-2 ri f R
pro~his'trp" as has been previously described. The B-
lactamase was transferred by simple conjugation from 51
clinical strains, Sa and X+ were used to mobilise the enzyme
from 11 strains. Fourteen E. col i strains, however, did not
transfer the TEM-1 B-lactamase and therefore only 62
transconjugants were available for study.
The transfer frequency of the TEM-1 B-lactamase to E. col i
J62-2 ranged from 1.3 x 10'2 per donor eel 1 to 5 x 10~8 per
donor cell, with the majority of strains transferring TEM-1
at a frequency in the range of 10-4 to 10-6 per donor eel 1.
Agarose gel electrophoresis of DNA extracted from
transconjugants revealed the number of plasmids present in
the 51 recipient E. col i J62-2 strains after simple
conjugation (Table 18). The majority of transconjugants
(30/51) contained only one plasmid.
The antimicrobial resistance patterns of the E. col i
transconjugants containing one plasmid were examined. Table
19 shows the seven resistance profiles found amongst these
30 transconjugants. The molecular sizes of the plasmids are
al so given.
The most common plasmid resistance profile was that of
ampicillin and cephal ori di ne resistance alone. Twelve
plasmids of varying sizes from 56 to 120kbases had this
profile. The second commonest plasmid resistance profile
found was ampicillin, cephaloridine, streptomycin and
153
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Resistance Profile and Molecular Sizes of the Single Plasmid Present
in 30 E. coli Transconjugants
Resistance Profile Number of Strains Molecular Sizes (kbases)
Ap Cer 12 56 - 120
Ap Cer Sm Su 8 65 - 90
Ap Cer Tc 6 64 - 115
Ap Cer Ka Sm 1 110
Ap Cer Sp Sm Tp Su 1 76
Ap Cer Tc Sm Tp Su 1 69
Ap Cer Tc Tp Su Gm Cm 1 120
Abbreviations
Ap, Ampici 1 1 in; Cer, Cephaloridine; Gm, Gentamicin; Ka,
Kanamycin; Sm, Streptomycin; Sp, Spectinomycin; Su, Sulphame-
thoxazole; Tc, Tetracycline; Tp, Trimethoprim.
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sulphamethaxole which characterised 8 plasmids. Four of
these plasmids were of the same size (80kbases), two from
Glasgow, one from Edinburgh and one from Dundee. A further
two plasmids found in transconjugants of Edinburgh strains
were 83kbases in size and may be similar or identical to the
four 80kbase plasmids. Similarly, three plasmids of the six
which had the ampicillin, cephaloridine and tetracycline
resistance profile were 115kbases, all were from Edinburgh's
City Hospital.
It appears that certain plamids may be more successful than
others and cross-infection of different E. col i strains by
certain plasmids has occurred in some cases.
Transconjugants of the 11 strains which transferred TEM-1 S-
1actamase only after mobilisation were also examined for
plasmid content. Seven transconjugants contained a plasmid
which was larger than the mobilising plasmid introduced into
the clinical strain (Figure 13, Track E). This increase in
size probably resulted from the acquisition by the
mobilising plasmid of one or more copies of TnA which
encodes TEM-1 and is 3kb in size. One of the seven strains
also had six small plasmids of less than lOkbases in size
(Figure 13, Track F). The four remaining transconjugants
from successful mobilisation experiments contained the
mobilising plasmid which had not apparently increased in
size, however the strains had smaller plasmids of varying
156
Figure 13
Agarose gel electrophoresis of DNA extracted from representative
E .coli J62~2 transconjugants following mobilisation of the TEM-1
genes by the X+ factor.
Method of Takahashi and Nagano (1984).
Track A - R1
Track C - R6K
Track E - E.coli J62-2 144(X+)
Track F - E.coli J62-p 135(X+)
Track G - E.cofi J62-2 458(X+)
c ; chromosomal
Track B - RP4




sizes (Figure 13, Track G), one or more of which was thought
to encode the TEM-1 B-lactamase.
The 62 transconjugants which produced TEM-1 all had an MIC
of ampicillin of lOOOmgL"! or above, in contrast to the
varied sensitivity of the clinical E. coli strains
(Appendix). All were sensiti ve to 32mgl_-l cephal oridi ne,
and the majority (40/62) were sensitive to 8mgL-! of
cephaloridine. The specific enzyme activity of the TEM-1 B-
1actamase in the E. col i J62~2 transconjugants did not mimic
that of the corresponding clinical isolates. Figure 14
compares the histogram of the specific enzyme activities of
the 62 E. col i clinical isolates which produced TEM-1 with
that of their E. col i J62~2 transconjugants. The B-
1actamase activity of the clinical isolates did not appear
to correlate with that of the transconjugants. The majority
of strains (82%) had a specific enzyme activity value of
between 0.58 and 35nmoles cephaloridine hydrolysed minute-!
mg protein-!, as had been found with the clinical isolates.
It appears that there was still diversity in the levels of
TEM-1 B-lactamase production even in the E. col i K12 strain
J62~2, variation of almost 800 fold in activity (compared
with variation of around 2000 fold in the clinical strains).
Seventeen of the 62 transconjugants had MICs of
cephaloridine of 16 or 32mgL-!. The average specific enzyme
activity of these strains was around 2.5 times that of the
cephaloridine sensitive transconjugants. Nine of these 17
strains were also tetracycline resistant.
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Figure 14
Histograms comparing the specific enzyme activities of TEM-1
producing E.coli clinical isolates compared with that of their
E.coli J62? transconjugants.
(Clinical strains are shown above and transconjugants below,
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CHARACTERIZATION OF A NOVEL PLASMID-MEDIATED 13-LACTAMASE
ENZYME
2. Introduction
Various pi asmid-mediated B-lactamases have been identified
in Klebsiella spp. These include TEM-1, TEM-2, SHV-1, OXA-1
and OXA-3 B-lactamase enzymes (Matthew 1979). The SHV-1 B-
Iactamase in most commonly found in K1ebsiel 1 a spp. This B-
lactamase is known to be transposon-mediated and it is now
distributed widely in many bacterial genera (Nugent and
Hedges 1979, Matthew 1979).
During the survey of B-lactamases produced by cephaloridine
resistant Gram negative bacteria (Results section 1), a
K. pneumoniae strain was isolated which produced three B-
lactamase enzymes. One of these was a novel plasmid-
mediated B-lactamase with a unique combination of
biochemical properties.
2.1 Results
K. pneumoniae 175 was isolated from a sputum specimen taken
from a patient in Edinburgh Royal Infirmary. The strain was
highly resistant to cephal oridine, ampicillin and other B-
1actams as well as nalidixic acid, gentamicin, streptomycin,




Resistance to B-lactam antibiotics was transferred to
E. coli J62-2 (3.5 x 10-6 per donor cell after an overnight
mating) when selection was made for cepha1oridine and
rifampicin resistant transconjugants. These transconjugants
acquired resistance to ampicillin, carbenici 11 in, sulpha-
methoxazole, and streptomycin as well as cephaloridine.
Streptomycin and sul phamethoxazole resistance could be
transferred together to E. col i J62-2 independently of the
B-lactam resistance by selecting for transfer of resistance
to either streptomycin or sul phamethoxazole (frequencies 9 x
10~7 and 2 x 10"6 per donor cell after overnight
incubation). Both resistances transferred together to
E. col i J62~2 at a frequency of 3 x 10"® per donor eel 1
after overnight incubation.
2.3 Analysis of the Plasmid Profile of K. pneumoniae 175 and
Transconjugants
K. pneumoniae 175 and the three transconjugants selected on
cephaloridine, streptomycin and sulphamethoxazole were
examined for plasmid profile (Figure 15). The clinical
strain 175 contained two large plasmids of approximately 100
and 133kbases and three other plasmids of less than lOkbases
(Figure 15, Track G). The mucoid character of K. pneumoniae
175 did not al 1 ow the eel 1 s to lyse completely and piasmids,




Agarose gel electrophoresis of DNA extracted from K.pneumoniae 175
and E.coli J62? transconjugants selected on streptomycin (Sm),
sulphamethoxazol e (Su) or cephaloridine (CER).
Method of Birnboim and Doly (1979).
Track A - R6K Track B - RP4
Track C - R1 Track 0 - E.coli J62-2 (Su)
Track E - E.coli J62-2 (Sm) Track F - E.coli J62-2 (CER)
Track G - K.pneumoniae 175
c : chromosomal
Mr






The first transconjugant, selected on cephal oridine,
contained a large plasmid of 135kbases (designated pUK 702)
which appeared as two bands (Figure 15, Track F) probably
open and covalently closed circular DNA. This trans-
conjugant also had three smaller plasmids. The transcon-
jugants selected on streptomycin and sul phamethoxazole did
not carry pUK 702 but had the three smal 1 er plasmids seen
previously in the cephaloridine transconjugant (Figure 15,
Tracks D and E). These results suggest that one or more of
the small plasmids encoded sulphamethoxazol e and
streptomycin resistance and they show that pUK 702 carried
the B-lactam resistance.
Isoelectric Focusing
Sonicated extracts from K. pneumoniae 175, and the
cephal oridine, streptomycin and sul phamethoxazol e E. coli
transconjugants were examined by analytical IEF.
K. pneumoniae 175 produced three B-lactamase bands with
isoelectric points (pi) corresponding to 5.4, 6.5 and 7.6
(Figure 16, Track A). The E. col i transconjugant containing
pUK 702, which confers cephaloridine, ampici11 in and
carbenici 11 in resistance, produced these three B-lactamase
bands and also the E. col i chromosomal enzyme of pi 8.9
(Figure 16, Track B). Conjugation experiments, selecting
for transfer of cephaloridine resistance were carried out
for a period of 1 hour, 2 hours, 3 hours and 5 hours. All
transconjugants produced all three B-lactamases. No
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Figure 16
Isoelectric focusing pattern of K.pneumoni ae 175 and its E.coli_
«J622 transcon jugants (selected on Streptomycin ~TSm7,
sulphamethoxazole (Su) or cephaloridine (CER)).
Track A - K.pneumoniae 175 Track B - E.coli J62-2 (CER)
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transfer of cephaloridine resistance took place with
conjugation experiments of less than one hour.
The streptomycin and sulphamethoxazole transconjugants were
sensitive to B-lactams and when examined by IEF they did
not produce a B-lactamase apart from the E. col i chromosomal
enzyme (Figure 16, Tracks C and D). These results strongly
suggest that pUK 702 alone carries the genetic information
for all three B-lactamase enzymes.
As can be seen from Figure 17, the B-lactamase of pi 5.4
corresponded to the TEM-1 B-lactamase, while the enzyme of
pi 7.6 corresponded to SHV-1. However, the B-lactamase of
pi 6.5 did not correspond to any of the known B-lactamase
enzymes.
Purification of the Novel B-lactamase Enzyme
The novel B-lactamase was purified from the original
clinical isolate K. pneumoniae 175. As three B-lactamases
were present in this strain, preparative IEF was used as the
purification technique. Sixty mi 11 i 1 itres of crude extract
was prepared from five litres of sonicated cells. This was
el ectrofocused with pH 3.5 - 10.0 ampholines and all the
fractions which contained the novel B-lactamase (as shown by
analytical IEF) were eluted from the ultradex. The pooled
fractions were electrofocused in a gradient made from a
mixture of pH 3.5 - 10.0 and pH 5.0 - 7.0 ampholines (50%
v/v). At this point, fractions containing only the new
T4F
Figure 17
Analytical isoelectric focusing of three 13-lactamase enzymes
purified from K.pneumoniae 175.
Track A - SHV-1, TEM-1 (standards) Track B - K .pneumorfi ae 175
Track C - Purified SHV-1 from K.pneumoniae 175
Track D - Purified novel enzyme from K.pneumoniae 175
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enzyme were identified by analytical IEF and retained
(Figure 17).
2.6 Molecular Weight Determination
The novel B-lactamase, when purified from SHV-1 and TEM-1
enzymes was run through a calibrated Sephadex G75 column
(material and methods). The enzymic peak, as determined by
enzymic activity and protein concentration corresponded to a
molecular weight of 19,000 (Figure 18).
2.7 Immunology
In order to compare the novel B-lactamase with SHV-1, TEM-1
and N-29 (which has the pi closest to that of the novel
enzyme) antisera was raised to each of the enzymes
(materials and methods), and cross reactions were observed
by Auchterlony gel diffusion tests and immuno-IEF.
Antisera was raised against TEM-1, SHV-1 and the novel B-
lactamase, however no detectable antisera was produced to
the N-29 B-lactamase. The novel enzyme appeared to contain
two antigens (2 bands on gel diffusion) and TEM-1 contains
at least three antigens, while SHV-1 appears to have only
one antigen (Figure 19).
The novel B-lactamase antiserum cross-precipitates with one
antigen of TEM-1, while TEM-1 antiserum cross-precipitates
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Figure 18
Molecular weight determination of the novel B-lactamase as measured
by gel filtration on Sephadex G-75.







gel diffusion tests of (3-lactamase antisera and
1. Novel (3-lactamase antigen (centre), antisera to novel (3-lactamase
(a), TEM-1 (b), SHV-1 (c) and N29 (d) (surrounding wells).
2. TEM-1 [3-lactamase antigen (centre), antisera to novel |3-lactamase
(a), TEM-1 (b), SHV-1 (c) and N29 (d) (surrounding wells).
3. SHV-1 13-1 actamase antigen (centre), antisera to novel (3-lactamase
(a), TEM-1 (b), SHV-1 (c) and N29 (d) (surrounding wells).
4. N29 (3-lactamase antigen (centre), antisera to novel (3-lactamase




with one of the novel B-lactamase antigens. SHV-l is
monospecific (Figure 19).
The immuno-IEF revealed the reactions of each B-lactamase to
their respective antisera. No cross reactions were observed
between TEM-1, SHV-l and the novel B-lactamase (Figure 20).
Immuno-IEF is a specific test for antisera to a B-lactamase,
as inhibition arcs are revealed when the gel is stained for
B-lactamase activity with nitrocefin. The Auchterl ony gel
diffusion will pick up all antigen/antibody precipitation
reactions. The cross precipitation observed between TEM-1
and the novel B-lactamase appears to result from an antigen
common to both preparations, the results of the immuno-IEF
strongly suggest that this antigen is not a B-lactamase.
The enzymes were purified by preparative IEF. This
separation by isoelectric point may have resulted in an
antigen such as a eel 1 wal 1 or eel 1 membrane component of
intermediate pi being present in both B-lactamase
preparations and resulting in a cross reaction.
2.8 The Substrate Profile and Michael is Menten Kinetics of the
Novel B-lactamase
The novel B-lactamase hydrolysed several B-lactams when
examined by the spectrophotometry assay system (materials
and methods). As can be seen in Table 20, benzyl
penicillin, ampicillin, carbenici 1 1 in, cephaloridine,
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Figure 20
Immuno isoelectric focusing of K .pneumoni ae 175 3-lactamase
enzymes.
Antisera: Track A - Control sera, Track R - Novel 3-1actamase,
Track C - TEM-1 , Track D - SHV-1 , Track E - Control
sera, Track F - N 29
Plates were incubated for 48 hours at 37 C after the addition of the
antisera. The novel enzyme did not retain any [3-lactamase activity
after this incubation, however, no cross reactions were seen between






















1110 0.0446 100 4.02 100
Ampici11 in 1602 0.0625 140 3.90 97
Carbenicillin nme 0.0058f 13 NM NM
Cephaloridine Does not obey first order kinetics (see text)
Nitrocefin 2080 0.044 99 2.12 53
Cephradine NM 0.00024f 0.5 NM NM
Cefuroxime No hydrolysis
Cloxacill in No hydrolysis
Methicillin No hydrolysis
Cefamandol e No hydrolysis
a Spectrophotometric assay method
b Vmax, pM substrate hydro!ysed minute-1 ml enzyme-*
c Expressed as a percentage of the value for benzyl penicillin
d Vmax per ml enzyme
Km
e NM, not measurable
f Vmax values for these substrates were obtained from the initial
reaction rates at maximal substrate concentration.
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cephradine and nitrocefin were al 1 hydrolysed by this B-
lactamase. There was no detectable hydrolysis of
cefuroxime, cloxacillin, methicillin or cefamandole by
spectrophotometric or macroiodometric assay techniques.
The Michael is-Menten kinetics of the 6-lactamase for the
hydrolysable substrates were examined by plotting substrate
concentration ( S ) against reaction velocity (V). The
hydrolysis of benzyl penicillin, ampicillin and nitrocefin
all obeyed first order kinetics and produced a hyperbolic
curve when S was plotted against V. The hydrolysis of
cephaloridine however, did not obey first order kinetics and
a sigmoid curve was obtained from a plot of S against V
(Figure 21). It was impossible therefore to obtain Km and
Vmax (maximum velocity) values for this enzyme with
cepha1oridine as substrate. In fact, from Figure 21, it
would appear that the Vmax for this substrate was never
reached. It was not possibl e to measure the Km val ues of
cephradine and carbenici11 in as these substrates were
hydrolysed very slowly by the novel B-lactamase.
The Vmax and Km values for benzyl penicillin, ampicillin and
nitrocefin were obtained from Lineweaver-Burk plots of 1
against * (Figure 22). Table 20 lists the Vmax and Km
values obtained with each substrate. From the relative Vmax
values, the novel B-lactamase appeared to be primarily a
penicillinase enzyme. It had a higher Vmax value for
ampicillin than obtained for benzyl penicillin. Nitrocefin
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Figure 21






























Lineweaver-Burk plots of the novel B-lactamase hydrolysing
(a) ampicil.lin (•) and benzyl penicillin (■), and (b) nitrocefin
Sir
The reciprocal of the substrate concentration Is] is plotted against




was hydro!ysed at almost the same rate as benzyl penicillin
and at a faster rate than carbenici 11 in or cephradine.
Similar Km values were obtained with benzyl penicillin,
ampicillin and nitrocefin, with the B-lactamase having the
lowest affinity for the latter. The relative efficiency of
hydrolysis of ampicillin was lower due to the enzyme having
a higher Km (lower affinity) for this substrate. The same
was true of nitrocefin when the relative efficiency of
hydrolysis of this substrate was compared with that of
benzyl penici 11 in.
The relative substrate profile of the novel B-lactamase is
similar to that published for the SHV and TEM-type enzymes.
The fact that the novel B-lactamase does not hydrolyse
cephaloridine by first order kinetics, however,
distinguishes the new enzyme from the TEM and SHV enzymes.
2.9 B-lactamase Inhibition Profile
The concentration of inhibitor required to inhibit by 50%
the hydrolysis of a substrate by a B-lactamase (ID50) was
determined by spectrophotometric assay. The novel B-
lactamase was sensitive to inhibition by cloxacillin,
clavulanic acid and parachl oromercuri benzoic acid (jdCMB)
when nitrocefin was used as a substrate (Table 21). When
benzyl penicillin was the substrate, the B-lactamase was
resistant to inhibition by jpCMB. This differential response
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to jdCMB as an inhibitor is also found with the SHV-1 S-
lactamase (Matthew ££ aj_ 1979) and has also been
demonstrated with the TEM-1 13-1 actamase.
Hydrolysis of nitrocefin by the novel 6-lactamase was
inhibited by addition of benzyl penicillin, carbenici 11 in
and to a much lesser extent by cefuroxime (Table 21).
Table 21
Inhibition profile of the novel [3-lactamase
(Nitrocefin O.lmM as substrate)
Potential Inhibitor ID50 Value (M)
Clavulanic Acid 8 x 1CT8
CIoxaci11in 9 x 10-5
£CMB 2 x 10"7
Carbenicillin 8 x 10-5
Cefuroxime 1 x 10"2
Benzyl penicillin 9 x 10-6
These ID^q results did not distinguish the novel (3-1 actamase
from the TEM and SHV-type enzymes. A newer technique, the
relative substrate affinity index (RSAI) (materials and
methods) can distinguish between TEM-1 and SHV-1 on the
basis of a differential response to inhibition by the
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cephalosporins. As this technique is semi-automated a large
number of B-lactams can be examined.
The RSAI value is the ratio of B-lactam concentration giving
50% inhibition of nitrocefin cleavage to the nitrocefin
concentration used in the assay. Table 22 shows the
average RSAI values obtained with cefotetan, cefoxitin and




B-lactamase Cefotetan Cefoxitin Cefsulodin
TEM-1 27 165 > 200
SHV-1 > 200 >200 >200
Novel B-lactamase 1.7 135 7
From these studies, TEM-1 can be clearly distinguished from
SHV-1 by comparing the RSAI values for cefotetan. The novel
B-lactamase can be differentiated from both SHV-1 and TEM-1
by comparing the results obtained with cefotetan and
cefsulodin for each B-lactamase.
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Biochemical characterisation has shown that the B-lactamase
enzyme purified from K. pneumoniae 175 is a novel B-
lactamase. The presence of three B-l actamases of similar
molecular weight in the bacterial strain made a classical
purification impractical.
The enzyme had a substrate profile very similar to that of
the SHV and TEM-type B-lactamases. The novel B-lactamase
could be distinguished from the TEM and SHV B-lactamases in
its failure to obey first order kinetics with cephaloridine
as a substrate. The inhibition profile of the novel B-
lactamase with conventional inhibitors is the same as that
found for SHV and TEM-type B-lactamases (sensitivity to
cloxacillin, clavulanate and £CMB). The RSAI results with
cefotetan and cefsulodin distinguished the novel B-lactamase
enzyme from SHV-1 and TEM-1. TLE-1 B-lactamase has the
closest molecular weight (19,800) to that of the novel S-
lactamase (19,000). The novel B-lactamase has a different
isoelectric point from those enzymes with a similar
substrate profile. Antisera raised to TEM-1 and SHV-1 do
not appear to cross-react specifically with the novel B-
1actamase.
From the information gathered, it appeared that the novel
enzyme was similar to the TEM-type B-lactamases, and it was
given the designation TEM-1ike enzyme (TLE-2).
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THE PSE-4 B-LACTAMASE AND ITS MIGRATION INTO THE
ENTEROBACTERIACEAE
3. Introduction
The four pseudomonas specific enzymes (PSE) were originally
believed to be mediated by genetic determinants confined to
P. aeruginosa (Hedges and Matthew 1979). Recent reports
have shown that there has been a spread of two of these B-
lactamases, PSE-1 and PSE-2, into the Enterobacteriaceae
(Medei ros et^ a_l_ 1982, Li vermore rt _al_ 1984). No similar
migration had been observed with the PSE-4 B-lactamase, even
though it is the most common piasmid-mediated B-lactamase
found in P. aeruginosa in the United Kingdom (Williams et al
1984).
The PSE-4 genetic determinant is not transferable by
conjugation amongst P. aeruginosa strains (Li vermore jrt aj_
1985), although Sinclair and Hoi 1oway (1982) have
demonstrated that the PSE-4 gene can reside in a
chromosomal 1 y located transposon (Tn2521) in this species.
During the B-lactamase survey of cephaloridine resistant
strains, two non-pseudomonal clinical isolates were found
which produced the PSE-4 B-lactamase enzyme. The
characteristics of the genetic determinant and biochemical




Two strains, K. pneumoniae 241 and E. cloacae A113 were
isolated in Edinburgh and Dundee respectively, and were
found to produce the PSE-4 B-lactamase during the 13-
lactamase survey. K. pneumoniae 241 was multiply resistant
to B-lactam antibiotics and other antimicrobial drugs,
E. cloacae A113 was resistant to carbenici 11 in, ampicillin
and cephal oridine (Table 23).
3.2 Transfer of the PSE-4 Determinant from Clinical Bacteria to
Standard Strains
The PSE-4 determinants were transferred from the clinical
strains to E. coli J62-2 and p- aeruginosa PA08 sel ecting
for carbenicil1 in resistance at lOOOmgL-1 (Figure 23).
As is shown in Figure 23, the PSE-4 determinant from
K. pneumoniae 241 (designated da 11)transferred by direct
conjugation to E. coli J62-2 and P« aeruginosa PA08. The
transfer frequency to strain PA08 was two orders of
magnitude less than the frequency of transfer to strain
J62~2# The determinant da 11 transferred freely from E. col i
J62-2 t0 — co^ ^ J53, however, further conjugation
experiments with P. aeruginosa PA08 da 11 transconjugant
failed to transfer dal 1 to either E. col i or P. aeruginosa
recipients.
In the case of the E. cl oacae A113 PSE-4 gene, designated
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Figure 23
Transfer of PSE-4 determinants from clinical bacteria to laboratory
standard strains.(frequency of transfer is given in square brackets)
Transfer of dal 1
K.pneumoniae 241 dal 1
i J6 2-2 P.aeruginosa
r fe«io6] fs.io-8^
E.col i J62-2 dal 1
E.coli J53
?«105]
E.coli J53 dal 1
P.aeruginosa PA08 dal 1
Transfer of dal ^
E.cloacae A113 dal 2
E.coli J62^(R751)
I.





E.coli J62-p (R751 dal 2) P.aerug- nosa PA08 (R751 dal 2)
E.coli J53 P.aeruginosa PA0381
f3-105] [4*10"®3
E.coli J53 (R751 dal 2) P.aeruginosa PA0381 (R751 dal 2)
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by direct conjugation was not possible and the da 12
determinant was mobilised by the introduction of the
trimethoprim resistant incP-1 plasmid R751. The R751
recombinant plasmid transferred to E. col i J62-2 and
P. aeruginosa PA08 after overnight conjugation at similar
frequencies (Figure 23). Both the E. col i J62-2 and
P. aeruginosa PA08 transconjugants containing R751 (dal^X)
could transfer resistance to carbenici 1 1 in to E. col i J53
and P. aeruginosa PA0381 recipients respectively (Figure
23).
The E. col i J62~2 dal 1 transconjugants of K. pneumoniae 241
had acquired resistancetocarbenicillin, ampicil 1 in and
cephaloridine as we 11 as other antimicrobial s (Table 23).
The PA08 transconjugant encoding dal 1 was also multiply
resistant to carbenici 1 1in, ampicillin, cephaloridine,
spectinomycin, streptomycin, sulphamethoxazole and
kanamycin. It was however sensitive to tetracycline,
chloramphenicol, gentamicin and trimethoprim, in contrast to
the E. col i J62~2 transconjugant (Table 23).
The R751 recombinant plasmid which encoded dal 2 conferred
resistance in E. col i J62~2 t0 carbenici 11 in, cephaloridine,
ampicillin, spectinomycin, sul phamethoxazol e and strepto¬
mycin as well as trimethoprim (Table 23).
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3.3 Plasmid Profiles of the PSE-4 Producing Strains
K. pneumoniae 241 was found to contain two large plasmids of
approximately 127kb and 290kb in size (Figure 24, Track D).
The smaller plasmid was the only plasmid visualised in the
E. col i J62-2 anc* transcon0u9ants (Figure 24, Tracks B
and C), this plasmid (pUK700) must therefore carry the gene
for PSE-4 production. The host E. col i J62-2 stra"'n was not
sensitive to phage PR4 and therefore pUK700 was not incP, N
or W.
Plasmid pUK700 was determined as being 132kb in size by
restriction endonuclease digest. No plasmid DNA could be
visualised in the P. aeruginosa PA08 transconjugant encoding
da!1 (Figure 24, Track A). This may be due to difficulty in
extracting intact large plasmids from Pseudomonas by
traditional DNA preparation techniques. However, the fact
that the PSE-4 determinant could not be transferred from the
PA08 transconjugant and that several pUK700 resistance
markers were not seen in this transconjugant strongly
suggested that the da 1 1 gene had integrated into the
P. aeruginosa PA08 chromosome.
The E. cloacae A113 transconjugants contained the
recombinant R751 plasmid which had increased in size by
approximately 13kb (Figure 25, Tracks B, C and D). This
additional piece of DNA encoding the dal2 determinant most
probably originated from the E. cloacae A113 chromosome, as
no plasmid DNA was visualised in this strain (Figure 25,
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Figure 24
Agarose gel electrophoresis of DNA extracted from the dal 1
containing strains.
Method of Kado and Lui (1981).
Track A - P .aerugi nosa PA08 dal_l Track 8 - E .col i J53 dal 1
Track C - E .col i J62-2 dal_ 1 Track D - K .pneumoniae 241 dal 1
Track E - R6K Track F - R1010












Method of Birnboim and Doly (1979).
of DNA extracted from the dal 2
Track A - R751
Track C - E .col i J53 dal_ 2
Track E - E^ cl_oacae A113 dal
Track G - RP4
c=chromosomal DNA
Track B - P.aeruginosa PA08 dal 2
Track D - E.coli J62-2 dal 2
Track F - R6K





Track E). The original R751 plasmid has monomeric and
dimeric forms (Figure 25, Track A).
3.4 Mobilisation of the dal 1 Determinant from P. aeruginosa
PA08 and Restriction Enzyme Analysis
Initially the i ncP-1 plasmid was used as the mobi 1 i si ng
plasmid in the case of the dal 2 determinant. During this
work R751 was found to promote a significant degree of
carbenici 11 in resistance (MIC = 16mgL-1) in the host E. col i
J62-2 strain. This phenomenon was examined further (Chapter
4).
In order to continue the study of the dal 1 and dal 2 genes,
the kanamycin and tetracycline resistant incP-1 plasmid R18-
18 (derived from R18, materials and methods) was used in
place of R751. This plasmid showed no predisposition
towards the induction of carbenicillin resistance.
R18-18 was introduced into P. aeruginosa PA08 dal 1 selecting
for tetracycline resistance. Conjugation experiments were
then carried out with E. col i J62-2 selecting for
carbenici 11 in resistance, which transferred to E. col i J62>2
at a frequency of 7 x 10-6 per donor cell after overnight
conjugation and from there to E. col i J53 at 2 x 10-5 per
donor cell after overnight incubation. The recombinant R18-
18 plasmid increased in size, and restriction enzyme
analysis was carried out (Figure 26).
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Figure 26
Agarose gel electrophoresis of restricted DNA extracted from
R18-18:dal 1 strains.
Track d,E -a(Hindlll) Track c - R18-18 (PstI)
Track a - E .col i J53 R18-18 :dal 1 (PstI) ,
Track b - E.col l J622R18-18:dal_ 1 (PstI)




A PstI digest of R18-18 gave four fragments of 25, 20.5, 6.0
and 1.9kb (Figure 26, Track C). Two recombinant plasmid
clones gave six fragments after digest with PstI (25, 20.5,
8.4, 1.9, 1.8 and 1.7kb). The recombinant plasmids had
increased in size by 6.0kb and the insertion had two
additional P st I sites (Figure 26, Tracks A, B). No
additional Hindl11 sites were found (Figure 26 , Tracks F, G
and H).
The 6.0kb da 11 determinant conferred ca rbenici 1 1 i n ,
ampicillin, spectinomycin, streptomycin and sulphamethox-
azole resistance.
Isoelectric Focusing
During the preliminary B-lactamase survey K. pneumoniae 241
and E. ci oacae A113 were found to produce a B-lactamase,
which when focused on a pH 3.5 - 10.0 IEF gradient appeared
identical to the prototype PSE-4 of the P. aeruginosa
Dalgleish strain (Figure 27). The B-lactamases from both
strains focused as a main band with a pi of 5.3 with two
satellite bands at pis 5.0 and 4.8. Species specific B-
lactamases were observed in both strains, the K. pneumoniae
B-lactamase at pi 7.5 and the E. cloacae B-lactamase at pi
9.0.
When the IEF was repeated with a mixture of narrow range (pH
4-6) and broad range (pH 3.6-10) ampholines (50% v/v), finer








Track A - TEM-1
Track C - K.pneumoniae
Track F. - E.coli J 62-9
Track G - P.aeruginosa PA08
Track I - E.coli J622da_l_ 2
Track K - PSE-4
Track B
241 dal 1 Track 0
Track F
da_l 1 Track H
Track J - P
- PSE-4
- E.col i J62-?dal 1
" P-aeruginosa PA08
- E.cloacae All3 dal 2
.aeruginosa PA08 dal 2
28). The pi of the B-lactamases from the two clinical
strains was marginally higher (0.05 pH units) than the
Dalgleish PSE-4 enzyme.
When the PA08 transconjugants of both K. pneumoniae 241 and
E. cloacae A113 were examined by expanded gradient IEF
(Figure 28, Tracks F and K), the pi of the PSE-4 B-lactamase
produced was identical to that of the prototype "Dalgleish"
enzyme. However, the E. col i transconjugants showed a
similardiscrepancy in pi to that found with the original
clinical isolates (Figure 28, Tracks D, E, I and J).
Mobilisations of da 11 from the PA08 transconjugant with the
R18-18 resulted in transconjugant E. col i J62~2 which
produced the prototype PSE-4 B-lactamase on IEF (Figure 29,
Tracks A and B).
3.6 Substrate Profiles of the PSE-4 B-lactamase Enzymes in the
Original Clinical Strains and Their Respective
Transconjugants
The PSE enzymes can be distinguished by their rapid
hydrolysis of carbenici 1 1 in and slower hydrolysis of
cephaloridine. The rates of hydro 1ysis of penici 1 1 in G,
carbenici 11 in, ampicillin and cephaloridine were measured by
spectrophotometry assay for both the clinical strains and
their transconjugants (Table 24).
In both cases the specific enzyme activities and the
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P. aeruginosa PA08 transconjugants closely resembled that of
the P. aeruginosa "Dalgleish" strain. The B-lactamase
enzymes from the clinical strains and their E. col i
transconjugants resembled each other and they differed from
the Dalgleish enzyme in their slower hydrolysis of
carbenici11 i n and ampicillin. The values for the
K. pneumoniae 241 B-lactamase extract are inflated because
of the presence of the active chromosomal enzyme.
3.7 The Enzyme Kinetics of the B-lactamase Enzymes from the
K. pneumoniae dall Transconjugants
The B-lactamase enzymes from the E. col i J62~2 (pl)K700
da 11), P. aeruginosa PA08 da 11 and E. coli J62-2 (R18-18
dall) transconjugant strains were purified from the
chromosomal B-lactamase by preparative isoelectric focusing.
The Km and Vmax values of these three B-lactamases for
carbenici1 1 i n and cephaloridine were determined as
previously described by spectrophotometry assay (Table 25).
The Km values for cephaloridine were similar for all three
B-lactamases with the E. col i (R18-18 dall) B-lactamase
having the highest affinity. The B-lactamase from the
E. col i dal 1 transconjugant had the highest affinity for
carbenici 11 in, with the other transconjugants having similar
affinity to each other.
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Table25 EnzymeKi eticsofthdallfi-lactamasefrThr etrans onjug nts B-lactamase E.coliJ62~2dal1Paeruginosal1li-2(R18-18) SubstrateKmaVmax*5V xKV Cephaloridine3572.81790.2279.04 Carbenicillin4460. 9238011.170.9 apM bpMsubstratehydrolysedmin te"* le zyme"*
The Vmax values varied considerably for the B-lactamases
produced by the transconjugants. The E. col i da 1 1
transconjugant had the highest Vmax value for cephaloridine,
which was greater than the specific acitivity value implying
that in the previous assay the Vmax had not been reached.
The P. aeruginosa PA08 da 11 transconjugant had the highest
Vmax value for carbenici 11 in with both E. col i B-lactamase
enzymes giving similar values. Again the Vmax values were
much higher than the specific activity values obtained
previously.
Molecular Weight Determinations
The molecular weights of the PSE-4 B-lactamases purified
from E. col i J62-2 (PUK70° da 11). P. aeruginosa PA08 da 1 1,
co^ J62~2 (R18-18 da 11) and P. aeruginosa "Dal gl ei sh"
were determined by gel filtration (Table 26).
Table 26
Molecular Weights of PSE-4 B-lactamase Enzymes
Strain B-lactamase Molecular Wt.
E. coli J62-? (PUK700 dall) 31,000
P. aeruginosa PA08 dall 31,000
E. coli J62-2 (R18.18 dall) 31,500
P. aeruginosa "Dalgleish" 31,800
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The molecular weights of these B-lactamase enzymes did not
differ significantly either from each other or from the
prototype Dalgleish PSE-4 B-lactamase.
The da 11 and dal2 determinants express much higher levels of
PSE-4 production in P. aeruginosa PA08 than in the
Enterobacteriaceae. The differences observed in pi and the
Vmax values of PSE-4 in the different strains suggests that
the biochemical and biophysical properties of the PSE-4
enzyme are host dependent.
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THE INC P-l PLASMID R751
4. Introduction
The incP-1 plasmids such as R751 are invaluable genetic
tools because of their exceptionally broad host range (Ward
and Grinsted 1982). The plasmid R751 (Jobanputra and Datta
1974) has been used for incompatibility testing (Datta 1974)
as well as for genetic analysis and manipulation (Hedges and
Jacob 1975, Meyer and Shapiro 1980, Ward and Grinsted 1982).
The majority of the incP-1 plasmids are resistant to
ampicillin and can therefore not be used in the analysis of
B-lactam resistance genes. R751 however, confers resistance
to trimethoprim only, which is encoded by Tn402 (Shapiro and
Sporn 1977) and this plasmid is therefore used in the
manipulation of B-lactam resistance determinants (Hedges and
Jacob 1975).
As described in the previous chapter, R751 was used as a
broad host range plasmid to mobilise the PSE-4 determinant
da 12 from E. cloacae to E. coli J 6 2 ~ £ 2nd P. aeruginosa
PA08. During this work, R751 itself was found to have
several previously undescribed properties which have been
examined in the following chapter.
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Results
The incP-1 plasmid R751 was found to confer a significant
degree of carbenicillin and ampici11 i n resistance on its
host strain E. col i J62during routine sensitivity
testing. In order to confirm that this was not an isolated
occurrence with the plasmid from our own laboratory culture
collection, a culture of E. col i J 62-1 (R751) was obtained
from the National Plasmid Collection at the Central Public
Health Laboratories, Colindale. The MICs of carbenici 11 in
(CARB), ampicil1 in (AMP), cefuroxime (CXM), cephaloridine
(CER) and trimethoprim (Tp) were determined for the
1aboratory strain E. col i J62-2 (R751) and the Colindal e
strain E. col i J62-1 (R751) (Table 27). Strains were
inoculated on to DSTA plates containing doubling dilutions
of antimicrobial drugs, the inoculum used was 106 CFU ml-1.
Table 27






E. coli J62-2 (R751) 16 16 4 8 >1000
E. coli J62-: (R751) 16 16 4 8 >1000
E. coli J62-2 0.5 0.5 0.5 1 2
E. coli J62-x 0.5 0.5 0.5 1 2
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The two strains did not appear to differ and the E. col i
J62-1 (R751) strain from the National Plasmid Collection was
also found to be resistant to low levels of carbenici 11 in
and ampicillin. The E. coli J62-l (R751) strain from
Colindale was used in further transfer experiments.
4.2 Transfer Studies
Trimethoprim resistance encoded by E. col i J62-^ (R751)
transferred to E. coli J62-2 at a frequency of 7.2 x 10"3
per donor cell after an overnight mating, selecting for
trimethoprim (10mgL-l) and rifampicin (20mgl_-l) resistant
transconjugants on suitably supplemented minimal medium.
When selection was made for ampicillin (8mgL-l) and
rifampicin resistant transconjugants, no transfer of R751
was observed. Similarly, no transconjugants were isolated
when selection was made on minimal plates containing
trimethoprim, ampicillin and rifampicin at the same
concentrations.
In order to study the properties of the B-lactam resistance
of R751, this plasmid was transferred to E. col i J62 which
had no chromosomal resi stance mutations. This conjugation
was carried out from E. col i J62-1 v"ia E« C°T "* J53 to allow
selection to be made for the transfer of the R751 plasmid.
The transfers of R751 to E. coli J53, E. coli J62 and the
other bacterial strains are detailed in Table 28. All
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donors were E. coli J62-1 (R75D except, as described above,
for the transfer into E. col i J 62. All mati ngs 1 asted 18
hours and selection was made on Davis and Mingioli agar
plates containing the supplements listed and trimethoprim at
the concentration given in Table 28.
Table 28
Transfer of the R751 Plasmids to Various Bacterial Host Strains
Frequency of transfer
Recipient strains Selection per viable donor cell
E. coli J53 TplO Pro Met 4.4 X 10"3
E. coli J62 TPio His Pro Trp 6.6 X 10"4
E. coli PB1150 recA TplO His 6.7 X io-4
E. coli 114 TPlO 9.8 X 10"7
P. aeruginosa PA08 TpiOOO 11v Met 3.7 X 10"5
These transconjugants were used in further studies of the
R751 plasmid.
4.3 Mutation Frequencies of Strains Containing the R751 Plasmid
to Carbenicillin Resistance
The mutation frequencies to carbenicillin resistance
(10mgL-l) for E. col i J62 (R751), E. col i PB1150 recA (R751)
and E. col i 114 (R751) and also carbenicillin resistance
(125mgL-l) for P. aeruginosa PA08 (R751) were compared with
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the mutation frequencies for the isogenic strains lacking
the plasmid. Overnight nutrient broth cultures (4.5mls)
were washed in Davis and Mingiol i minimal medium and then
resuspended in (4.5ml s) minimal medium. These suspensions
were plated on to DSTA plates containing carbenicil1 in. The
culture was diluted in tenfold steps (in minimal medium) to
10-6 and each dilution was plated on the same medi urn. The
mutation ra4es- per viable cell for each strain are given in
Table 29.
The plasmid R751 confers a low level of resistance to
carbenici 11 in and ampicillin in E. col i J62 and in E. col i
PB1150 recA and also increases the mutation frequency of
resistance to carbenici11 in in E. coli J62 and E. col i
PB1150 recA (Table 29). Elevated mutation frequencies to
ampicillin resistance (10mgL-l) were also found, 3.7 x 10"^
for E. coli J62 (R751) and 4.0 x 10-6 for E. coli PB1150
recA.
The expression of this resistance to ampicillin and
carbenicillin and its mechanism were examined further.
Colonies of E. col i J62 (R751) taken from both a
carbenicillin plate and an ampicillin plate (10mgL-l) were
purified and the MICs of both carbenicillin and ampicillin
for these strains were determined.
Both the strains isolated from the carbenicillin (10mgL-l)
plate E. coli (R751C) and the strain isolated from the
ampicillin (10mgL-l) plate E. coli J62 (R751A) had the same
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Table29 MutationRatesof751C n ainingStrai stoCarben cillinResista ce E.coliJ62 E.coliPB1150recA E.coli114 P.aeruginosaA08MutationFreque cyperVi bleCe loldIncrease
(R751strain)
StraincontainingIsogenic(i istra ) R751strain 1.6x0"4 1.27x0"6 1.1x0"8 2.0x10"92.5x10"8 9.3x10"9 3.4x10"8 1.0x0"9
6.4x103 1.4x02 0.32 2
MICs ofcarbenicillin and ampici11in, (125mgL-l compared
with 16mgL-l for strains which had not been pre-exposed to
these B-lactams).
In order to determine whether these changes had arisen from
physical alterations of the R751 plasmids in these strains,
restriction enzyme analysis was carried out.
4.4 Restriction Enzyme Analysis of the R751 Plasmid
The R751 plasmid isolated from E. col i J62 was compared by
restriction endonuclease digest to the plasmids isolated
from both the high level ampicillin resistant strain,
E. col i J62 (R751A) and the high level carbenici 1 1 in
resistant strain, E. col i J62 (R751C). The plasmids were
isolated from the three strains and digested with either
Hind111 or EcoRl restriction endonucleases (Figure 30). No
differences were seen in the restriction patterns of these
three plasmids. It appears, therefore, that there are
almost certainly no changes in the DNA of plasmids R751A or
R751C when compared with R751, and that these plasmids are
the same.
4.5 Mutation Frequencies of R751 Containing Strains to a Variety
of Antimicrobial Agents
It had been found that R751 in E. col i J62 and E. col i
PB1150 increased the mutation frequency to carbenicil 1 in
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mutation rates of resistance to other B-lactam and non-B-
lactam antimicrobial drugs in E. coli J62 and E. col i 114.
Mutation rates were determined as before, plating tenfold
dilutions of washed overnight cultures of the strains. The
antimicrobial drugs tested were cephal ori dine (CER),
streptomycin (Sm), chloramphenicol (Cm), nalidixic acid (Na)
and tetracycline (Tc). All were tested at 10mgL-l in DSTA
plates and comparison was made with the results previously
obtained for carbenici 11 in (4.3). The results obtained are
detailed in Table 30.
As expected, low mutation frequencies were observed with
E. coli J62 and E. col i 114 which did not contain R751. The
E. coli J62 (R751) strain had increased mutation frequencies
to cephaloridine, streptomycin and tetracycline as well as
carbenicil 1 in. However the E, col i J62 (R751) strain which
had mutated to high level ampicil1 in and carbenici11 in
resistance had low mutation frequencies to cephaloridine,
streptomycin and tetracycline resistance and increased
mutation frequencies to chloramphenicol and nalidixic acid
resistance. The E. col i 114 (R751) strain had low mutation
frequencies for all the antimicrobial drugs tested.
Colonies of E. col i J62 which had mutated to antimicrobial
drug resistance were taken from the DSTA plates containing
the individual drugs and tested for cross-resistance to the
other antimicrobial agents. None of the mutant colonies had
cross-resistance to the remaining antimicrobial drugs
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Table30 MutationFrequenciesofR751ContainingStr instVar tyAn imicrobialg t MutationFrequencies StrainsCARBERmNaTc E.coliJ622.5x10"8493 6^lO"11.1 710"10 E.coliJ62(R751)1.6x0"47.41 "36 909 3"105973 E.coliJ62(R751A)-1.x0"87 97483<10 U E.coli1143.2x0"896 7~9<10"n<-10-u< 0~n E.coli114(R751).1x0"8294 6^lO"11810" 0<.10"n
although some mutant colonies from carbenici11 in plates grew
on cephaloridine plates and vice versa.
In contrast, with strains containing the R751 plasmid,
mutations which had resulted in resistance to a particular
antimicrobial drug also produced cross-resistance to several
other antimicrobial agents. This was especially true of
E. col i J62 (R751) mutant colonies isolated from DSTA plates
containing individual antimicrobial drugs (Table 31).
Table 31











Carbenicill in + +/- + - +
Cephaloridine + + + +
Streptomycin + + + + +
Nalidixic Acid + - - + - +
Tetracycl ine + + + + + +
Chioramphenicol + + + + + +
a +, growth; no growth; +/-, poor growth
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It appeared from these results that the presence of the R751
plasmid in E. col i J62 may encourage a mutation or mutations
which produced broad spectrum antimicrobial drug resistance.
4.6 Response of E. coli J62 (R751) to Increasing Doses of
Ampicil1 in
Two E. col i J62 strains containing R751 were studied
further; E. col i J62 (R751) which had not been pre-exposed
to ampicil 1 in or carbenicil 1 in (MIC = 16mgL-l), and E. coli
J62 (R751A) which had been pre-exposed to ampicillin and had
an MIC of 125mgL-l. In order to assess whether these two
strains had different responses to ampicillin, they were
challenged by increasing doses of ampicillin and their
response was compared to that of the sensitive strain
E. col i J62.
Overnight broth cultures were diluted in isosensitest broth
to give a viable count of 9.1 x 106 bacteria ml -1 (E. col i
J62); 3.2 x 107 bacterial ml-1 (E. coli J62 (R751)) and 8.8
x 106 bacterial ml-1 (E. col i J62 (R751A)). Doubling
dilutions of ampicillin (64 - 2mgL-l) were added to 5ml
amounts of the cultures which were incubated statically
overnight and the viable counts determined (Figure 31).
The results show that E. col i J62 exhibited the expected
bactericidal response to increasing doses of ampicillin.
Both E. col i J62 (R751) and E. col i J62 (R751A) were less
susceptible to the action of ampicillin and were
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Figure 31
The growth of piasmid-containing strains (E.coli J62 (R751) and
E.coli J62 (R751A)) in increasing concentrations of ampiciTlin
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bacteriostatic in their response. Although the two strains
containing R751 differed markedly in their MICs of
ampicillin no great difference was seen in their dose
response to ampicillin.
It appeared that E. col i J62 (R751) and E. col i J62 (R751A)
had a resistance mechanism(s) to ampicillin that enabled
them to overcome the bacteriocidal action of this drug.
Therefore, growth of E. col i J62 (R751) was examined in the
presence of a fixed concentration of ampicillin.
%
4.7 Growth of E. col i J62 (R751) in the Presence of a Constant
Concentration of Ampicillin
The effect of ampicillin (5mgL-l) on the growth of a
1 ogarithmic (1 og) phase cul ture of E. col i J62 (R751) was
examined. This was compared with the effect of the same
concentration of ampicillin on a log phase culture of
E. col i J62.
Static overnight isosensitest broth cultures of the two
strains were diluted 1 in 10-4 in prewarmed broth to get
cultures into log phase, and the viable counts were
determined every hour. Each culture was divided in half at
two hours and ampicillin (5mgL-l) added to one half only
(Figure 32).
Ampicillin had a bactericidal effect on a log phase culture
of E. col i J62 and the viable count dropped after the
addition of ampicillin 5mgL-l at two hours. The effect of
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Figure32Therowthc rveofE.coliJ62(R751)nt pres nceandb ncef 5mgL~1ofampicillin,com aredwiththeisogenicstra nE.co iJ62 Shadedsymbolsreculturestowhich5mgL~la pi illinadd dt time=2hours.
ampici 11 in on the viable count of the E. coli J62 (R751)
strain was markedly different from that of E. col i J62.
Ampicillin had no immediate effect on the growing E. col i
J62 (R751) culture. The culture however did enter
stationary phase at around 108 organisms/ml. This was one
order of magnitude lower than seen with the control culture.
These results, in effect, confirmed those of the dose
response curve, indicating that R751 had allowed the E. col i
J62 strain to overcome the bactericidal effect of
ampicillin.
4.8 Possible Resistance Mechanisms to Ampicillin and
Carbenicillin Mediated by the R751 Plasmid
Outer membrane proteins and penicillin binding proteins
The outer membrane proteins (OMPs) and penicillin binding
proteins (PBPs) of E. col i J62 (R751) and E. col i J62
(R751A) were examined in order to determine whether R751 was
causing a mutation in these types of protein which resulted
in a resistant phenotype.
No major changes were seen in the outer membrane proteins of
E. col i J62 (R751) when compared with E. col i J62 (Figure
33, Lanes A and B). The major outer membrane proteins,
OmpA, OmpC and OmpF were present in both strains. An outer
membrane preparation of E. col i J62 (R751A) was also
examined (Figure 33, Lane c). The three major OMPs were
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Figure 33
SDS-PAGE of outer membrane proteins extracted from R751 containing
strains.
Track A - E.col i J62 Track B - E.col i J62 (R751)
Track C - E.coli J62 (R751A)
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present in this strain, however, some minor outer membrane
proteins appeared to be over-produced when compared to the
E. col i J62 profile.
Densitometry traces of the SDS-PA6E gel were made to compare
the relative amounts of each major outer membrane protein in
the three strains (Figure 34). OmpC and OmpA appeared to be
present in the same relative amounts, however the porin OmpF
was produced in smal ler proportions in both strains which
contained R751 when compared with E. col i J62 without the
plasmid. A mutation, resulting in the reduction of the
amount of porin protein OmpF (the larger porin channel in
E. col i) may explain the broad spectrum drug resistance of
E. col i J62 (R751) strains (Section 4.5). Reduction in the
permeability of the outer membrane can affect the
sensitivity of bacteria to a variety of antimicrobial
compounds.
The PBPs of both R751 containing strains were compared with
those produced by E. col i J62 which did not contain the
plasmid. Competition assays with non-radioactive ampicillin
were carried out in order to obtain S50 va^ ues ^or eac^ °f
the PBPs (materials and methods). Low S50 values indicate
that the competing ampicillin had high affinity for the PBP.
Figure 35 shows the fluorographs obtained for strains
E. coli J62, E. coli J62 (R751) and E. col i J62 (R751A).
The most obvious difference between the strains was that
A
E. col i J62 (R751') appeared to have a very low affinity
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Figure 34
Densitometry traces of the outer membrane protein profiles of E.coli
J62 strains containing the plasmids R751A (a) and R751 (b), compared
to the isogenic strain E.coli J62 (c)
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Figure 35
Fluorographs of penicillin binding proteins extracted from
(a) E.COH 062 (b) E.COli J62 (R751) and (c) E.coli J 6 2 (R751A).
The concentrations of ampicillin used in the competion assays are
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PBP3. This PBP is the principal lethal target for
amp i c i 1 1 in in E. col i and its loss would explain the high
MIC of ampicil 1 in for E. col i J62 (R751A) of 125mgl_l. The
ampicillin S50 values for each of the strains are given in
Table 32.
Table 32
Binding of Ampicillin to Target Proteins
Ampicillin S50 value for PBPsa
Ampicillin
Strain MIC (mgL-1) la lb 2 3 4 5 6
E. coli J62 0.5 0.5 4 0.5 0.5 2 >16 >16
m • 0 0 J62 (R751) 16 . 0.5 4 4. 1.0 2 64 8
m • 0 0 J62 (R751A) 125 2 4 2 - 2 64 16
a See materials and methods (mgL-1)
The E. col i J62 (R751) strain appears to have a similar PBP
profile to that of E. col i J62, although PBP2 may have less
affinity for ampicillin. It is probable that changes in the
affinity of the PBPs do not account for the ampicillin
re si stance of E. col i J62 (R751) in the same way as they do
for E. coli J62 (R751A).
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4.9 Isoelectric Focusing of Cell-Free Extracts from R751
Containing Strains
The results obtained from OMP and PBP studies might not
account wholly for the ampicillin resistance of the R751-
containing strains. Therefore, the resistant strains were
examined for the presence of B-lactamase enzymes. IEF of
eel 1 free extracts from E. col i J62 (R751A) and E. col i J62
(R751C) did reveal a B-lactamase in addition to the
chromosomal enzyme. The B-lactamase pi corresponded to that
of SHV-1 on IEF (Figure 36a, Lanes E and F). No B-lactamase
enzyme was seen in extracts from E. coli J62 (R751) which
had not been pre-exposed to ampicillin. Similarly mutant
E. coli J62 (R751) colonies from the cephaloridine and
nalidixic acid plates (section 4.5) did not produce SHV-1
(Figure 36a, Lanes A, B and C). The E. col i 114 (R751)
strain taken from an ampicillin plate (10mgL-l) produced
very weak SHV-1 activity on IEF.
The cultures of P. aeruginosa PA08 (R751) and E. col i PB1150
recA (R751) did not produce this B-lactamase even after
mutation to higher levels of ampicillin resistance (section
4.5). However, the culture of P. aeruginosa PA08 (R751) did
produce large amounts of chromosomal B-lactamase in the
region of the SHV-1 B-lactamase (pi 7.0 to 8.0) which made
identification of SHV-1 difficult in this strain (Figure
36b, Lanes A, B and C). The SHV-1 B-lactamase has been
identified in both chromosomal and plasmid locations.
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Figure 36





A - E .coli J62(R751) Track R - E .coli J62(R751CER)
C - E.coli J62(R751Na) Track n - E.coli J62
E - E .col i" J62(R751A) T rack F - E .coli J62(R751C)
G - SHV-1 Track H - OXA--1 Track I - OXA-2







Therefore it was decided to cure the SHV-1 producing strain
(E. col i J62 (R751A)) in order to determine the location of
the 13-1 actamase gene.
4.10 Curing the E. coli J62 (R751) SHV-1 Producing Strains
To determine the genetic location of the SHV-1 [3-1 actamase
gene a culture of E. col i J62 (R751A) which produced SHV-1
was cured of R751 and tested for the presence of the SHV-1
[3-1 actamase. Nutrient broth cultures (4.5ml s) of E. col i
J62 (R751A) were grown statically to log phase and lOOpl of
phage PRR1 was added (109 pfu ml-1). Phage PRR1 only lyses
those cells which contain R751. After overnight incubation,
the culture was enriched for cells which had spontaneously
lost the R751 plasmid. The overnight culture was diluted
10-6 in minimal media and plated on to nutrient agar,
individual colonies were then tested for the loss of
trimethoprim resistance. Nine trimethoprim sensitive clones
were isolated (138 colonies were tested), purified and the
loss of R751 from these bacteria confirmed by agarose gel
electrophoresis (Figure 37). All nine clones were found to
be resistant to both carbenici 11 in and ampicillin (10mgL-l)
but sensitive to tetracycline, chloramphenicol, gentamicin,
nalidixic acid and streptomycin as well as trimethoprim (all
tested at 10mgL-l).
When examined by IEF at least three of the nine clones
produced SHV-1, albeit at a very low level (Figure 38).






gel elecrophoresis of DNA extracted from
clones of E.coli J62 cured of the R751 plasmid.
Takahashi and Nagano (1984).
ampici11in
Tracks A - I - E.coli J62 clones 1 to 9.








Isoelectric focusing of cell-free extracts from ampici11in resistant
E.coli J62 cured of the R751 pi asmid.
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was tested in the presence of clavulanic acid (16mgL~l), all
were sensitive. As clavulanic acid is an inhibitor of the
SHV-1 B-lactamase this would strongly suggest that SHV-1 is
the resistance mechanism to ampicillin and carbenici 11 in in
the nine cured strains and that the SHV-1 B-lactamase is
situated on the chromosome of E. col i J62. The 1 evel s of
production of SHV-1 were extremely low and it would be
necessary to concentrate the enzyme extracts in order to
visualise SHV-1 in the six cured E. col i J62 strains which
did not appear to produce the B-lactamase.
It is possible that the SHV-1 gene may have transposed from
the R751 plasmid to the chromosome of the cured strains.
The high incidence of the B-lactamase amongst the cured
strains (at least a third and probably as high as nine out
of nine, in view of the clavulanic acid resuits) would be
too high a frequency for such a transposition event.
An E. col i J62 strain which had been mutated to ampicillin
resistance was also examined by IEF, and no additional B-
lactamase activity was found. It appears therefore that the
presence of R751 is required for the expression of the SHV-1
B-lactamase in the E. coli J62 chromosome.
The R751 plasmid appears to have the effect of mutating
E. col i J62 strains to antimicrobial drug resistance. The
same effect was also seen with carbenici11 in when the
plasmid was present in E. col i PB1150 recA. The recA strain
was included to confirm that no generalised recombination
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between R751 and the E. col i J62 chromosome was responsible
for the increased mutation frequencies observed. The
mechanism by which the R751 plasmid causes mutation remains
undiscovered. It appears, however, that the presence of the
R751 plasmid is necessary to maintain such a mutation or
mutations conferring broad spectrum resistance to a variety
of antimicrobial drugs. Cured E. col i J62 strains were
found to be sensitive to all antimicrobial drugs tested
except carbenici 11 in and ampicillin (section 4.10).
The mutation mechanism present on the R751 plasmid has
resulted in the identification of a previously unexpressed
SHV-1 B-lactamase enzyme, probably located on the chromosome
of E. col i J62. When selection was made on ampicil lin or
carbenici 11 in containing plates, R751 appeared to promote a
mutation which allowed the expression of this otherwise
silent B-lactamase. It is possible that this enzyme is also
produced by a non-K12 strain E. col i 114, in the presence of
the R751 plasmid, however this result remains to be
confirmed.
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6-LACTAM RESISTANCE NOT ASSOCIATED WITH THE PRODUCTION OF
A B-LACTAMASE ENZYME
5. Introduction
B-lactamase enzymes play a major role in bacterial
resistance to B-l actam antibiotics (Richmond and Sykes 1973,
Medeiros 1984). There are, however, increasing numbers of
reports of enterobacterial strains which owe their B-lactam
resistance to a mechanism other than the production of a B-
lactamase. Changes in the PBPs and OMPs can both result in
B-lactam resistance (reviewed by Spratt 1983, Nikaido 1985).
Transferable B-lactam resistance is mainly attributable to
piasmid-mediated B-lactamase enzymes (reviewed by Medeiros
1984). There have been no reports of transferable genes
encoding altered PBPs, although there have been reports of
reductions in the porin proteins being associated with the
presence of a plasmid (Iyer et a_l_ 1978, Rossouw and Rowbury
1984).
During the survey of cepha 1 oridine resistant strains, a
group of six strains wajS identified which could transfer
resistance to B-lactams which was not B-lactamase mediated.
5.1 Results
Six enterobacterial strains were isolated from patients in
Edinburgh's Royal Infirmary. The strains were resistant to
low levels of ampicillin (AMP), cepha 1 ori di ne (CER) and
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cephradine (CED) in addition, some of the strains were
resistant to tetracycline (Tc) and spectinomycin (Sp) (Table
33). The strains comprised one E. col i isolate, and five
P. vulgaris isolates.
Table 33







A182 E. col i 8 16 4 Tc
A261 P. vulgaris 32 32 16 TcSp
A263 P. vulgaris 16 64 16 Tc
A264 P. vulgaris 32 8 8 TcSp
A265 P. vulgaris 16 2 16
A266 P. vulgaris 8 16 16 Sp
Cell free extracts were examined by analytical IEF and all
six strains produced a B-lactamase enzyme (Figure 39).
Conjugation experiments were carried out to ascertain






















5.2 Transfer of the B-lactam Resistance Genes
Conjugation experiments were carried out with E. col i J62-2
and P. aeruginosa PA08 as potential recipients. Overnight
conjugation mixtures were plated on to Davis and Mingioli
minimal agar plates containing appropriate supplements and
antimicrobial drugs.
Initially, strain A182 was mated overnight with E. col i J62-
2 and selection was made for transfer of either cephradine
resistance (8mgL-l), ampicillin resistance (2mgL-1) or
cephaloridine resistance (4mgL~l). No transfer was observed
when selection was made on cephaloridine containing plates,
however transfer was observed when selection was made on
cephradine (2.7 x 10-5 per donor cell) or ampicillin (8.1 x
10-6 per donor cell) containing plates.
The remaining five P. vulgaris strains were conjugated
overnight with E. col i J62-2 selecting for transfer of
ampicillin resistance and all transferred their resistance
at the frequencies given in Table 34. Transfer of the B-
1actam resistance to P. aeruginosa PA08 was attempted for
all six strains. An overnight conjugation mixture was
plated on to minimal media supplemented with amino acids,
streptomycin (lOOmgL-l) and carbenici 1 1 in (125mgl_-l). No




Transfer of Ampicillin Resistance to E. coli J62-?
Transfer Frequency
Strain (per viable donor cell)
A182 8.1 x 10-6
A261 1.3 x 10-6
A263 4.9 x 10"7
A264 4.8 x 10-7
A265 9.3 x 10"7
A266 1.0 x 10-6
It appeared therefore that the B-lactam resistance
transferred from the clinical strains to E. col i J62-2 but
was not freely transferable to P. aeruginosa PA08 and the
resistance determinant has a narrow host range. The E. col i
^*>2-2 transconjugants were further conjugated overnight with
E. coli J53, with selection again made for transfer of
ampicillin resistance. This experiment was to determine
whether the frequency of transfer of the B-lactam
determinants was higher or lower between strains of E. col i




Transfer of Ampicillin Resistance from E. coli J62-2 to
E. coli J53
Original Clinical Transfer Frequency to E. coli J53
Strain (per viable donor eel 1)
A182 ro • 00 X 1^10f-H
A261 3.5 X 10-7
A263 00•00 X 0
A264 3.0 X 10"7
A265 3.2 X ►—1 0 1 -^1
A266 4.4 X 10"7
The transfer frequencies between E. coli K12 strains were
all slightly 1ower than those observed from the clinical
isolates to E. coli J62-2' Although the transfer frequency
of the B-lactam resistance was low, no colonies grew on the
control plates and the transfer frequency was approximately
two logs higher than the mutation frequency of E. col i J62~2
to ampicillin resistance (1.0 x 10-9 per viable cell).
The sensitivity of the E. col i J 6 2 — 2 transconjugants to a




Sensitivity of E. coli J62-£ Transconjugants
MICs
Original Clinical
Strains CER CED AMP
Other
Resistances
A182 4 8 32 Tc
A261 4 32 32 Sp
A263 4 64 32 Tc
A264 4 8 16
A265 4 16 16
A266 4 32 16 Tc
E. coli J62-o 4 8 2
All the transconjugants were sensitive to cephaloridine but
showed similar sensitivity to cephradine and ampicillin as
seen in the clinical strains. However, the transconjugant
of A182 is more resistant to ampicillin than the original
clinical strain.
Isoelectric Focusing and DNA Analysis of Transconjugants
Isoelectric focusing of cell free extracts from the E. col i
J62~2 transconjugants was carried out to determine whether
any of the clinical isolates had transferred a 6-lactamase
enzyme to E. col i J62~2 which could account for the B-lactam
resistance. The only B-lactamase visualised in the
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transconjugants was the E. col i J62-g chromosomal enzyme.
In addition, spectrophotometric assays were carried out with
the crude B-lactamase extracts. Cephaloridine, cephradine
and ampicillin were used as substrates in the assays, but no
hydrolysis was observed.
The DNA of the six E. coli J62-£ transconjugants was al so
examined for the presence of plasmids by the alkaline
denaturation method (Figure 40). Only one transconjugant
(that of A182) contained a plasmid which was designated
pUK703 and was 97kbases in size. The plasmid pUK703 was
seen in the clinical isolate and also in the E. col i J 53
transconjugant. No plasmid DNA could be visualised in the
five P. vul gari s E. col i J62-2 or transconjugants.
It appears that in the case of E. col i A182, the 6-lactam
and tetracycline resistance is associated with plasmid
pUK703, however, the genetic carrier of resistance in the
P. vulgaris transconjugants is less clear.
It does appear that some exchange of genetic material was
taking place as the frequencies of transfer were higher than
the strain mutation frequencies.
In the absence of an obvious B-lactamase to explain the
resistance, the outer membrane proteins and penicillin





Method of Takahashi and Nagano (1984).
Track A - E.coli J622(A261) Track B
Track C - E.coli J622(A182) Track 0
Track E - E.coli J622(A265) Track F
Track G - RFi< ~ Track H
Track I - R1
c=chromosomal DNA











5.4 Examination of the Outer Membrane Proteins of the
Transconjugants
As the B-lactam resistance mechanism of the transconjugants
could not be attributed to a B-lactamase, the OMPs of the
six strains were examined by SDS-PAGE (Figure 41). The
outer membrane profile of three of the transconjugants
(A182, A264 and A265) looked very similar to that of E. col i
J62-2* reroaining three transconjugants (A266, A263 and
A261) all showed changes in their major OMPs. Densitometry
traces of the proteins produced by these three strains are
shown in Figure 42 and compared with that of E. col i J62-?.
The E. coli J62-2 transconjugant of A266 did not appear to
produce OmpF which functions as a porin protein,
alternatively the protein may only be present in very small
amounts. Similarly, the transconjugant of A263 under¬
produced OmpF which is evident both from the SDS-PAGE gel
and the densitometry trace (Figures 41 and 42). OmpF was
also greatly diminished in the transconjugant of A261,
however, this strain differed from the transconjugants of
A266 and A263 in that it produced a larger amount of OmpA
which does not function as a porin protein (Figures 41 and
42).
In three of the six transconjugants therefore, the B-lactam
resistance may be attributable to changes in the OmpF porin
protein which provides a channel for the entry of B-lactam
antibiotics. However, the resistance mechanism of the
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Figure 41
SDS-PAGE of outer membrane proteins extracted from transconjugants
of the (3-lactam resistant, !3-lactamase negative strains.
Track A - E.coli J622 Track B - E.coli J622(A182)
Track C - E.coli J62?(A264) Track D - E.coli J62?(A265)
Track E - E.coTT J62?(A266) Track F - E.coTT J62?(A263)
Track G - E.coli J622(A261)
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Figure 42
Densitometry traces of the outer membrane profiles of the
transconjugants of strains A266, A263 and A261 compared with that of
the isogenic strain E.coli J62-?.
(a) E.col i -J62-P(A266) (b) E.col i J62-?(A263)
(c) E.coli J62-2(A261) (d) E.coli J62-2
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remaining three transconjugants was still undetermined and
therefore the PBPs of two of the strains A182 and A265 were
examined.
Examination of the Penicillin Binding Proteins of Two of the
Transconjugants
The transconjugants of strains A182 and A265 were examined
for possible changes in their PBPs, again comparison was
made with the profile of E. col i J62-q
Competition assays were carried out with isolated PBPs from
each of the three strains. Unlabel led ampicillin was used
as the competing B-lactam in doubling dilutions around the
MIC of the strain (materials and methods). The concen¬
tration of ampicillin (mgl-1) which reduced the binding of
the radi ol abel 1 ed benzyl penicillin by 50% (S$q) was
determined by eye and the results are given in Table 37.
Table 37
Inhibition of Binding of (14c) Benzyl Penicillin by
Ampicil1 in
MIC of S50 (mgL-1) of PBP
Strain Ampicillin
(mgL-1) la lb 2 3 4 56
E. coli J62-2 2 0.25 4 0.5 1 2 >16 8
E. coli J62-2 A182 32 0.5 4 2 2 4 >64 32
E. coli J62-? A265 16 0.5 1 1 1 2 >65}- 8
21+0
No significant difference in the S50 valUes of ampicillin
for any of the PBPs was observed in either transconjugant.
The MICs of ampicillin for both of the transconjugants,
however, are higher than the S50 va1ues f°r the essential
PBPs. This indicates that there is another resistance
mechanism playing a role in these strains. The resistance
of three of the transconjugants to tetracycline and of one
to spectinomycin (Table 36) suggests that the resistance
mechanism may be less specific than changes in the B-lactam
target sites and may have more to do with alterations in the
permeability of the strains. Alterations in OMPs were found
in three transconjugants and it is possible that other
changes such as those in the 1ipopolysaccharide may account
for the B-lactam resistance of the remaining three
transconjugants
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AMPICILLIN RESISTANCE MECHANISMS IN HAEMOPHILUS INFLUENZAE
6. Introduction
A population of 105 clinical isolates of Haemophi 1 us
infl uenzae were collected in Edinburgh in 1983/4 from sputum
specimens provided by patients at the City Hospital,
Edinburgh.
H. infl uenzae are intrinsically resistant to intermediate
levels of first generation cephalosporins (Garrod et al
1981), therefore clinical strains were screened for
resistance to ampicillin.
Ampicillin resistance in H. inf1uenzae was first reported in
1974 (Thomas e_t 1974) and since then the incidence of
resistant isolates has increased worldwide (Schwartz 1978,
Scheifele 1979, Lerman et_ a_l_ 1980). The most common
resistance mechanism to ampicillin in H. influenzae is the
production of the TEM-1 B-lactamase enzyme (Medeiros 1984).
More recently, there have been reports that a new plasmid-
mediated B-lactamase, designated R0B-1, can also mediate
ampicillin resi stance in this species (Rubin et al 1981,
Medeiros 1984). Ampicillin resistant H. influenzae have
also been isolated in which no detectable B-lactamase
activity can be found (Parr and Bryan 1984, Mendelman et al
1984). In these studies, a limited number of strains were
examined and changes in the PBPs appear to have been the
causative resistance mechanism.
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Changes in outer membrane proteins (OMPs) of Gram negative
bacteria can also lead to 6-lactam resistance as a
consequence of reduced permeability (Nikaido 1985).
However, studies of OMPs in H. inf 1 uenzae are compl icated
because there may be a correlation between OMP profile and
biotype (Barenkamp et aj_ 1981, 1982, van A1 phen _et £l_ 1983).
Permeability changes in one H. inf1uenzae strain have been
found associated with the loss of a 27,000 dalton protein
from the outer membrane (Mendelman et a_l_ 1984).
This study examined the incidence and principal mechanism of
ampicillin resistance amongst 105 non-sero-typable
H. i nf 1 uenzae strains.
6.1 Results
Fifteen (14.3%) of the 105 H. i nf 1 uenzae strains were
resistant to ampicillin at lmgL-1. The ampicillin resistant
strains were non-serotypabl e. however, representatives of
six of the seven H. inf1uenzae biotypes were found (Tab! e
38). The nitrocefin spot test (Materials and Methods)
indicated that nine of the 15 strains were B-lactamase
producers.
6.2 Minimum Inhibitory Concentration (MIC) Determination
The MICs (Table 39) of ampicillin for the B-lactamase
positive strains were generally higher (8-500mgL-l) than
those for the B-lactamase negative strains (2-16mgL_1).
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Table 38
Biotype and B-lactamase activity of ampicillin resistant
H. influenzae
Strain Nitrocefin B-lactamase B-lactamase Biotype
No. spot test activity*
52 + TEM-1 4.8 I
74 + TEM-1 21.0 I
572 + TEM-1 5.4 I
584 + TEM-1 12.0 III
585 + TEM-1 7.4 IV
588 + TEM-1 1.2 II
639 + TEM-1 14.2 II
714 + TEM-1 12.6 V
733 + TEM-1 8.0 V
118 - NONE 0.1 VI
156 - NONE 0.1 II
243 - NONE 0.1 I
564 - NONE 0.1 II
621 - NONE 0.1 V
684 - NONE 0.1 II
1184E - NONE 0.1 III
* = nmoles cephaloridine hydrolysed minute-1 mg protein"*
2Ub
Table 39




PIP CED CFX CXM CTX
52 16 0.125 4 16 8 0.5 0.01
74 8 0.125 4 16 4 0.5 0.01
572 125 0.125 32 8 4 0.5 0.01
584 500 0.125 16 250 8 2 0.01
585 250 0.125 64 250 4 0.5 0.01
588 16 0.125 0.2 64 4 1 0.01
639 500 0.125 32 8 2 0.5 0.01
714 64 2. 64 16 32 4 0.01
733 125 0.125 2 16 4 0.5 0.01
118 8 4 0.05 125 4 4 0.06
156 2 1 0.05 16 2 0.5 0.01
243 4 2 0.5 64 4 1 0.01
564 16 4 0.2 16 8 4 0.01
621 16 2 0.05 16 4 1 0.01
684 4 2 0.05 64 8 2 0.01
1184 E 0.125 0.125 0.03 16 2 0.5 0.01
AMP = AmpiciHin, PIP = Piperacillin, CED = Cephradine,
CFX = Cefoxitin, CXM = Cefuroxime, CTX = Cefotaxime,
CLAV = Clavulanic Acid.
* All concentrations, mgL"*
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However, in the presence of a fixed concentration of
clavulanic acid at 8mgL-l, an inhibitor of the TEM-1 B-
lactamase, the MICs of ampicillin for eight of the 6-
lactamase positive strains were reduced to 0.125mgL-l. The
MIC of ampicillin of the remaining B-lactamase positive
strain 714 was reduced from 64 to 2mgL-l. The MICs of
ampicillin of all the B-lactamase negative strains were only
marginally reduced in the presence of clavulanic acid,
giving values greater than for the B-lactamase positive
strain (i.e. 1 to 4mgL-l).
The MICs of the ureidopenici 1 1 in, piperacillin, were
generally considerably higher for the B-lactamase positive
strains (4 to 125mgL-l) than the B-lactamase negative
strains (0.05 to 0.2mgL-l).
B-lactamase production did not appear to affect resistance
to the test cephalosporins. All of the strains gave MICs of
0.01 to 0.06mgL-l for cefotaxime, 0.5 to 4mgL~l for
cefuroxime and, all were resistant to cephradine (MICs^-
8mgL-l). Strain 714 had an MIC of cefoxitin of 32mgL-l, the
remaining strains gave MICs of 2 to 8mgL-l.
6.3 B-lactamase Production and Identification
Cell free extracts of the B-lactamase positive strains gave
B-lactamase specific activities ranging from 1.2 to
21nmoles cephaloridine hydrolysed minute-1 mg protein"*
(Table 38). Isoelectric focusing (IEF) showed that in all
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nine strains the B-lactamase specific activity was directly
attributable to the TEM-1 B-lactamase (Figure 43). The B-
lactamase specific activities of the six B-lactamase
negative strains were less than O.lnmoles cepha1oridine
hydrolysed minute-1 mg protein-1 and no B-lactamase enzymes
could be detected by isoelectric focusing.
It was concluded from the B-lactamase specific activities
and MICs in the presence of clavulanic acid that B-lactamase
production was the principal mechanism of ampicillin
resistance in eight of the nine B-lactamase positive
strains. The B-lactamase positive strain 714 appeared to
have an additional resistance mechanism(s) due to the
residual ampicillin resistance in the presence of clavulanic
acid. Accordingly, the penicillin binding proteins (PBPs)
and outer membrane proteins (OMPs) of 714 and the six B-
1actamase negative strains were examined.
6.4 Penicillin Binding Proteins
The PBPs of the six B-lactamase negative strains and the B-
1actamase positive strain 714 were compared to those of the
ampicillin sensitive control strain 1184E. Strain 1184E
produced eight major PBPs with apparent molecular sizes of
87, 77, 69, 58, 48, 43, 39 and 37 k daltons (Figure 44).
Four of the ampicillin resistant isolates gave similar PBP
profiles to the sensitive control strain 1184E. The
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Figure 43
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remaining three strains (118, 243 and 714) exhibited marked
changes in their PBP profiles (Figures 44 and 45).
H. inf1uenzae 118 produced three PBPs (91, 86 and 80 k
daltons) which were in the region of the expected PBPs 1 and
2 but they exhibited different mobilities. In addition,
there was less binding of radiolabel to PBPs 3 and 7. Strain
243 produced a PBP (75 k daltons) which differed markedly in
mobility from PBP2 seen in H. i nf1uenzae 1184E. The 3-
lactamase positive strain 714 also produced an unexpected
PBP profile, having a total of three PBPs in the region of
PBPs 2 and 3 but exhibiting different mobilities (83, 76 and
71 k daltons) from either PBP2 or PBP3 visualised in strain
1184E.
6.5 Outer Membrane Proteins
Five of the seven biotypes produced characteristic patterns
of OMPs when pairs of ampicillin sensitive strains were
examined (Figure 46). Strains representing the two
remaining biotypes, IV and V, gave dissimilar OMP profiles.
A1 1 strains produced a 1 imited number of major OMPs with
molecular sizes between 30 and 50 k daltons (Figure 46).
The OMP profiles of the seven ampicillin resistant strains
were compared to that of their ampicillin sensitive biotypic
counter parts. Two of the ampicillin resistant B-lactamase
negative strains (621 and 243) and the B-lactamase positive
strain (714) gave very similar OMP profiles to their
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Figure 45
Densitometry traces of PBP fluorograms of H. influenzae strains 118,
243 and 714.
Comparison is made with the PBP profile of the ampicillin sensitive
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respective biotype standards (Figure 47). Strain 118
produced an additional OMP of molecular size 33 k daltons
when compared to the biotype VI standard. The three biotype
II ampicillin resistant isolates (156, 564 and 684) gave
very similar OMP profiles to one another, but different from
the biotype II standard strains.
It would be necessary to carry out transformation
experiments and compare isogenic strains to confirm that
ampicillin resistance did result from OMP or PBP changes.
This study has established that B-lactamase enzymes are not
the sole mechanism of ampicillin resistance in the
H. inf1uenzae population and resistance may also result from
PBP and OMP alterations.
Tabl e 40 summarises the ampicillin resistance mechanisms
identified in the H. influenzae population.
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Figure 47
SDS-PAGE of outer membrane proteins (OMPs) of ampicillin resistant
H. influenzae compared to those of the respective Haemophi 1 us
























52 + - ND ND 6-1actamase
74 + - ND ND II
572 + - ND ND II
584 + - ND ND II
585 + - ND ND II
588 + - ND ND II
639 + - ND ND II
733 + - ND ND II
714 + + + - 6-1actamase/
PBPs
118 - + + + PBPs/OMPs
156 - + - + OMPs
243 - + + - PBPs
564 - + - + OMPs
621 - + - - Not
identified
684 - + - + OMPs
* CLAV = Clavulanic acid
+ = difference from "normal" ampicillin sensitive strain




The studies described in this thesis were undertaken to identify and
characterize novel genetic and biochemical aspects of B-lactam
resistance in Gram negative bacteria. It has been generally
accepted that B-lactamase enzymes are the most common resistance
mechanism to the B-lactam antibiotics (Richmond and Sykes 1973,
Sykes and Matthew 1976, Medeiros 1984). As a result, several
surveys have been carried out examining the types of B-lactamase
enzyme produced by ampicillin resistant populations of Gram-negative
Enterobacteria (Simpson et aj_ 1980, Roy et a]_ 1983, Stobberingh et
al 1985, Simpson et aj_ 1986).
Recently, the use of cephalosporins has increased considerably and
thus the survey conducted in this thesis was arranged to monitor
specifically the resistance to this group of B-lactam antibiotics.
Therefore, in contrast with previous surveys, resistance to a
cephalosporin, cepha 1 oridine, was used to identify resistant Gram
negative strains. The subtle change in selection pressure isolated
a bacterial population with a different distribution of B-lactamases
from those found in previous studies. The population also contained
strains with novel B-lactam resistance mechanisms.
Bacterial strains were isolated from three centres: Dundee,
Edinburgh and Glasgow. The incidence of ampicillin resistance in
each centre was higher than the incidence of resistance to
cephaloridine. Between 50 and 63% of the ampicillin resistant
strains from each centre were cephaloridine resistant. On the other
hand, almost all the cephal ori di ne resistant strains were also
ampicillin resistant. The incidence of cephaloridine and ampicillin
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resistance in strains isolated in Dundee and Edinburgh are similar
to those reported by Gruneberg (1984) for London (between 45.2% and
48.4% ampici 1 1 in resistance and 22.6% and 28.4% cephal oridine
resistance). However, the Glasgow survey revealed 71.9% of strains
as ampicillin resistant and 45.1% as cephaloridine resistant. This
level of ampicillin resistance is believed to be unprecedented in
the UK (Simpson jet aj_ 1980, Gruneberg 1984).
Two hundred and thirty four cephaloridine resistant strains were
collected from the three centres. The selection of resistant
strains on cephaloridine, rather than ampicillin, resulted in the
production of only species specific chromosomal B-lactamases by the
majority of strains (50.8%); these were mainly the class I
cephalosporinases identified by Richmond and Sykes (1973). B-
lactamases typically associated with plasmids were found in 112
strains (47.9%). The most common of these was the TEM-1 B-lactamase
(41.9% of all the strains tested) while TEM-2 was produced by only
3.5% of strains. Only four strains isolated produced OXA class B-
lactamases. This contrasts with the results of previous surveys
where the pi asmi d-mediated B-lactamases (principally TEM-1)
predominated amongst ampicillin resistant isolates (Simpson et al
1980, Roy et aj_ 1983, Stobberingh _et aj_ 1985, Simpson _et £]_ 1986).
The plasmid 6-lactamases generally hydrolyse cephal oridi ne less
ef f i ci ent 1 y than ampicillin (Medei ros et a_l_ 1974, Medeiros 1984).
The most effective B-lactamases active against cephaloridine are the
chromosomal class I B-lactamases (Richmond and Sykes 1973). These
two facts may provide the explanation for the lower incidence of
piasmid-mediated B-lactamases found in this present survey.
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In previous surveys, the designation of pi asmid-mediated 6-1actamase
enzyme was made purely on the basis of biochemical results (Matthew
1979, Simpson et_ a_l_ 1980, Roy et aj_ 1983, Stobberingh et_ a_l_ 1985,
Simpson et a]_ 1986). However, the results of this thesis show this
to be a misnomer. Genetic experiments were carried out to confirm
the location of the 6-lactamases which were predicted to be plasmid-
mediated. Selection in all cases was made for the transfer of
ampicillin resistance, the principal enzyme substrate. One hundred
and twelve strains produced "piasmid mediated B-lactamases", but
only 78 strains transferred the 6-1 actamase gene in question. The
6-lactamase gene from a further 15 strains transferred after
mobilisation. However, a high proportion of strains, 19 out of 112
(17%), could not transfer their 6-lactamase genes. Fifteen of these
strains produced the TEM-1 6-lactamase. It appears therefore, that
genetic classification made on the basis of biochemical evidence is
far from definitive.
Subsequent surveys of 6-lactamases within bacterial populations
should, therefore, include genetic tests along with the biochemical
analysis. Such comprehensive surveys would also reveal whether
genetic changes were taking place within the population, such as a
move towards the chromosomal carriage of 6-lactamase genes. This
has already been observed with two 6-lactamase transposons: the
PSE-4 transposon (Tn2521) in P. aeruginosa (Sinclair and Holloway
1982) and the TEM-1 transposon (Tn2) in H. inf1uenzae (Murphey-Corb
^t _al_ 1984). The migration of resistance genes, normally associated
with plasmids, into the bacterial chromosome is becoming more
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prevalent and has occurred on a large scale with other resistances,
notably trimethoprim (Amyes et al 1986).
The determination of the genetic locus of resistance genes can be
time consuming and more recently genetic probes have been used to
identify the location and types of S-lactamase and other resistance
genes (Sinclair and Holloway 1982, Cooksey ejb aj_ 1985, El well and
Fal kow 1986). However, although they are highly sensitive, they do
have limitations as reported by Cooksey et aj_ (1985) who identified
a silent copy of the TEM B-lactamase on the OXA-2 plasmid R46 with a
TEM-1 probe. The presence of repressed or mutated genes among
target DNA may make the interpretation of gene hybridisations
difficult. Therefore, in epidemiological studies, it is essential
to include biochemical investigations in parallel with gene probing.
Frequently, there is no correlation between the specific activity of
the B-lactamase present in the cell and the B-lactam resistance
level (Richmond and Curtis 1973, Medeiros 1984). The B-lactamases
isolated from the cepha1oridine resistant strains hydrolysed
cephaloridine at variable rates. One group, comprising 72 E. col i
producing the TEM-1 B-lactamase, were studied in detail. The
specific enzyme activity varied by 650 fold with the majority (85%)
in the range of 1 to 35nM cepha 1 ori di ne hydrolysed minute"! mg~l
protein. Hedges .et aj_ (1974) also found that the TEM-type enzyme
was heterogeneous in the levels of B-lactamase produced.
Quantitative differences in the levels of B-lactamase production can
result from mutations in the promoter region of the B-lactamase
gene, resulting in more efficient transcription (Yamamoto et al
1982). Gene amplification or multiple transposition also have a
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quantitative effect, increasing the amount of B-lactamase produced
(Uh1 in and Nordstrom 1977). The study also found that variation in
TEM-1 expression, even within one species (E. col i) was
considerable. When the plasmids carrying the TEM-1 B-lactamase were
transferred into the isogenic background of E. col i J62-?> variation
in the specific enzyme activity was still observed.
The relative specific activities of the plasmid enzymes in the
clinical hosts, however, was not mirrored in the transconjugants.
In addition, the specific activities did not correlate with the
resistance level of the transconjugant strains. In the
transconjugants the variation in specific activity was around 500-
fold, but all the strains were resistant to high levels of
ampicillin (MIC ^1000mgL~l). On the other hand, most of the
transconjugants (45/62) were sensitive to cepha1oridine (MIC
4l6mgL-l), even though the cl inical E. col i parent strains were
resistant. Therefore, it appears that the TEM-1 B-lactamase is not
the principal mechanism of resistance to cephaloridine in these
clinical strains.
Two significant biochemical differences between cephaloridine and
ampicillin may provide an explanation for the different sensitivies
observed. Firstly, the TEM enzymes have a much lower affinity for
cephaloridine (16-20 fold) than for ampicillin (Medeiros 1974, Bush
and Sykes 1984). Secondly, the crypticity value of cephal oridine is
1 for E. col i K12 indicating that this strain presents no barrier to
the entry of this drug whereas ampicillin has a comparatively high
crypticity value of 65 (Richmond and Sykes 1973), indicating that
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ampicillin enters the periplasmic space more slowly. In
combination, these differences in permeability to cephalosporins and
penicillins as well as the differences in the TEM-1 affinity for the
substrates may explain why the E. col i K12 J62-2 transconjugants are
susceptible to cephal ori di ne but highly resistant to ampicillin.
A1 though in vitro the Vmax values for both substrates are generally
high, in vivo the hydrolysis of cephal oridine is not rapid enough to
inactivate sufficient B-lactam and thus the level of cephaloridine
rises to a lethal concentration for E. col i K12.
The remaining E. col i J62-2 transconjugants (17/62) were more
resistant to cephaloridine and had MICs of cephaloridine of 16 or
32mgL~l. The enzyme specific activity of these strains was, on
average, just over two fold higher than that found in the
cephaloridine sensitive transconjugants. This two fold increase in
enzyme production could provide greater protection against the
incoming cephal oridine in these strains. However, one strain with a
very low specific activity (0.63mM cephal oridine hydrolysed minute-1
mg protein-1) had an MIC of cepha 1 ori di ne of 32mgL~l. Thus,
increases in enzyme production alone cannot explain the
cephaloridine resistance of these strains.
A further explanation is that the plasmid DNA transferred to E. col i
j62-2 may have had an effect on the outer membrane of the recipient
strains, resulting in an alteration in permeability and thus the
strains" susceptibility to cepha1oridine. There have been two
reports of plasmids which have an effect on the composition of
the outer membrane of E. col i. In the first, plasmids of the N
incompatibility group, when introduced into E. col i B/r reduced the
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amount of the outer membrane protein (the OmpF equivalent).
However, no similar effect was observed when the plasmid was
introduced into E. col i K12 (Iyer et £l_ 1978). In the second, R124
an incFIV plasmid reduced the level of expression of OmpF in E. coli
K12 and influenced the sensitivity of the organism to a wide variety
of inhibitory agents (Rossouw and Rowbury 1984). Both these
plasmids confer tetracycl ine resistance which, interestingly, is
also co-transferred with TEM-1 to the E. col i J62-g cephal oridine
resistant strains of the present work. Significantly, E. col i K12
strains harbouring a plasmid (related to R124), which produced an
even greater reduction in the amount of OmpF, had an increase in
resistance to cephaloridine (Rossouw and Rowbury 1984). A similar
transferable impermeability barrier may be present on some of the
TEM-1 plasmids. A resistance mechanism of this nature, genetically
linked to a B-lactamase gene would significantly increase the
resistance of the strains to a variety of B-lactams.
During the B-lactamase survey, a K. pneumoniae strain was isolated
which produced a B-lactamase of novel pi. The bacterial isolate was
itself unusual as it produced three B-lactamase enzymes, TEM-1, SHV-
1 and the novel enzyme. The strain transferred all three B-
1actamase genes to E. coli J62-? on a single plasmid, pUK702.
The novel B-lactamase enzyme had a pi of 6.5 which was unlike that
of any previously described piasmid-mediated B-lactamase (Table 2).
It had a molecular size of 19,000 daltons, similar to the size of
TLE-1 which is 19,800 daltons (Medeiros £t aj_ 1985). Conventional
substrate hydrolysis assays and inhibition profiles showed the novel
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enzyme to have similar properties to the TEM enzymes which has a
broad spectrum of activity. In addition, it was most effective
against benzyl penicillin and ampicillin, and sensitive to
inhibition by cloxacillin, clavulanic acid and pCMB.
The classification of B-lactamase enzymes is largely dependent on
their substrate and inhibition profiles (Richmond and Sykes 1973,
Sykes and Matthew 1976). The substrate profile of the novel B-
lactamase was established with the parameter relative efficiency of
hydrolysis (Bush et _al_ 1982) which takes account of the Vmax and the
Km of the B-lactamase. This index provides more information about
the enzyme than relative rates of hydrolysis (which may, or may not,
be carried out at the Vmax of the B-lactamase).
Evaluation of the kinetics of hydrolysis revealed that, unlike TEM
and SHV type enzymes, the novel B-lactamase did not obey first order
kinetics during the hydrolysis of cephaloridine (Bush and Sykes
1984, Kliebe£t^l_ 1985). It was also apparent that even at the
high substrate concentrations used the enzyme did not reach its Vmax
of hydrolysis of cephaloridine.
The RSAI (James 1983) is a measure of the affinity of the enzyme for
a wide variety of B-lactam antibiotics. The number and variety of
compounds which can be tested allows the differentiation of even
closely related B-lactamase types. The novel enzyme was
differentiated from TEM-1 and SHV-1 by its extremely high affinity
for cefsulodin. As the B-lactamase was very similar in other
respects to the TEM-type B-lactamases it was given the designation
TLE-2 (TEM-1 ike enzymes). There is a great deal of diversity of B-
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lactamase enzymes and the discovery of TLE-2 brings the number of
piasmid-mediated B-lactamases to 28.
One group of piasmid-mediated B-lactamases are the Pseudomonas
specific enzymes (PSE). Two of the cepha1oridine resistant
enterobacteria produced PSE-4. This was the first identification of
this S-lactamase outwith P. aeruginosa. Previously, PSE-1 (Medeiros
et a]_ 1982) and PSE-2 (Livermore et aj_ 1984) B-lactamases had been
found in enterobacterial strains and with the isolation of PSE-4 in
enterobacteria, the designation "Pseudomonas specific" is misleading
and the enzymes would be better classified as carbenici11 in
hydrolysing enzymes. The PSE-4 B-lactamase determinants dall and
dal 2 transferred from both the original clinical strains to E. col i
J62-2 and P. aeruginosa PA08.
When the expression of the enzyme in various host bacteria was
examined it was found that the biochemical and biophysical
properties of the B-lactamase were host dependent. Subtle changes
in the enzyme's isoelectric point and hydrolysis kinetics were found
to take place when dall or da 1 2 were transferred from
enterobacterial strains to P. aeruginosa. However, when the
determinants were transferred from P. aeruginosa to E. col i the
enzyme maintained the characteristic Pseudomonas biochemical and
biophysical profile. In P. aeruginosa the structural gene for the
production of PSE-4 may have been altered slightly, resulting in a
protein which differed from that found in the enterobacterial
isolates. A few changes in the amino acid composition of an enzyme
can change the tertiary structure of the protein, thereby affecting
such properties as the pi. This has been observed with TEM-1 and
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TEM-2 which differ by one amino acid (Matthew et a_l_ 1975). Brive et
al (1977) also noted changes in the IEF patterns of piasmid-mediated
13-1 actamases from different host strains. Changes in the folding of
the enzyme may al so al ter the 13-1 actamases" abi 1 ity to process 13-
lactam substrates and thus increase or reduce the turnover rate.
Variation in Vmax was observed with the PSE-4 [3-1 actamases isolated
from different hosts. Alterations in the enzyme folding would be
less likely to affect the affinity of the (3-lactamase for the
substrate, and indeed it was confirmed that there was little
alteration in the Km values of the various PSE-4 13-1 actamases.
Alteration in the nucleic acid sequence of the PSE-4 determinants
could have occurred when the gene integrated into the P. aeruginosa
chromosome, perhaps removing a terminal region. Chromosomal
integration has also been observed with the PSE-4 transposon
(Tn2521) in natural isolates of P. aeruginosa (Sinclair and Hoi 1oway
1982). Restriction enzyme analysis of the dal 2 determinant was very
similar to that found for Tn2521 (Sinclair and Holloway 1982).
This, together with the translocation of dal1 into the P. aeruginosa
chromosome, strongly suggests that the PSE-4 determinants dal 1 and
dal2 are carried on transposons similar or identical to Tn2521.
Apart from the two isolations in enterobacteria reported in this
thesis, PSE-4 does appear to be restricted to P. aeruginosa.
Livermore et aj_ (1985) examined a group of PSE-4 producing
P. aeruginosa strains and found that there was an association
between the serotype 0:16 and this 13-1 actamase. They speculated
that the PSE-4 gene may be transferred via a serotype specific
phage. The PSE-4 transposon Tn2521 and the da 11 and da 12
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determinants have a prede 1iction for insertion into the
P. aeruginosa chromosome and they consequently become "trapped".
P. aeruginosa may thus act as a reservoir for such transposons.
It is difficult to establish if the Pseudomonas reservoir has been
the source of the PSE-4 genes in the two enterobacterial strains
from the survey. The results of this thesis show that chromosomal
insertion of PSE-4 into Pseudomonas is accompanied by an alteration
in the gene product. This change persists even when the gene is
mobilised from Pseudomonas into an enterobacterial strain. The
permanent alteration argues against Pseudomonas as the source of the
enzyme.
The use of incP-1 plasmids to study the genetics and expression of
S-lactamase genes is commonplace (Hedges and Jacob 1975, Sinclair
and Holloway 1982, Seeberg _et _al_ 1983). The initial studies of dal 2
were carried out with R751 as the mobilising plasmid; however, the
plasmid was found to induce mutations in the E. col i J62 host
strain. The mutations resulted in resistance to carbenici 11 in and
ampicillin and a variety of other antimicrobial compounds. In
isogenic strains which lacked the R751 plasmid, chromosomal
mutations occurred at a very low frequency. The E. col i R751-
containing strains which were resistant to carbenici 11in/ampici11 in
were found to produce the 13-lactamase SHV-1.
It was not clear whether this 13-lactamase was encoded by the R751
plasmid or was situated on the E. col i K12 chromosome, and was, in
some way, derepressed by the plasmid. The SHV-l 8-lactamase itself
appears to have originated in Klebsiel1 a spp. (Matthew 1979, Nugent
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and Hedges 1979) and the R751 plasmid was originally isolated from a
rare K. aerogenes strain (Jobanputra and Datta 1974).
The early evidence suggested that the R751 plasmid may possess a
"silent" SHV-1 gene which had originated in the K. aerogenes strain.
This would be similar to the carriage by the R46 plasmid of a silent
copy of the TEM B-lactamase, as has been previously described
(Cooksey et_ aj_ 1985). However, it was found that the SHV-1 13-
lactamase was produced by strains which had been cured of the R751
plasmid. This evidence strongly suggests that the 13-lactamase is
not piasmid-mediated. However, the presence of the plasmid was an
absolute requirement for the initial expression of the 6-1actamase.
The high frequency with which the SHV-1 B-lactamase was found in the
cured strains also ruled out transposition of the SHV-1 gene from
the R751 plasmid to the E. col i chromosome. It was concluded
therefore, that the B-lactamase gene resides on the E. col i J62
chromosome but its initial expression is dependent on the presence
of the R751 pi asmid.
The mechanism by which R751 affected chromosomal genes is unclear.
Resistance plasmids have been reported to increase the mutation
frequency of host bacterial strains (Ginoza and Painter 1964, McCann
et_ 1975, Amyes and Smith 1977). McCann et _al_ (1975) postul ated
that the plasmid enhanced an error-prone recA dependent DNA repair
mechanism thus increasing the mutation rate of the pi asmid-bearing
strain. In the present study, increased mutation rates to
carbenici 11 in resistance were observed in E. col i PB1150 recA ruling
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out a recA dependent system or the integration of R751 into the host
chromosome as the cause of mutations.
Insertion sequences are mutagenic (Kl eckner jit a_l_ 1975) at
frequencies of 1-4 x 10~4 (Foster 1976) and the inverted
complementary base pair sequences which flank some transposons may
have a similar effect. Such regions may flank the trimethoprim
transposon (Tn402) on R751 (Shapiro and Sporn 1977), or IS sequences
may be present elsewhere on the plasmid. Alternatively, the R751
plasmid may produce a protein which switches on or off a variety of
regulatory systems in the bacterial cell.
During the survey of cephaloridine resistant strains, six isolates
were identified which transferred resistance to B-lactams not
associated with the production of a (3-1 actamase. The 6-lactam
resistance transferred to E. col i recipient strains at a low
frequency. In one case this was associated with the presence of a
plasmid (pUK703); however, in the remaining five cases, no plasmid
DNA was isolated. It is possible that the DNA isolation techniques
used may have broken up any large plasmids as the resolution of the
techniques used is in the region of 200kb. Alternatively, it is
possible, but less likely, that no pi asmA DNA transferred in these
strains but the B-lactam resistance was carried by a conjugative
transposon such as those identified by Franke and Clewell (1981).
The B-lactam resistance mechanism of the strains was examined and
three of the six E. col i J62-2 transconjugants were found to have
changes in their outer membrane protein profiles. There have been
two other reports (previously described) of resistance plasmids
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affecting the permeability of the outer membrane (Iyer et_ _al_ 1978,
Rossouw and Rowbury 1984). The three transconjugants were found to
have reduced amounts of porin protein OmpF. This was similar to the
effect of the plasmids reported by Iyer et ^1_ (1978) and Rossouw and
Rowbury (1984). However, in the cases reported by Rossouw and
Rowbury (1984) the plasmids conferred resistance to cephal oridine.
In contrast the transconjugants described here were sensitive to
cephaloridine.
In the remaining three transconjugants, including the strain
containing the plasmid pUK703, no changes in the outer membrane
proteins were observed. In addition, no changes were seen in the
affinity of the penicillin binding proteins for ampicillin. It has
been observed that some types of resistance mechanism may only be
expressed under certain types of growth conditions. This variation
has been found with the low affinity PBP of S. aureus (Fontana 1985)
which may also be the case with these strains. Alternatively, the
resistance may arise from a mechanism such as enzymic modification
of the B-lactam, which is distinct from hydrolysis. Bacterial
amidases remove the acyl side chain, of principally the penicillins
forming the less active aminopenicillanic acid (Batchelor et al
1961, Hamilton-Miller 1966). However, the role of such enzymes in
resistance is unclear.
In H. influenzae, ampicillin resistance is generally attributed to
the production of the TEM-1 (3-1 actamase. The present study of this
species has established that non-B-1actamase mediated resistance
mechanisms acting either alone or in combination are equally
prevalent.
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The nitrocefin spot test identified those strains which produced a
B-lactamase. However, determination of the ampicillin MICs in the
presence and absence of the B-lactamase inhibitor, clavulanic acid
yielded further information and separated the 15 ampicillin
resistant strains into three groups: (i) eight strains owing their
resistance primarily to TEM-1 B-lactamase activity, (ii) strain 714
whose resistance depended on TEM-1 B-lactamase activity and some
other mechanism(s), and (iii) six strains whose resistance resulted
from factors other than B-lactamase activity. The levels of
ampicillin resistance seen with non-B-1actamase producing strains
were generally less than for the B-lactamase producing strains.
There was no clear correlation between the specific activity of the
B-lactamase and the MIC of ampicil 1 in. The MIC of ampicil 1 in of
strain 714 was not reduced to fully sensitive levels in the presence
of clavulanic acid, indicating a major involvement of other
resistance factors. This conclusion was further supported by the
strain's usually high resistance to cefoxitin, a compound stable to
hydrolysis by TEM-1 B-lactamase (Onishi £t jil_ 1974).
Strain 714 and strains 118 and 243 showed marked differences in the
mobilities of PBPs in the 69 to 86 kdalton region relative to the
ampicillin sensitive control strain 1185E. The PBP2 of
H. influenzae is the major target site with the highest affinity for
all of the B-lactams except mecillinam (Makover et_ ^_1_ 1981).
Changes in this PBP would have the greatest effect on the
susceptibility of the bacteria to B-lactams. However, the
significance of these mobility differences or the appearance of
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additional (^4C) benzyl penicillin labelled proteins in this region
remains unclear.
Alterations in the outer membrane proteins of H. inf1uenzae can also
result in increased B-lactam resistance. Permeability changes in
one H. inf1uenzae strain have been found associated with the loss of
a 27,000 dalton protein from the outer membrane (Mendelman et al
1984). Examination of the OMP profiles of seven pairs of ampicillin
sensitive H. influenzae biotype standard strains revealed a high
degree of biotype specificity. Indications of such a correlation
have been previously reported for non-typable and Type b
H. infl uenzae strains (Barenkamp £t £l_ 1981, van Al phen et a_l_ 1983).
Porras et aj_ (1986) examined the OMP profiles of non-typable strains
of five H. inf1uenzae biotypes and found variation in the OMPs
produced by biotypes I and II. The antimicrobial drug suscept¬
ibility of the strains was not examined however, and no account was
taken of possible mutations having occurred in OMPs which would
result in an altered profile.
In the present study there was a non-specificity of biotype IV and V
strains which may reflect a greater variation within these biotypes
than previously acknowledged.
Four of the six B-lactamase negative strains gave different OMP
profiles from their respective biotype standards. This infers
mutation in the omp genes gives a more resistant phenotype. It
would be necessary to transform these genes into an isogenic
background to confirm this. It was apparent, however, that 13-
lactamase enzymes are not the sole mechanism of ampicillin
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resistance in the H. influenzae population and resistance may also
result from PBP and OMP alterations.
It can be concluded from the studies carried out in this thesis that
B-lactamase enzymes are an important mechanism of B-lactam
resistance in Gram negative bacteria. However, it can also be seen
that this resistance mechanism is inextricably interwoven with a
variety of other host factors which affect the cells"
susceptibility. It has been shown from the studies of TEM-1 B-
lactamase in E. col i that jjn vitro studies of B-lactamase efficiency
do not necessarily give an indication of the cells^ in vivo B-lactam
resistance. Caution must therefore be observed when extrapolating
from results obtained in test tubes.
New piasmid-mediated S-lactamases such as TLE-2 continue to be
found, and they are obviously of importance. Of more worrying
significance is the discovery of a transferable B-lactam resistance
mechanism not attributable to a B-lactamase. In some strains, this
mechanism was identified as the loss of the OmpF porin, and in
another instance the R751 plasmid was found to induce generalised
resistance mutations. These mechanisms may produce cross resistance
to a variety of B-lactams and possibly other groups of antimicrobial
drugs. Similar, non-B-1 actamase, resistance mechanisms were also
found in H. infl uenzae although the genetic location of the
resistance mechanism was not examined. It may only be a matter of
time before such "alternative" B-lactam resistance mechanisms become
transferable in this species.
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It is apparent that B-lactam resistance in Gram negative bacteria is
a multifactorial defence system which continues to evolve.
Developments in chemotherapy must evolve at a similar pace if we are
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1. Cephaloridine Resistant Strains - Identific¬
ations and Sources.
No Date Source Infection Organism H/No. API Resistances
1 831129 G.P. LTTI Escherichia coli 864 5044552 ApCer
6 831213 C-G.P. UTI Escherichia coli 3128 7144532 ApCer
8 831214 C-140P UTI Escherichia coli 3270 5144532 ApCer
12 831214 C-18B UTI Klebsiella pneumonia 3348 5215773 ApCer
13 831214 C-G.P. UTI Escherichia coli 3349 5144512 ApCer
15 831212 C-2 UTI Klebsiella pnetmonia 2895 5215773 ApCer
19 831213 C-G.P. UTI Cltrobacter freundii 3106 3604572 ApCer
21 831212 C-G.P. UTI Escherichia col I 2972 5144512 ApCer
23 831212 C-G.P. UTI Klebsiella oxytoca 3002 5245773 ApCer
28 831213 C-G.P. UTI Escherichia coli 3160 5144112 ApCer
36 831214 C-G.P. UTI Proteus vulgaris 3407 0476021 ApCer
43 831215 R-20 Chest Enterobacter aerogen 6357 5305773 ApCer
44 831215 R-17 Chest Pseudomonas aeruglno 6316 2202004 ApCer
49 840114 R-19 Chest Pseudomonas aerugino 5107 2202004 ApCer
50 831215 R-19 Chest Proteus mirabi1 is 6379 0536000 ApCer
52 831219 pu.Ho. Chest Haemophilus Influenz 47 ApCer
54 831217 R-SC8U Oral secret . Escherichia col I 7352 5144572 ApCer
55 831216 R-52 Eye swab Pseudomonas aeruglno 7075 2202004 ApCer
60 831216 C-G.P. UTI Escherichia coli 3617 5144572 ApCer
64 840214 DRI-5 UTI Klebsiella oxytoca 11705 5255773 ApCer
67 831216 C-G.P. UTI Pseudomonas aerugino 3644 2206006 ApCer
72 840215 NW-1 UTI Escherichia coli 11887 1044562 ApCer
73 831212 C-G.P. UTI Escherichia coli 2974 5144572 ApCer
74 831220 R-30 Chest Haemophi1 us inf1uenz 8322 ApCer
85 831221 R-33 Gut Escherichia coli 9003 5144552 Cer
93 840114 R-35 UTI Pseudcmonas fluor gp 4984 6206004 ApCer
94 831220 R-15 UTI Enterobacter cloacae 8260 7305573 ApCer
99 831218 R—51 Gut Hafnia alvei 7592 4104102 Cer
100 840116 R-16 UTI Proteus morganii 5265 0374000 ApCer
101 831219 R—13 Mound swab Enterobacter cloacae 8101 3305573 ApCer
102 831218 R-17 Blood Enterobacter sakazak 7604 3304173 ApCer
103 831220 R-SCai CSF Enterobacter cloacae 8601 7305573 ApCer
104 831219 R-53 UTI Escherichia coli 8026 7044562 ApCer
107 840112 R-SCai Eye swab Enterobacter cloacae 4112 3305573 Cer
108 831219 R-19 Chest Pseudomonas aerugino 7749 2206004 ApCer
110 840103 R-9 UTI Enterobacter cloacae 149 7305573 ApCer
115 831224 R-19 - Chest Pseudcmonas fluor gp 9851 6202004 ApCer
118 840104 R-45 Chest Haemophi1 us inf1uenz 588 ApCer
122 840104 SM4= Wound swab Enterobacter cloacae 809 7305573 ApCer
126 840104 R-16 UTI Enterobacter cloacae 818 3305573 ApCer
131 840104 R-33 UTI Citrobacter freundiI 620 3204573 ApCer
132 840104 R-6 UTI Escherichia coli 636 7144532 ApCer
134 840105 R-6 UTI Escherichia coli AO 76 5044542 ApCer
135 840105 R-6 UTI Escherichia col 1 976 5144572 ApCer
138 840104 R-10 Wound swab Proteus mirabi1 is 900 0736000 ApCer
140 831219 R-16 UTI Proteus mirabilis 7736 4336000 ApCer
141 840116 R-24 Wound swab Pseudomonas aerugino 5607 2606000 ApCer
144 831219 R-24 UTI Escherichia coli 7825 5044500 ApCer
150 831222 R-24 UTI Escherichia col 1 9128 1144552 ApCer
151 831222 R-2 UTI Escherichia coli 9262 7144533 ApCer
156 840109 R-Haem Chest Haemophilus influenz 2874 ApCer
163 840105 R-10 UTI Pseudomonas ma 1 tophi 1361 4002000 ApCer
313
No Date Source Infection Organism H/No. Wl Resistances
167 840107 R-52 Pacemaker Escherichia col 1 2127 5144572 ApCer
175 840109 R-20 Chest Klebsiella pneumonia 2390 5216773 ApCer
179 840102 C-2 UTI Pseudomonas aerugino 5298 2602000 ApCer
180 831231 C-8A irri Pseudomonas 5238 2602000 ApCer
188 840104 C-18A UTI Pseudomonas 5594 2602000 ApCer
189 840105 C-G.P. UTI Escherichia col I 5723 5144572 ApCer
193 840106 C-G.P. UTI Escherichia col 1 AO 5947 5044542 ApCer
196 840106 C-5 UTI Proteus mirabi1 Is 5866 0536000 ApCer
198 840105 C-G.P. UTI Escherichia col I 5806 7144532 ApCer
199 840105 C-G.P. UTI Escherichia coli 5804 5144552 ApCer
201 840105 C-G.P. UTI Escherichia col i 5777 5144572 ApCer
216 840106 C-G.P. UTI Escherichia col 1 5971 5144532 ApCer
219 840106 C-G.P. UTI Escherichia col 1 5958 7144532 ApCer
220 840110 C-16 Vaginal swab Escherichia coll 6440 7144532 ApCer
221 840109 C-G.P. UTI Proteus mirabi1 is 6277 2736000 ApCer
230 840110 C-G.P. UTI Klebsiella ozaenae 6415 7306573 ApCer
235 840110 C-G.P. UTI Escherichia col I 6423 5144562 ApCer
241 840112 R-23 Throat swab Klebsiella pnetmonia 4245 5205773 ApCer
243 840111 R-29 Chest Haemophilus lnfluenz 3775 ApCer
253 840110 R-52 Wound swab Serratia odor ifera 3147 5344573 ApCer
259 840112 R-49 Blood Citrobacter freundii 3971 1404572 ApCer
261 840111 R-ENT Ear swab Proteus mirabi1 is 3861 0776021 ApCer
264 840111 C-14CP UTI Escherichia co11 6598 5144552 ApCer
288 840112 C-G.P. UTI Enterobacter spp 6846 3305121 ApCer
294 840113 C-G.P. UTI Escherichia col i 6961 7044553 ApCer
296 840115 C-8 UTI Proteus mirabiI Is 7161 0536000 ApCer
297 840113 C-G.P. UTI Escherichia col 1 7014 5044512 ApCer
301 840113 C-G.P. UTI Escherichia col 1 6963 5144572 ApCer
303 840113 C-16A UTI K1ebsie11 a pneumonia 6928 5205773 ApCer
307 840215 DRI-6 UTI Pseudomonas aerugino 12041 2202004 ApCer
308 840112 OkG.P. UTI Escherichia coli 6991 1144512 ApCer
326 840117 C-G.P. UTI Escherichia col 1 7332 5144532 ApCer
330 840117 C-16A UTI Escherichia coli 7379 5044552 ApCer
334 840117 C-G.P. UTI Escherichia coli 7417 5144552 ApCer
337 840117 C-G.P. UTI Escherichia coli 7461 5144512 ApCer
339 840117 C—15 UTI Klebsiella axytoca 7523 5244773 ApCer
340 840118 C-198 UTI Pseudomonas spp 7558 2716004 ApCer
342 840119 R-33 Gut Proteus mirabi1 is 6701 0536000 Cer
344 840120 R-10 Gut Proteus mirabi1 Is 7026 0736000 Cer
345 840120 R-13 Wound swab Serratia marcescens 7180 5307761 ApCer
347 840121 R32 Gut Pseudomonas aerugino 7443 2206004 ApCer
348 840121 R-16 UTI Escherichia col I 7447 5144512 ApCer
350 840121 R-16 UTI Escherichia col I 7518 5044512 ApCer
352 840122 R-6 Gut Enterobacter cloacae 7599 3305573 ApCer
353 840122 R-6 Gut Pseudomonas aerugino 7602 2202004 ApCer
357 840122 R-2 UTI Escherichia coli 7674 7144573 ApCer
358 840122 R-2 UTI Escherichia col I 7678 5144572 ApCer
360 840123 R-16 Drain fluid Pseudomonas aerugino 7744 6302004 ApCer
361 840123 R-16 Nephrostomy Enterobacter cloacae 7747 3105573 ApCer
363 840123 R-16 UTI Enterobacter cloacae 7802 3305573 ApCer
364 840123 R-10 Gut Enterobacter aerogen 7821 5305773 ApCer
365 840123 R-6 UTI Klebsiella ozaenae 8063 5004552 ApCer
314
No Date Source Infection Organism
367 840123 R-R/0 UTI Escherichia col i
369 840123 R-5 Drain fluid Pseudomonas aerugino
372 840123 R-ENT Ear swab Acinetobacter calco.
373 840119 C-8 UTI Escherichia coli AD
374 840119 C-G.P. UTI Escherichia col i
378 840119 C-G.P. UTI Escherichia coli AD
380 840119 C-G.P. UTI Escherichia col 1
391 840123 R-28 Gut Escherichia coli
394 840123 R-53 Wound swab SerratIa odor ifera
395 840126 R-CCU UTI Proteus mirabi1 is
398 840201 GRI UTI Escherichia co 1 i
401 840201 GRI UTI Escherichia col i
402 840201 GRI UTI Escherichia col 1
404 840201 GRI UTI Escherichia coli AO
407 840102 GRI UTI Escherichia col i
408 840201 GRI UTI Escherichia coli
410 840201 GRI UTI Escherichia coli
411 840201 GRI UTI Pseudomonas aerugino
413 840201 GRI UTI Escherichia col I
416 840201 GRI UTI Escherichia col I
419 840201 GRI UTI Escherichia col 1 AD
420 840201 GRI UTI Pseudanonas
421 840201 GRI UTI Pseudcrronas aerugino
423 840201 GRI UTI Escherichia coli
427 840201 GRI UTI Escherichia col I
430 840201 GRI UTI Pseudomonas aerugino
432 840201 GRI UTI Escherichia col i
434 840201 GRI UTI Proteus morgan if
435 840201 GRI UTI Escherichia coli
437 840201 GRI UTI Pseudomonas aerugino
438 840201 GRI UTI Acinetobacter calco.
439 840201 GRI UTI Escherichia coli
441 840201 GRI UTI Escherichia col I
446 840201 GRI UTI Proteus morganiI
450 840201 GRI UTI Pseudomonas flucr.gp
451 840201 GRI UTI Escherichia col I
456 840201 GRI UTI Escherichia coli
458 840201 GRI UTI Escherichia coli
461 840201 GRI UTI Escherichia col I
463 840201 GRI UTI Escherichia col 1
465 840201 GRI UTI Citrobacter freundii
466 840201 GRI UTI Escherichia coli
470 840202 GRI UTI Enterobacter cloacae
474 840202 GRI UTI Klebsiella axytoca
475 840202 GRI UTI Escherichia coli
479 840202 GRI UTI Escherichia coli
480 840202 GRI UTI Escherichia col I
490 840212 NW-12 UTI Proteus morgan 1i
492 840213 DRI-5 UTI Proteus mirabi1 is
494 840215 NW-GP UTI Escherichia coli
500 840214 DRI-5 UTI Klebsiella axytoca






















































No Date Source Infection Organism H/No. API Resistances
514 840211 NW-15 UTI Proteus morgan 11 10881 0174000 ApCer
519 840214 DRI-5 UTI Enterobacter cloacae 11720 7305573 ApCer
525 840215 NW-GP UTI Escherichia col 1 11994 7144532 ApCer
530 840214 NW-GP UTI Citrobacter freund1I 11661 3764133 ApCer
531 840215 NW-BCLI UTI Escherichia col 1 12015 5144572 ApCer
535 840214 NW-GP UTI Pseudomonas aerugino 11681 2302004 ApCer
542 840214 NW-4 UTI Enterobacter cloacae 11026 7305573 ApCer
543 840213 RVH UTI Enterobacter cloacae 11381 3305573 ApCer
546 840215 NW-5 UTI Escherichia col I 11807 5044562 ApCer
548 840215 RVH-7 UTI Escherichia col 1 11851 1044152 ApCer
555 840212 KXH-1 UTI Escher1ch1a col 1 11121 5156572 ApCer
559 840214 Ash-14 UTI Enterobacter cloacae 11492 7345573 ApCer
560 840213 KXH-6 UTI Escherichia col 1 11123 5576512 ApCer
564 830105 C-8A Chest Haemophilus Influenz 53610 ApCer
572 830122 0-8A Chest Haemophilus Influenz 56090 ApCer
584 830126 C-8 Chest Haemophilus influenz 56571 ApCer
585 830126 C-19A Chest Haemophilus Influenz 56650 ApCer
588 830128 C-6 Chest Haemophilus Influenz 56970 ApCer
621 830212 C-8A Chest Haemophi1 us influenz 59572 ApCer
639 830223 C-GP Chest Haemophi1 us infiuenz 61350 ApCer
684 830616 C-GP Chest Haemophi1 us Influenz 77415 ApCer
714 830810 C-GP Chest Haemophi1 us Influenz 84832 ApCer
733 830913 C-5A Chest Haemophilus influenz 89805 ApCer
No Date Source Infection Organism H/No. API Resistances
A006 830302 R-2 UTI Proteus vulgaris 16-4 0676020 ApCer
AO15 830303 R-2 UTI Enterobacter cloacae 26-2 3305573 ApCer
A055 820218 GRI UTI Enterobacter cloacae 9026 3304573 ApCer
AO56 820223 GRI UTI Proteus morgani1 10083 0154000 ApCer
A057 820319 GRI UTI Escherichia col 1 14999 5144552 ApCer
A058 820420 GRI UTI Enterobacter cloacae 21005 3305773 ApCer
A059 821019 GRI UTI Enterobacter cloacae 53624 3305523 ApCer
A060 821019 GRI UTI Serratia sp. 53771 5317763 ApCer
A061 811211 GRI UTI Escherichia col 1 64135 5144772 ApCer
A062 830201 GRI UTI Escherichia col 1 5265 5144572 ApCer
A063 820525 GRI UTI Provideneia stuartii 27580 0034020 ApCer
A064 820322 GRI UTI Escher Ich1a co11 15293 5144572 ApCer
A066 820125 GRI UTI Serratia marscesens 3855 5316561 ApCer
A067 820206 GRI UTI Serratia marscesens 6655 5317721 ApCer
AO68 820304 GRI UTI Escherichia col 1 11916 5144572 ApCer
A069 811201 GRI UTI Escherichia col I 61959 5144572 ApCer
A070 811019 GRI UTI Proteus vulgaris 53706 0076021 ApCer
A071 811125 GRI UTI Escherichia col I 60747 5044552 ApCer
A072 820423 GRI UTI Escherichia col I 21418 1040542 ApCer
A073 820315 GRI UTI Klebsiella oxytoca 13802 5254773 ApCer
A074 811201 GRI UTI Escherichia col 1 62070 5144572 ApCer
A075 811019 GRI UTI Proteus morganii 51764 0154000 ApCer
A076 811208 GRI UTI Klebsiella oxytoca 62997 5254773 ApCer
A077 820125 GRI UTI Escherichia col I 3862 5144572 ApCer
A078 820000 GRI Chest Serratia marcescens 2677-8 5306763 ApCer
A079 820000 GRI Chest Serratia marscesens 2677-8 5306763 ApCer
A080 840109 NW UTI Klebsiella oxytoca 01535 5254773 ApCer
A081 840111 NW-GP Wound swab Klebsiella pneumonia 01562 4214773 ApCer
A083 840107 NW-10 Wound swab Proteus vulgaris 01563 0476020 ApCer
A084 840109 NW-GP UTI Escherichia col I 01606 1044552 ApCer
A085 840109 NW-UR UTI Escherichia coli 01760 1044552 ApCer
AO88 840110 NW-GP UTI Enterobacter agglome 02075 1044532 ApCer
A089 840110 NW-GP UTI Escherichia coll 02079 1044552 ApCer
A091 840110 NW-GP Wound swab Enterobacter cloacae 02217 3304573 Cer
A092 840110 NW-GP Wound swab Klebsiella ozaenae 02217 7204572 ApCer
A094 840111 NVMP UTI Enterobacter cloacae 02755 3305573 ApCer
A095 840112 NW-11 Wound swab Escherichia col i 02788 5144512 ApCer
A096 840112 NW-11 Wound swab Klebsiella pneumonia 02789 5254773 ApCer
A097 840112 DRI-5 UTI Klebsiella oxytoca 02971 5254773 ApCer
A099 840113 DRI-5 Wound swab Klebsiella oxytoca 03129 5254773 ApCer
A101 840113 NW Wound swab Enterobacter cloacae 03461 3305575 ApCer
A102 840113 NW-15 Chest CItrobacter freund11 03457 3604573 ApCer
A103 840114 NW-40 ET Tube Klebsiella oxytoca 03481 5246572 ApCer
A104 840113 NW-GP CAPO Fluid Enterobacter cloacae 03126 7305573 ApCer
A109 840116 NW-28 Wound swab Escherichia col 1 04042 5144512 ApCer
A111 840116 NW-GP Wound swab K1ebsie11 a oxytoca 04137 5244773 ApCer
A113 840118 NW-6 Wound swab Enterobacter cloacae 04459 3307573 ApCer
A114 840119 NW-GP UTI Escherichia co11 04713 5144572 ApCer
A116 840121 NW-24 Eye swab Proteus morgani1 05429 0374000 ApCer
A117 840121 NW-7 Wound swab Escherichia col I 5466 7144572 ApCer
All9 840120 NW-GP UTI CItrobacter freund11 05622 3104573 ApCer
A121 840123 NW-GP Wound swab Proteus morgan 1i 05717 0374000 ApCer
317
No Date Source Infection Organism H/No. API Resistances
A123 840125 NW-GP Wound swab Escherichia col I 06323 7144512 ApCer
A125 840127 NW-GP CAFD-Fluid Serratia marsescens 06758 5317763 ApCer
A128 840130 NW-GP UTI Escherichia col 1 07795 4144402 ApCer
A131 840203 NW-16 Wound swab Escherichia col I 08752 5144572 ApCer
A134 840206 NW CAPO Fluid Serratia marsescens 09263 5317763 ApCer
A136 840207 NW-40 Chest Escherichia col 1 09529 5144572 ApCer
A137 840206 NW-7 Wound swab Klebsiella pneunonia 09550 7215773 ApCer
A138 840206 NW-7 Wound swab Escherichia col I 09550 5146572 ApCer
A139 840206 NW-Ped Wound swab Escherichia col I 09603 5044572 ApCer
A141 840207 NW-GP Wound swab Proteus mirabi1 is 09886 0536000 ApCer
A142 840207 DRI—15 Wound swab Escherichia col 1 09923 5476533 ApCer
A143 840208 NW-GP Wound swab Proteus spp. 10045 5044532 ApCer
A182 830202 E-2 UTI Escherichia col 1 00012 5144520 ApCer
A261 841203 E-2 Wound swab Proteus vulgaris 00150 0076021 ApCer
A263 841212 R-2 UTI Proteus vulgaris 00151 0076021 ApCer
A264 841123 R-2 Wound swab Escherichia co1i 00153 5144520 ApCer
A265 841013 R-2 UTI Proteus vulgaris 00153 0076021 ApCer




No. CED CFZ CER CXM CM) CFX CTX
372 64 125 64 2.0 32.0 8.0 4.00
438 500 500 1000 32.0 125.0 64.0 16.00
CItrobaeter freund11
No. CED CFZ CER CXM CMD CFX CTX
19 16 8 64 2.0 2.0 64.0 0.25
131 16 125 500 4.0 16.0 64.0 0.25
259 2000 1000 500 64.0 125.0 250.0 16.00
465 2000 1000 500 64.0 64.0 64.0 1.00
530 250 64 250 2.0 2.0 4.0 0.25
A102 16 2 32 2.0 0.5 32.0 0.25
A119 2000 2000 500 125.0 250.0 250.0 16.00
Enterobac+er aerogenes
No. CED CFZ CER CXM CM) CFX CTX
43 8 4 16 2.0 4.0 4.0 0.25
364 2000 500 500 64.0 125.0 250.0 4.00
Errterobacter agglomerans
No. CED CFZ CER CXM CM) CFX CTX
A068 16 2 4 2.0 1.0 8.0 0.25
Enterobac+er cloacae
No. CED CFZ CER CXM CM) CFX CTX
94 125 1000 1000 4.0 2.0 125.0 0.25
101 64 64 250 4.0 2.0 1000.0 0.25
103 64 125 250 4.0 2.0 500.0 0.25
107 16 8 250 4.0 1.0 500.0 0.25
110 16 4 125 4.0 2.0 250.0 0.25
122 16 16 125 4.0 1.0 250.0 0.25
126 2000 2000 500 250.0 500.0 125.0 16.00
352 1000 2000 1000 8.0 8.0 250.0 0.25
361 2000 16 125 8.0 8.0 500.0 0.50
363 2000 2000 1000 8.0 8.0 250.0 0.25
470 2000 2000 1000 500.0 500.0 250.0 4.00
519 16 4 125 8.0 2.0 250.0 0.25
542 125 8 16 2.0 8.0 8.0 0.25
543 500 2000 500 8.0 4.0 125.0 0.25
559 2000 2000 1000 32.0 64.0 125.0 1.00
A015 2000 2000 2000 500.0 1000.0 250.0 32.00
A055 2000 2000 2000 250.0 125.0 64.0 2.00
A058 2000 2000 2000 1000.0 1000.0 1000.0 64.00
A059 16 4 64 2.0 1.0 250.0 0.25
A091 8 2 16 1.0 0.5 64.0 0.25
A394 500 2000 1000 8.0 8.0 250.0 0.25
A101 64 16 250 4.0 2.0 500.0 0.25
A104 32 32 500 8.0 2.0 125.0 0.25










































































































































































































































































No. CED CFZ CER Q04 CM3 CFX CTX CAZ CTN CTR AM5 CPS PIP AZT Other resistances
102 2000 2000 1000 1000.0 1000.0 250.0 250.00 125.00 125.0 250.00 2000.0 500.0 500.0 64.00 QnSmTpSuKhOnTchNHg
Enterobacter spp
kb. CED CFZ CER OW OO CFX CTX CAZ CTN CTR AfP CPS PIP AZT Other resistances
288 250 500 250 8.0 4.0 1000.0 0.25 0.50 500.0 0.25 250.0 250.0 4.0 0.25 Co
Escherichia col I






































































































































































































































































































































































































































































































































































































































































































































































































































































































427 16 8 32 8.0 16.0 8.0 0.25 0.25 0.5 0.25 2000.0 500.0 125.0 0.25 SmTpSuGrHg
432 16 1000 32 8.0 32.0 125.0 2.00 1.00 1.0 0.25 2000.0 250.0 250.0 0.25 NaSmTpSuKnOnTcNfHg
435 16 4 8 16.0 2.0 4.0 0.25 0.25 0.5 0.25 8.0 125.0 4.0 0.25 Hg
439 16 8 64 16.0 16.0 32.0 0.25 0.50 0.5 0.25 2000.0 500.0 125.0 0.25 NaSmTpSuONfHg
441 16 8 32 16.0 16.0 16.0 0.25 1.00 0.5 0.25 2000.0 125.0 125.0 0.25 ChUg
451 8 4 8 8.0 4.0 4.0 0.25 0.25 0.5 0.25 1000.0 125.0 125.0 0.25 SmSuHg
456 8 4 16 8.0 4.0 4.0 0.25 0.50 0.5 0.25 1000.0 125.0 125.0 0.25 Hg
458 8 4 16 2.0 8.0 4.0 0.25 0.25 0.5 0.25 1000.0 125.0 64.0 0.25 SmSuHg
461 8 4 16 4.0 4.0 4.0 0.25 0.25 0.5 0.25 1000.0 125.0 125.0 0.25 SmSuTcHg
463 1000 32 64 2.0 16.0 64.0 2.00 8.00 8.0 1.00 250.0 64.0 16.0 4.00 SmSuQnTcHg
466 16 8 16 4.0 8.0 4.0 0.25 0.25 0.5 0.25 2000.0 125.0 250.0 0.25 Hg
475 16 8 64 4.0 16.0 4.0 0.25 0.25 0.5 0.25 2000.0 125.0 125.0 0.25 SfrtHg
479 8 4 16 4.0 8.0 4.0 0.25 0.50 0.5 0.25 2000.0 125.0 250.0 0.25 Hg
480 8 8 16 4.0 8.0 4.0 0.25 0.50 0.5 0.25 2000.0 125.0 250.0 0.25 Hg
494 16 8 32 2.0 8.0 8.0 0.25 0.25 0.5 0.25 2000.0 250.0 125.0 0.25
525 64 8 125 2.0 8.0 4.0 0.25 0.25 0.5 0.25 2000.0 250.0 125.0 0.25 SmCoOTcHg
531 16 4 16 2.0 8.0 4.0 0.25 0.25 0.5 0.25 2000.0 250.0 125.0 0.25 SmTpSuGnTcHg
546 16 8 64 2.0 8.0 4.0 0.25 0.25 0.5 0.25 2000.0 125.0 250.0 0.25 SmTpSu
548 8 4 16 2.0 4.0 4.0 0.25 0.25 0.5 0.25 2000.0 125.0 125.0 0.25 TcHg
555 64 8 16 4.0 4.0 8.0 0.25 0.25 0.5 0.25 1000.0 125.0 125.0 0.25 SmSuCoCmTcHg
560 16 8 32 4.0 8.0 4.0 0.25 0.50 0.5 0.25 2000.0 250.0 250.0 0.25 CoOnTcHg
*357 1000 32 125 64.0 16.0 64.0 4.00 8.00 8.0 2.00 500.0 125.0 32.0 2.00 SmSu
A061 1000 32 64 64.0 16.0 64.0 2.00 8.00 8.0 1.00 500.0 64.0 32.0 8.00
*362 250 16 32 32.0 8.0 32.0 1.00 4.00 4.0 0.50 125.0 125.0 16.0 2.00 SmSuKnOnTcHg
*364 1000 32 64 64.0 8.0 64.0 2.00 8.00 8.0 1.00 250.0 64.0 16.0 4.00 SmTpSuTc
*368 250 16 32 32.0 8.0 32.0 1.00 4.00 4.0 0.50 125.0 125.0 8.0 1.00 SmSuKnOnTc
*369 500 16 32 32.0 8.0 32.0 1.00 4.00 4.0 0.50 125.0 64.0 8.0 2.00 TcSmSuKjrOrHg
*371 64 4 8 4.0 2.0 8.0 0.25 0.50 0.5 0.25 500.0 125.0 32.0 0.25 Hg
*372 64 8 32 2.0 8.0 16.0 0.25 0.25 0.5 0.25 500.0 125.0 32.0 0.25 TcNaSirNfHg
*374 32 4 64 4.0 4.0 4.0 0.25 2.00 1.0 0.25 1000.0 250.0 125.0 0.25 SmTpSuCoQiiTc
*577 16 8 8 2.0 4.0 32.0 0.25 0.25 2.0 0.25 1000.0 64.0 2.0 0.25 NaNfHg
*364 500 16 64 32.0 8.0 32.0 2.00 8.00 4.0 1.00 500.0 125.0 32.0 4.00 TcSmTpSuKnOn
*385 16 32 125 2.0 64.0 4.0 0.25 1.00 0.5 0.25 2000.0 500.0 500.0 0.25 TcSmTpSu
*389 16 2 4 4.0 1.0 8.0 0.25 0.50 0.5 0.25 8.0 32.0 4.0 0.25 QrHg
*395 250 2 4 32.0 1.0 32.0 8.00 0.50 1.0 16.00 32.0 32.0 16.0 0.25 QnTcHg
A109 8 2 4 0.5 0.5 4.0 0.25 0.25 0.5 0.25 4.0 64.0 2.0 0.25
A114 1000 32 64 64.0 16.0 64.0 2.00 8.00 8.0 1.00 1000.0 250.0 125.0 4.00 SmTpSuTc
AT 17 8 2 8 4.0 2.0 4.0 0.25 0.50 0.5 0.25 500.0 125.0 32.0 0.25 SmSu
A123 8 4 16 4.0 8.0 4.0 0.25 0.50 0.5 0.25 2000.0 125.0 250.0 0.25 SmSuTc
A128 1000 32 64 32.0 16.0 64.0 2.00 8.00 8.0 1.00 250.0 64.0 16.0 4.00 SmSuTc
A131 1000 1000 500 64.0 16.0 64.0 2.00 8.00 8.0 1.00 500.0 125.0 32.0 4.00 RfCoHg
A136 16 8 32 8.0 16.0 8.0 0.25 0.50 0.5 0.25 2000.0 250.0 250.0 0.25 SmQiHg
A138 125 8 16 2.0 4.0 16.0 0.50 2.00 2.0 0.25 125.0 64.0 8.0 1.00 SmSuKmQnTc
A139 8 4 16 8.0 8.0 8.0 0.25 0.50 0.5 0.25 2000.0 250.0 125.0 0.25 SmSuOrtHg
A142 500 250 500 64.0 32.0 4.0 0.25 0.25 0.5 0.25 250.0 125.0 2.0 0.25 SmTpSuCoTcHg
A182 16 4 8 1.0 0.5 1.0 0.25 0.15 0.2 0.25 4.0 32.0 2.0 0.15 Tc
Haemophilus influenzae
No. CED CFZ CER CXM CM) CFX CTX CAZ CTN CTR CPS PIP AZT Other resistances
52 16 32 32 0.5 1.0 8.0 0.01 0.12 2.0 0.01 16.0 32.0 4.0 0.06
74 16 16 16 0.5 1.0 4.0 0.01 0.25 1.0 0.01 8.0 32.0 4.0 0.06 CoQnTpTcNfSxNaKmSm
118 125 32 64 4.0 4.0 4.0 0.06 0.50 8.0 0.01 8.0 125.0 0.0 0.50
156 16 1 16 0.5 0.5 2.0 0.01 0.12 1.0 0.01 2.0 32.0 0.0 0.06 NfSx
243 64 32 32 1.0 2.0 4.0 0.01 0.12 2.0 0.01 4.0 64.0 0.5 0.06 Nf
564 16 32 16 4.0 0.5 8.0 0.01 0.12 1.0 0.01 16.0 8.0 0.2 0.06 Nf
572 8 1 16 0.5 0.5 4.0 0.01 0.12 1.0 0.01 125.0 8.0 32.0 0.06 Nf
584 250 16 32 2.0 4.0 8.0 0.01 0.25 2.0 0.01 500.0 32.0 16.0 0.06 NfSx
585 250 16 32 0.5 1.0 4.0 0.01 0.06 1.0 0.01 250.0 32.0 64.0 0.06 Sx
588 64 8 16 1.0 2.0 4.0 0.01 0.25 2.0 0.01 16.0 64.0 0.2 0.06 Nf
621 16 1 16 1.0 0.5 4.0 0.01 0.12 1.0 0.01 16.0 64.0 0.0 0.06 NfSx
639 8 125 32 0.5 1.0 2.0 0.01 0.06 1.0 0.01 500.0 32.0 32.0 0.06 NfSxtta
684 64 32 32 2.0 1.0 8.0 0.01 0.06 2.0 0.01 4.0 32.0 0.0 0.06 Nt
714 16 32 125 4.0 4.0 32.0 0.01 0.12 2.0 0.01 64.0 32.0 64.0 0.06 TcNf
733 16 16 32 0.5 1.0 4.0 0.01 0.12 2.0 0.01 125.0 32.0 2.0 0.06 NfSx
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Hafnia alval
No. CED CFZ CER CXM CMD CFX CTX CAZ CTN CTR AW CPS PIP AZT Other resistances
99 8 8
Klebsiella axytoca
32 2.0 1.0 4.0 0.25 1.00 0.5 0.25 4.0 8.0 4.0 0.25 CoHg
No. CED CFZ CER CXM CMD CFX CTX CAZ CTN CTR AM3 CPS PIP AZT Other resistances
23 8 125 64 32.0 16.0 2.0 0.25 0.25 0.5 1.00 2000.0 125.0 500.0 4.00 Hg
64 125 500 250 125.0 250.0 4.0 1.00 0.50 0.5 4.00 2000.0 500.0 500.0 8.00 GmSmTpSuKmHg
339 8 8 8 2.0 8.0 2.0 0.25 0.25 0.5 0.25 64.0 64.0 8.0 0.25 Hg
474 500 250 500 32.0 4.0 16.0 0.25 1.00 0.5 0.25 250.0 250.0 32.0 0.25 RtCcHg
500 125 500 250 250.0 500.0 8.0 1.00 0.50 0.5 8.00 2000.0 500.0 500.0 64.00 GftiSmTpSuKnHg
A073 64 500 250 64.0 125.0 2.0 0.50 1.00 0.5 4.00 2000.0 500.0 500.0 8.00 RtHg
A076 64 500 250 64.0 125.0 2.0 0.50 0.50 0.5 4.00 2000.0 250.0 500.0 8.00 Hg
A080 125 500 250 125.0 250.0 4.0 1.00 0.50 0.5 8.00 2000.0 500.0 500.0 64.00 GmSmTpSuKirHg
A097 125 500 250 125.0 250.0 8.0 1.00 0.50 0.5 8.00 2000.0 500.0 500.0 32.00 QnSraTpSuKra
A099 125 500 250 125.0 250.0 8.0 1.00 1.00 0.5 8.00 2000.0 500.0 500.0 64.00 QnSmTpSuKm
A103 1000 2000 500 64.0 64.0 32.0 0.25 0.50 1.0 0.25 2000.0 250.0 250.0 0.25 RfSmCoCmTcHg
A111 125 1000 250 500.0 500.0 4.0 1.00 1.00 0.5 8.00 2000.0 500.0 500.0 32.00
Klebsiella ozaenae
to. CED CFZ CER CXM CMD CFX CTX CAZ CTN CTR AM3 CFS PIP AZT Other resistances
230 2000 2000 2000 500.0 1000.0 1000.0 16.00 2.00 500.0 4.00 2000.0 32.0 32.0 4.00 NaSmTpKmQrtHg
365 16 500 250 64.0 125.0 125.0 4.00 8.00 32.0 8.00 500.0 64.0 32.0 4.00 SnKmHg
A092 64 16 64 2.0 0.5 64.0 0.25 0.50 0.5 0.25 16.0 32.0 2.0 0.25 NfHg
Klebsiella pneunoniae
to. CED CFZ CER CXM CMD CFX CTX CAZ CTN CTR AM3 CFS PIP AZT Other resistances
12 8 2 4 4.0 2.0 8.0 0.25 0.50 0.5 0.25 64.0 64.0 8.0 0.25 RfNaTpSuQtNfHg
15 8 16 64 2.0 8.0 4.0 0.25 0.50 0.5 0.25 1000.0 500.0 125.0 0.25 Hg
175 2000 2000 500 500.0 1000.0 125.0 16.00 4.00 32.0 4.00 2000.0 250.0 500.0 4.00 NaOnSmTpSuKnOnTcHc
241 16 32 64 4.0 64.0 2.0 1.00 1.00 0.5 1.00 2000.0 500.0 250.0 0.25 GnSmTpSuKmQnTcHg
303 8 16 64 4.0 16.0 8.0 0.25 1.00 0.5 0.25 2000.0 500.0 500.0 0.25 OnSmTpSuKnOnTcHg
A081 8 4 4 1.0 0.5 2.0 0.25 0.25 0.5 0.50 64.0 125.0 4.0 0.25 Hg
A096 8 2 4 2.0 1.0 4.0 0.25 0.25 0.5 0.25 64.0 125.0 8.0 0.25 Hg
A137 8 2 4 1.0 0.5 2.0 0.25 0.25 0.5 0.25 16.0 64.0 8.0 0.25 RtHg
Proteus mlrabllis
to. CED CFZ CER CXM CMD CFX CTX CAZ CTN CTR AW CFS PIP AZT Other resistances
50 64 64 250 4.0 2.0 500.0 0.25 0.50 4.0 0.25 64.0 125.0 4.0 0.25 CoCmTcHg
138 1000 500 500 64.0 125.0 64.0 16.00 8.00 125.0 16.00 64.0 64.0 32.0 32.00 SmTpSuCoOiTcMxNfHg
140 500 500 500 32.0 125.0 64.0 16.00 8.00 125.0 16.00 1000.0 250.0 125.0 16.00 GhiSmSuKmQnTcttaNtHg
196 2000 16 125 125.0 8.0 8.0 2.00 0.25 0.5 1.00 1000.0 125.0 125.0 0.25 TpSuKmCoTcHg
221 16 8 16 2.0 2.0 4.0 0.25 0.25 0.5 0.25 250.0 64.0 8.0 0.25 SmTpSuCoTcHg
261 32 64 32 4.0 2.0 4.0 0.25 0.25 0.5 0.25 8.0 125.0 1.0 0.25 SmCoTcHg
296 16 4 16 2.0 1.0 2.0 0.25 0.25 0.5 0.25 250.0 64.0 8.0 0.25 CoTcHg
342 16 8 8 2.0 4.0 4.0 0.25 0.25 0.5 0.25 2.0 64.0 1.0 0.25 CroTc
344 16 4 8 2.0 1.0 4.0 0.25 0.25 0.5 0.25 2.0 64.0 1.0 0.25 CoTcHg
395 16 8 8 2.0 2.0 4.0 0.25 0.25 0.5 0.25 4.0 64.0 2.0 0.25 CoOnTcHg
492 32 4 16 8.0 8.0 4.0 0.25 0.50 0.5 0.25 4.0 64.0 1.0 0.25 CoOnTcHg
A141 64 8 16 8.0 4.0 8.0 0.25 0.25 0.5 0.25 8.0 125.0 2.0 0.25 CoQnTcHg
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No. CED CFZ CER CXM oo CFX CTX CAZ CTN CTR 44P CFS PIP AZT Other resistances
253 8 4 64 4.0 1.0 125.0 0.25 0.25 0.5 0.25 4.0 64.0 4.0 0.25 Hg
345 250 2000 250 32.0 16.0 16.0 0.25 0.25 0.5 0.25 64.0 125.0 4.0 0.25 RfCoHg
394 16 4 32 4.0 1.0 125.0 0.25 0.25 2.0 0.25 64.0 125.0 4.0 0.25 SraSuTc
A060 500 2000 500 64.0 32.0 32.0 0.50 1.00 1.0 0.25 125.0 125.0 4.0 0.25 CoQnTcRt
AO66 1000 2000 1000 64.0 64.0 32.0 0.50 1.00 1.0 0.50 64.0 125.0 4.0 0.25 QnTcRfHg
4067 1000 2000 500 64.0 64.0 32.0 0.50 1.00 1.0 0.25 125.0 125.0 8.0 0.25 CoOnTcRf
4078 125 500 125 16.0 16.0 8.0 0.25 0.25 0.5 0.25 16.0 125.0 2.0 0.25 RfCcCmTcHg
4079 2000 2000 2000 1000.0 1000.0 64.0 4.00 2.00 16.0 16.00 500.0 250.0 125.0 2.00 OrRtSfiKmCoQnTcM<
A125 1000 2000 1000 64.0 64.0 32.0 0.25 1.00 1.0 0.25 1000.0 125.0 8.0 0.25 RfCoQnTc
A134 1000 2000 1000 64.0 64.0 32.0 0.25 0.50 1.0 0.25 1000.0 125.0 8.0 0.25 RfCoOnTc
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3. B-lactama.se Profiles.
No. Organism B-lactamase Chrcmos- Sp Act/
anal pi mg protein
1 Escherichia col 1 TEM-1 0.00 0.02144
6 Escherichia col I TEM-1 7.50 0.03907
8 Escherichia col I TEM-1 7.50 0.02147
12 Klebsiella pneumonia 7.00 0.00020
13 Escherichia col 1 TEM-1 7.50 0.00846
15 Klebsiella pneunonia 7.80 0.01688
19 Ci+robac+er freundll 8.45 0.00036
21 Escherichia col I TEM-1 0.00 0.01625
23 Klebsiel la cocytoca 7.40 0.00778
28 Escherichia col 1 TEM-1 7.60 0.03036
36 Proteus vulgaris 0.00 0.00048*
43 Enterobacter aerogen 7.41 0.03120
44 Pseudomonas S&A 7.6 0.00114
49 Pseudomonas S&A 8.21 0.00201
50 Proteus mirabllis 8.3 0.00036
52 Haemophilus Influenz TEM-1 0.00 0.00477
54 Escherichia col I 7.50 0.00048
55 Pseudomonas S&A 7.2 0.00012
60 Escherichia col 1 TEM-1 8.60 0.00160
64 Klebsiella axytoca K1 2.27907
67 Pseudomonas S&A 7.2 0.00112
72 Escherichia col 1 TEM-1 8.60 0.00374
73 Escherichia col 1 0XA-3 8.60 0.09023
74 Haemophilus Influenz TEM-1 7.50 0.02101
85 Escherichia col 1 TEM-1 8.60 0.00034
93 Pseudarenas S&A 8.30 0.00050 *
94 Enterobacter cloacae Enzyme A 8.50 0.00094
99 Hafnla alvel 0XA-1 8.25 0.01690
100 Proteus morgan 11 TEM-1 7.30 0.02115
101 Enterobacter cloacae P99 0.00034
102 Enterobacter sakazak TEM-1 P99 0.56237
103 Enterobacter cloacae Enzyme A 8.60 0.07054
104 Escherichia col 1 TEM-1 7.73 0.00012
107 Enterobacter cloacae 0XA-2 8.2 0.00168
108 Pseudarenas S&A 7.25 0.00033
110 Enterobacter cloacae 7.92 0.00097
115 Pseudomonas S&A 7.60 0.00011
118 Haemophilus Influenz None 0.00 0.00000
122 Enterobacter cloacae Enzyme A 8.20 0.00163
126 Enterobacter cloacae TEM-1 8.20 0.04946
131 CItrobacter freund11 TEM-1 8.20 0.04651
132 Escherichia col 1 8.50 0.00030
134 Escherichia col 1 TEM-1 7.60 0.00397
135 Escherichia col 1 TEM-1 9.00 0.00032
138 Proteus mirabilis 9.00 0.00161
140 Proteus mirabi1 Is TEM-1 9.00 0.00030
141 Pseudcmonas TEM-1 8.20 0.00428
144 Escherichia coll TEM-1 8.60 0.00594
150 Escherichia coll TEM-1 7.49 0.01627
151 Escherichia col I TEM-1 0.00 0.00337
"156 Haemophilus Influenz None 0.00 0.00000
163 Pseudomonas TEM-1 8.00 0.36345
167 Escherichia col 1 TEM-1 8.30 0.00018
175 Klebsiella pneunonia TEM-1 ,S-1 7.60 0.07843
179 Pseudomonas S&A 8.32 0.00039
180 Pseudomonas S&A 7.80 0.00142
188 Pseudomonas S&A 7.80 0.00031
189 Escherichia col I TEM-1 8.70 0.05375
193 Escherichia col 1 TEM-1 9.00 0.02022
196 Proteus mirabilis TEM-2 0.00 0.00016
198 Escherichia col I TEM-1 7.40 0.01204
199 Escherichia col 1 TEM-1 7.40 0.07002
201 Escherichia col 1 TEM-1 8.70 0.00226
216 Escherichia col 1 TEM-1 8.70 0.00132
219 Escherichia col I TEM-1 7.40 0.02040
220 Escherichia col 1 TEM-1 7.60 0.08199
221 Proteus mirabilis TEM-1 0.00 0.00023
230 Klebsiella ozaenae TEM-1,S-1 7.60 0.00464
235 Escherichia col 1 TEM-1 7.40 0.00819
241 Klebsiella pneumonia PSE-4 7.20 0.01611
243 Haemophilus Influenz None 0.00 0.00000
315
»*
No. Organism B-lactamase Chrcmos- Sp Act/
anal pi mg protein
253 Serratla 8.00 0.00054
259 Citrobacter freundll 8.60 0.24680
261 Proteus mlrabi1 is TEM-1 0.00 0.00059
264 Escherichia coll TEM-1 8.60 0.01963
288 Enterobacter spp 8.20 0.01744
294 Escherichia coll 7.40 0.00029
296 Proteus mlrabi1 is TEM-1 0.00 0.00152
297 Escherichia coli TEM-1 7.40 0.00573
301 Escherichia col I 8.59 0.09582
303 Klebsiella pneuncnia TEM-1 8.50 0.04207
307 Pseudomonas TEM-1 8.20 0.00321
308 Escherichia coli TEM-1 8.50 0.00524
326 Escherichia coll TEM-1 8.59 0.02826
330 Escherichia coli TEM-1 8.24 0.00157
334 Escherichia coll TEM-1 8.59 0.00221
337 Escherichia coll 8.50 0.00093
339 Klebsiella axytoca TEM-1 0.00 0.00987
340 Pseudomonas S&A 8.33 0.00027
342 Proteus mirabilis None 0.00 0.00026 x
344 Proteus mlrabills None 0.00 0.00017 X
345 Serratia 8.40 0.00211
347 Pseudomonas S&A 8.00 0.00094
348 Escherichia col 1 TEM-1 7.80 0.01138
350 Escherichia coli TEM-2 7.80 0.00466
352 Enterobacter cloacae 8.70 0.00039
353 Pseudarenas S&A 8.22 0.00126
357 Escherichia coll TEM-1 8.70 0.00300
358 Escherichia coll 8.75 0.00454
360 Pseudoncnas S&A 8.80 0.00970 x
361 Enterobacter cloacae 8.20 0.00460
363 Enterobacter cloacae 8.63 0.00066
364 Enterobacter aerogen 8.22 0.11127
365 Klebsiella ozaenae 8.63 0.00070
367 Escherichia coli TEM-1 8.75 0.00247
369 Pseudomonas S&A 8.50 0.11030 X
372 Acinetobacter calco. 9.00 0.00503
373 Escherichia coli TEM-1 8.30 0.01126
374 Escherichia coll TEM-1 9.33 0.20840
378 Escherichia coli TEM-1 8.60 0.00212
380 Escherichia coll TEM-1 8.80 0.04724
391 Escherichia coli TEM-1 9.4 0.10365
394 Serratia 8.60 0.00272
395 Proteus mirabi1 Is 8.75 0.00123
398 Escherichia coll TEM-1 8.80 0.01642
401 Escherichia coll 8.90 0.01178
402 Escherichia coli TEM-1 9.50 0.02121
404 Escherichia coll TEM-1 8.68 0.00626
407 Escherichia coll TEM-1 8.80 0.01584
408 Escherichia coli 8.85 0.00082
410 Escherichia coli TEM-1 9.33 0.02736
411 Pseudomonas 0.00 0.00159 x
413 Escherichia col I TEM-1 8.75 0.00432
416 Escherichia coli 8.60 0.02481
419 Escherichia coli TEM-1 8.40 0.01006
420 Pseudomonas S&A 8.20 0.00022
421 Pseudomonas S&A 8.30 0.00118
423 Escherichia coli TEM-1 9.33 0.07140
427 Escherichia coli TEM-1 8.46 0.02666
430 Pseudomonas S&A 8.20 0.00031
432 Escherichia coll TEM-1 8.60 0.07360
434 Proteus morganiI 7.80 0.00075
435 Escherichia coli 8.60 0.00053
437 Pseudomonas S&A 7.90 0.00073
438 Ac Inetobacter calco. TEM-1 9.00 0.06442
439 Escherichia coll TEM-1 8.60 0.00790
441 Escherichia coli TEM-1 7.50 0.03101
446 Prorteus morgan 1 i 7.70 0.00094
450 Pseudcmonas S&A 7.60 0.00045
451 Escherichia col 1 TEM-1 7.40 0.00122
456 Escherichia coll TEM-1 8.40 0.00197
458 Escherichia coll TEM-1 8.40 0.01043
326
No. Organ I an B-lactamase Chromos- Sp Act/
omal pi mg protein
461 Escherichia coll TEM-1 8.60 0.02018
463 Escherichia coll 8.90 0.01562
465 CItrobacter freundll 8.80 0.03849
466 Escherichia coll TB1-1 7.60 0.02527
470 Enterobacter cloacae P99 0.24806
474 Klebslella axytoca 7.40 0.00154
475 Escherichia coll TEM-1 8.62 0.00705
479 Escherichia coll TEM-1 7.49 0.01422
480 Escherichia col 1 TEM-1 8.60 0.03245
490 Proteus morgan II 7.60 0.00025
492 Proteus mirabilis None 0.00 0.00899 *
494 Escherichia coll TEM-1 8.50 0.00734
500 Klebslella axytoca K1 0.05554
510 Pseudarenas SAA 8.30 0.00036
514 Proteus morgan!! 7.60 0.00035
519 Enterobacter cloacae TEM-1 8.00 0.00083
525 Escherichia coll TEM-1 9.50 0.01305
530 CItrobacter freundll 5.00 0.00029
531 Escherichia col 1 TEM-1 9.00 0.00417
535 Pseudarenas SAA 8.20 0.01370
542 Enterobacter cloacae TEM-1 9.00 0.01063
543 Enterobacter cloacae 8.37 0.00074
546 Escherichia coll TEM-1 9.40 0.03186
548 Escherichia coll TEM-1 8.40 0.00694
555 Escherichia coll TEM-1 8.40 0.00422
559 Enterobacter cloacae 8.40 0.00097
560 Escherichia coll TEM-1 9.40 0.00869
564 Haemophilus Influenz None 0.00 0.00000
572 Haemophilus Influenz TEM-1 0.00 0.00540
584 Haemophilus Influenz TEM-1 0.00 0.01206
585 Haemophilus Influenz TEM-1 0.00 0.00739
588 Haemophilus Influenz TEM-1 0.00 0.00116
621 Haemophilus influenz None 0.00 0.00000
639 Haemoph11 us Inf1uenz TEM-1 0.00 0.01418
684 Haemophilus influenz None 0.00 0.00000
714 Haemophilus Influenz TEM-1 0.00 0.01255
733 Haemoph11 us Inf1uenz TEM-1 0.00 0.00802
A006 Proteus vulgaris 7.00 0.00223 *
A015 Enterobacter cloacae TEM-1 P99 0.13517
A055 Enterobacter cloacae TEM-2 8.60 0.02224
A056 Proteus morgan 11 6.50 0.00055
A057 Escherichia coll 7.00 0.15821
A058 Enterobacter cloacae TEM-2 8.60 0.02215
AO59 Enterobacter cloacae TEM-2 9.37 0.00182
A060 Serratla 8.90 0.00173
A061 Escherichia coll 8.60 0.01730
NXt2 Escherichia coll 8.60 0.01161
fiC63 Providencla stuartll 6.65 0.00058
A064 Escherichia coll 9.00 0.01488
A066 Serratia 9.10 0.00276
A067 Serratla 9.10 0.00183
A068 Escherichia coll 9.00 0.00692
A069 Escherichia coil 9.00 0.00400
A070 Proteus vulgaris 9.10 0.00117
A071 Escherichia coll TEM-1 8.70 0.00213
A072 Escherichia coll TEM-1 8.80 0.00184
A073 Klebslella axytoca K1 0.07128
A074 Escherichia coll TEM-1 0.00 0.00398
A075 Proteus rrcrgan 11 TEM-1 7.70 0.00516
A076 Klebslella axytoca TEM-2 K1 0.20682
A077 Escherichia coll TEM-2 8.89 0.00145
A078 Serratla 8.80 0.02597
AD79 Serratia 9.00 0.00127
A080 Klebslella axytoca K1 0.00644
A081 Klebsiella pneumonia 7.60 0.00087
A083 Proteus vulgaris 8.20 0.00025 *
A084 Escherichia coll TEM-1 7.80 0.05858
A085 Escherichia coll TEM-1 7.80 0.05224
A088 Enterobacter agglcme 7.70 0.00118
A089 Escherichia coll 7.80 0.00045
A091 Enterobacter cloacae 7.54 0.00145
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No. Organism B-lactamase Chrcmos- Sp Act/
omal pi mg protein
A092 Klebsiella ozaenae 9.20 0.00104
A094 Enterobacter cloacae 7.54 0.00081
A095 Escherichia coli 7.80 0.00228
A096 Klebsiella pneumonia 7.68 0.00219
/097 Klebsiella oxy+oca K1 0.01184
A099 Klebsiella oxytoca K1 0.00401
A101 Enterobacter cloacae Enzyma A 7.00 0.00422
A102 Cltrobacter freundll 9.00 0.00182
A103 Klebsiella oxytoca TEM-1 9.3 0.00161
A104 Enterobacter cloacae P99 0.00182
A109 Escherichia coll 7.00 0.00046
A111 Klebsiella oxytoca K14 1.12132
A113 Enterobacter cloacae PSE-4 9.30 0.00733
A114 Escherichia coll TEM-1 7.60 0.01462
AI16 Proteus morgan II 6.80 0.00024
A117 Escherichia coll TEM-1 7.49 0.00265
A119 Cltrobacter treundll TEM-1 8.50 0.45102
A121 Proteus morgan II 7.20 0.00064
A123 Escherichia coli TEM-1 7.6 0.02506
A125 Serratla 9.30 0.02080
A128 Escherichia coll 8.50 0.00260
A131 Escherichia coll 8.50 0.05226
A134 Serratla OXA-3 9.30 0.07561
A136 Escherichia coll TEM-1 7.50 0.03261
A137 Klebsiella pneumonia 7.20 0.00030
A138 Escherichia coll 9.00 0.01861
A139 Escherichia coll TEM-1 9.00 0.00838
A141 Proteus mirabllls TEM-2 9.00 0.00032
A142 Escherichia coll 9.00 0.00008
A143 Proteus spp. 9.00 0.00012
A182 Escherichia coll 9.00 0.00010
A261 Proteus vulgaris 8.90 0.00020
A263 Proteus vulgaris 8.90 0.00010
A264 Proteus vulgaris 6.90 0.00010
A265 Proteus vulgaris 6.90 0.00010
A266 Proteus vulgaris 8.90 0.00010
L li1t u r e
IFF.
'quired induction before R-i actamase was visualised on
S&h, P.aeruqinosa Sabbath and Abraham (1964) B-1 act amass.
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0.02100 16.0 2000.0 Tc
0.01170 16.0 2000.0 SuSmTcSp
0.03460 <8.0 2000.0 SpSmTpSu
0.03400 8.0 2000.0 Tc
0.02030 <8.0 2000.0 SuSm
0.01550 -<8.0 2000.0 SuSm
0.01490 <8.0 2000.0
0.04650 16.0 2000.0
0.01659 <8.0 2000.0 SuSm
0.00640 <9.0 2000.0
0.00190 -8.0 2000.0
0.02810 16.0 2000.0 Km
0.01300 '<8.0 2000.0 TcSmSu
0.01910 <8.0 2000.0 SuSm
0.01290 <8.0 1000.0
0.01445 <8.0 2000.0 Tc
o.otzoo <9.0 zooo.0
0.01050 <8.0 2000.0
0.07430 16.0 2000.0 Tc
0.05430 16.0 2000.0 SuGnQriTpTc
0.03980 <8.0 2000.0 SuSm
0.00064 16.0 2000.0
0.00061 32.0 2000.0




0.01230 <8.0 2000.0 SuSm
0.00620 <8.0 2000.0
0.18990 16.0 2000.0 KmTcSmSu
0.06076 <8.0 1000.0 SuSm
0.00512 <8.0 2000.0
0.02980 16.0 2000.0 SuSmTc
0.02270 <8.0 2000.0 Tc
0.01790 <8.0 2000.0 SuSm










0.00170 16.0 2000.0 KmSm
0.01141 <8.0 2000.0








0.01385 <8.0 2000.0 SuSmQnTcSp
0.00167 <8.0 2000.0
0.01420 <8.0 2000.0 SuSm
0.01650 <8.0 2000.0 SuSm
0.28530 16.0 2000.0 Tc
0.06240 16.0 2000.0 Sm
0.00880 32.0 2000.0 SuSm
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Plasmid Penicillin Resistance in Vibrio cholerae: Identification
New ^-Lactamase SAR-1
ALISON J. REID and SEBASTIAN G. B. AMYES*
Department ofBacteriology, The Medical School, University ofEdinburgh, Teviot Place, Edinburgh EH8 9AG,
United Kingdom
Received 3 January 1986/Accepted 5 May 1986
Two strains of Vibrio cholerae biotype El Tor, isolated in Tanzania, possessed a single IncC resistance
plasmid of 113 kilobases. Both plasmids encoded the production of a novel fj-lactamase, SAR-1, which was
33,700 daltons in size and was able to hydrolyze carbenicillin as well as penicillin G. The SAR-1 ^-lactamase
was quite distinct from all other plasmid (3-lactamases by virtue of its unusually low isoelectric point and a
combination of its size, substrate profile, and inhibition properties. This enzyme is only the second P-lactamase
identified in V. cholerae species and the first to be reported in V. cholerae strains isolated in Southern Africa.
The most common resistance mechanism to (3-lactam
antibiotics is the production of a p-lactamase enzyme which
hydrolyzes the drug and renders it inactive. Most of the
plasmid-encoded resistance is manifested by one p-
lactamase, TEM-1 (7, 18). and there are more than 20 other
plasmid-determined p-lactamases which account for the
remainder (12). Transferable resistance to p-lactam antibiot¬
ics has been slow to develop in Vibrio cholerae: and the first
stable resistance plasmid (R plasmid) carrying ampicillin
resistance, which could successfully be transferred to and
maintained in Escherichia coli, was obtained from a strain of
V. cholerae isolated in Algeria (16). Transferable ampicillin
resistance emerged in Asia in the late 1970s (5, 20), and only
the TEM-1 p-lactamase was identified (5). This p-lactamase
also accounted for the plasmid-mediated ampicillin resis¬
tance found in a recent V. cholerae strain isolated from a
patient who had recently returned to France from a stay in
Algeria (4).
Ampicillin resistance has been described in V. cholerae
strains isolated in Tanzania (13), and some was shown to be
mediated by R plasmids (21). Here we report the first
identification of new plasmid-determined p-lactamases from
V'. cholerae w hich were isolated from patients in Tanzania.
MATERIALS AND METHODS
During a recent outbreak of V. cholerae in Tanzania, four
ampicillin-resistant strains were identified in the Department
of Microbiology, Muhimbili Medical Centre, Dar es Salaam.
Two of these strains (DT137 and DT139) possessed a single
plasmid encoding the production of the TEM-1 p-lactamase.
The other two strains (DT136 and DT138) each possessed a
single IncC plasmid of 113 kilobases (pUK657 and pUK658,
respectively) (22). Strains DT136 and DT138 were kindly
typed at the Division of Enteric Pathogens at the Central
Public Health Laboratory, Colindale, England, and shown to
be biotype El Tor serotype 01 inaba. The rifampin-resistant
E. coli K-12 strain J62-2 his pro trp (3) was used as the
recipient in all conjugation experiments.
Antibacterial drug susceptibility and plasmid transfer. Sus¬
ceptibility tests and MICs of antibacterial drugs were deter¬
mined on solid medium as described previously (1). Piasmid
transfer was performed by the method of Amyes and Gould
(1).
P-Lactamase preparation and purification. p-Lactamase
extracts for isoelectric focusing were prepared from bacteria
grown on nutrient agar slopes (6). For further purification of
the enzyme, 500-ml overnight broth cultures (brain heart
infusion broth CM 225; Oxoid Ltd., Basingstoke, England)
were concentrated and disrupted by ultrasonication. Ammo¬
nium sulfate was added to the cleared lysates to 35%
saturation. After centrifugation and removal of the pellet,
additional ammonium sulfate was added to 70% saturation.
Following centrifugation, the pellet was suspended in a
minimum volume of 50 mM sodium phosphate buffer (pH
7.0) and applied to a Sephadex G-75 gel filtration column (2
cm2 by 90 cm) and eluted with the same buffer at 9 ml/h.
Molecular size determinations were performed by gel filtra¬
tion on a Sephadex G-75 column with internal standards (2).
p-Lactamase activity and isoelectric focusing. Enzyme ac¬
tivity was determined by spectrophotometric assays (14),
and the effect of the p-lactamase inhibitors was examined by
same assay (14). All inhibitor studies were performed with
nitrocefin (100 pM) as the substrate. The inhibitor was added
at the start of the assay at various concentrations ranging
from 10 to 100 nM. The effect of the inhibitors was expressed
as the concentration required for 50% inhibition (ID50) of
enzyme activity. The Km and Vmax values were obtained by
measuring the rate of hydrolysis at limiting substrate con¬
centrations and by plotting the reciprocal of the substrate
concentration against the reciprocal of the rate by the
Lineweaver-Burk method. The Vmax values were normalized
with respect to penicillin G, i.e., relative Lmax = t(VmaX per
pi of enzyme) of substrate/ (Vmax per pi of enzyme) of
penicillin G] x 100. The efficiency of hydrolysis of the
enzyme was obtained with the same parameter as Pollock
physiological efficiency, as outlined by Sykes et al. (19), in
which efficiency of hydrolysis = Vmax per pi of enzyme/L„,.
The relative efficiency of hydrolysis was also normalized
with respect to penicillin G, i.e., relative efficiency = (effi¬
ciency of hydrolysis of substrate/efficiency of hydrolysis of
penicillin G) x 100.
The isoelectric points of the B-iactamases were deter¬
mined by the method ofMatthew et ai. (8). The pH gradient
was formed by mixing equal amounts of pH 4 - 6 (catalog no.
1809-116) and pH 3.5 - 10 (catalog no. 1809-101) ampholines
(LKB, Bromma, Sweden).Corresponding author.
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TABLE 1. Resistance profile of V. cholerae strains and
their transconjugants
MIC (mg/liter)
Strain Ampi- Carbeni¬ Cephalo¬ Cephr;
cillin cillin ridine dine
V. cholerae DT136(pUK657) >1,000 >1.000 16 16
E. coli J62-2(pUK657) >1.000 >1.000 <8 <8
E. coli J62-2(pUK657a) <8 <8 <8 <8
V. cholerae DT138(pUK658) >1.000 >1.000 16 16
E. coli J62-2(pUK658) >1.000 >1.000 <8 <8
E. coli J62-2 <8 <8 <8 <8
RESULTS
V. cholerac DT136 and DT138 and their respective E. coli
transconjugants were all highly resistant to both ampicillin
and carbenicillin (Table 1). Although the original V. cholerae
showed a slight degree of resistance to cephradine and
cephaloridine. this was not evident in the transconjugant
strains (Table 1). Both V. cholerae strains were resistant to
sulfamethoxazole, streptomycin, chloramphenicol, and tri¬
methoprim, as well as ampicillin: and all these resistance
markers transferred at the same high frequency during a 5-h
conjugation experiment to E. coli (frequency. 10~3 transcon¬
jugants per donor strain). In each case, a single plasmid was
found in the recipient, and when selection was made on
ampicillin, all the other resistance markers were present in
the transconjugant strain. However, ampicillin resistance
was not always found in transconjugants selected on trimeth-
oprim-containing plates (pUK657a, Table 1), which infers
that this ampicillin resistance gene may be unstable.
Isoelectric focusing. The sonicated extracts from both V.
cholerae DT136 and DT138 and their E. coli transconjugants
revealed a single ^-lactamase band with a pi corresponding
to 4.9 (Fig. 1). This novel (3-lactamase was designated
SAR-1. The extracts from these V. cholerae strains showed
no additional (3-lactamase bands, and thus, V. cholerae
seemed to possess no demonstrable chromosomal (3-lac-
tamase. Therefore, strain DT136 was used for further puri-
ABCDE FGBIJK
FIG. 1. Isoelectric focusing pattern of the SAR-1 (s-iactamase.
3-Lactamase standards: TEM-1 (pi = 5.4), lane A; PSE-4 (pi = 5.3!.
lane B: HMS-1 (pi = 5.2). lane C: PSE-4. lane H: TEM-1, lane I:
TEM-2 (pi = 5.6), lane J: PSE-1 (pi = 5.7). lane K. SAR-1
3-lactamase samples: V. cholerac DT136(pUK657). lane D: £. coli
J62-2(pUK657), lane E: V. cholerae DT138(pUK658), iane F: E. coli
J62-2(pUK658), iane G
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ficatior; of the SAR-1 enzyme, as it lacked any contaminating |
B-lactaxnave.
Purification and molecular weight determination. The
SAR-1 B-lactamase was not completely precipitated by 509J j
saturation with ammonium sulfate. Indeed, considerably less 1
than half of the enzyme was found in this fraction. However,
a fraction betw een 35 and 7097 saturation precipitated 6497 of
the available enzyme. Separation of this enzyme by gel
filtration resulted in a purification of over 80-fold. When the f
enzyme was run through a calibrated column, the enzymatic
peak corresponded to a molecular weight of 33,700.
Substrate profile and Michaelis-Menten kinetics. The
SAR-1 B-lactamase is primarily a penicillin-hydrolyzing en¬
zyme and had a reduced effect against the cephalosporins.
This enzyme hydrolvzes ampicillin and carbenicillin at ap¬
proximately the same rate as penicillin G (Table 2) and had
a similar profile to that of the PSE-1 3-lactamase (10). The
relative efficiencies of hydrolysis of ampicillin and carbeni¬
cillin by the SAR-1 enzyme were less than that of penicillin
G. but they were not noticeably different from each other.
However, this similarity resulted, in the case of carbenicil¬
lin. from a high AT value and. in the case of ampicillin, from
a lowered V'max (Table 2). In addition, the relative efficiency
of hydrolysis of SAR-1 with cephaloridine was low, which
resulted from its low relative Vmax. The enzyme was sensi¬
tive to inhibition by cloxacillin (IDS0 = 7 pM) and clavulanic
acid (ID><, = 5 n.Mi but was resistant to inhibition by pCMB
(ID50 > 100 pM). Therefore, although SAR-1 showed a
similar substrate profile to those of PSE-1 and CARB-4, its
inhibition profile was more like that of TEM-1 and, to a
lesser extent. HMS-1 (10. 15).
DISCUSSION
The SAR-1 (3-iaeta.mase is a novel plasmid-mediated en¬
zyme with a unique combination of biochemical properties.
It has a low pi value in the same region as that reported
recently for CARB-4 (pi = 4.3) (15). In our hands, both
enzymes appeared to have similar, but discrete, pi bands.
Before the identification of SAR-1 and CARB-4, the 3-
lactamase which had the lowest pi was HMS-1, with a
published value of 5.2 (9). The relative rates of hydrolysis of
penicillin G and carbenicillin confirmed that this enzyme is
not HMS-1. Its relativ e efficiency of hydrolysis suggests that
SAR-1 is primarily a penicillinase, and therefore, it differs
from the broad-spectrum TEM enzymes and HMS-1. In
substrate profile this enzyme resembles the so-called Pseu-
domonas-specific enzymes (PSE) (7, 11; A. J. Reid. 1. N.
Simpson. P. B. Harper, and S. G. B. Amyes, Abstr. 14th
Int. Congr. Chemother.. Kyoto, Japan, 1985). Indeed, one
enzyme in this group (PSE-4) is the only plasmid-directed
enzyme that has a molecular size similar to that of SAR-1.
TABLE 2. A'„, values and relative efficiency of hydrolysis of






Penicillin G 42 100 100
Ampicillin 68 63 39.3
Carbenicilltr, 190 122 07 e
Cephaloridine 9? 21 9.6
Cefamanaoie 95 53 TO
Nitrocefin 83 89 91
" There was do detectabk hydrolysis of methiciliin. cloxacillin. or cefotax¬
ime by the spectrophotometry method.
" Expressed as a percentage of the value for penicillin G
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However, the inhibition profile of SAR-1 is quite unlike that
of the PSE or CARB-4 p-lactamases (10. 15).
These two V. cholerae plasmids are unique not only
because they are the first such plasmids to harbor the gene
for the trimethoprim-resistant type 1 dihydrofolate reductase
(22) but also because we have now shown that they carry a
gene encoding a new |3-lactamase. The only (3-lactamase
previously described in V. cholerae strains has been TEM-1
(4, 5), for no chromosomal enzyme has been demonstrated in
this species. The identification of SAR-1 in the V. cholerae
population is analogous to the discovery of ROB-1 in Hae¬
mophilus influenzae, in that TEM-1 had been the only
plasmid-borne (^-lactamase previously found in the species
(17). It is not clear why a new penicillin-hydrolyzing enzyme
should emerge in V. cholerae strains in Tanzania, especially
when the TEM-1 enzyme has been found in other strains
from the same outbreak and that treatment for infection by
this organism has relied heavily on antibacterial drugs other
than p-lactam antibiotics.
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0900 pin Unusual Resistance Plasmid Conferring Delayed Resistance to Trimethoprim in Complex Media
H-K. YOUNG and S.G.B. AMYES (Department of Bacteriology, University of Edinburgh)
The unusual plasmid pUK1123, isolated in India, confers moderate resistance to trimethoprim
(minimum inhibitory concentration =160 mg/1) on solid minimal medium but no resistance on
Isosensitest agar. However, growth experiments in Isosensitest broth show that pUK1123 enables
the host organism to remain viable in 10 mg/1 trimethoprim and eventually provides a mechanism
which allows the inhibitory effect of trimethoprim to be overcome.
0915 Resistance to Gentamicin and Related Aminoglycosides in Salmonella typhimurium Endemic in
Cattle in Britain
E.J. THRELFALL, J.L. FERGUSON, L.R. WARD and B. ROWE (Central Public Health Laboratory,
London)
Plasmid profile visualization and plasmid characterization have been used to study gentamicin-
resistant strains of Salmonella typhimurium phage type 204c isolated from outbreaks in cattle and
humans in Britain. The study has demonstrated the existence of three lines of gentamicin-resistant
strains, two of which have been found only in cattle and one in cattle and humans.
0930 Expression ofPSE-4 (3-Lactamase in Different Hosts
A.J. REID, I.N. SIMPSON*, P.B. HARPER* and S.G.B. AMYES (Department of Bacteriology,
University of Edinburgh and *Glaxo Group Research, Greenford)
The genetic determinant for PSE-4 ^-lactamase has now been found in Enterobacteria. The dal 1
gene is carried on a self-transferable plasmid (pUK700) in Klebsiella pneumoniae 241. This plasmid
carrier is lost on transfer to Pseudomonas aeruginosa PA08. Expression of the dal 1 gene product
in P. aeruginosa is not only higher than in the original clinical isolate but displays modified bio¬
chemical properties.
0945 An Automated in vitro Model to Investigate the Activity ofMultiple Antibiotic Combinations
D.H. STOKES, B. SLOCOMBE, R. SUTHERLAND and A.R. WHITE (Beecham Pharmaceuticals
Research Division, Betchworth, Surrey)
The bactericidal effects produced by combinations of antibiotics with differing pharmacokinetic
characteristics were measured in a computer-controlled kinetic model in which concentrations
simulating those obtained in man were reproduced in vitro. Synergistic activity was obtained with
simulated doses of a formulation of ticarcillin and clavulanic acid combined with gentamicin or
tobramycin against ticarcillin/aminoglycoside-resistant bacteria.
1000 Inactivation of Ticarcillin by Bacterial (3-Lactamase in Mixed Culture and Protection by Clavulanic
Acid in an in vitro Kinetic Model
C.E. COOPER, R. SUTHERLAND and A.R. WHITE (Beecham Pharmaceuticals Research Division,
Betchworth, Surrey)
The bactericidal activity of simulated doses of ticarcillin and ticarcillin/clavulanic acid was deter¬
mined in a kinetic model against a mixed culture of Pseudomonas aeruginosa (ticarcillin-sensitive)
and a (3-lactamase-positive Staphylococcus aureus. Ticarcillin was inactivated by S. aureus (3-
lactamase and was ineffective against P. aeruginosa', in the presence of clavulanic acid the ^-lactamase
was inhibited and ticarcillin/clavulanic acid was effective against both organisms.
1015 The Effect of Iron-Stress on Streptomycin Uptake in Escherichia coli
G. MORRIS and S.M. HAMMOND (Department of Microbiology, University of Leeds)
Iron-stressed E. coli showed decreased uptake of dihydrostreptomycin compared with iron-replete
cells. Induced phenotypic changes in the outer membrane of iron-stressed cells are not responsible
for the differential uptake as verified by uptake studies using spheroplasts. The role of induced
changes in the cytoplasmic membrane and to the transmembrane electrochemical gradient will be
discussed with regard to streptomycin uptake.
1030 Inhibition of Sterol Metabolism by N-Imidazole Antifungals
R.O. NICHOLAS and D. KERRIDGE (Department of Biochemistry, University of Cambridge)
The (V-imidazole antifungals partially inhibit the growth of Candida albicans over a wide concen¬
tration range. This has lead to problems in determining the conventional parameter, minimal
inhibitory concentration. The most sensitive target site of these compounds is apparently cyto¬
chrome P450-dependent sterol demethylase, and there is a direct correlation between the inhibition
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Discovery of PSE-4 (3-Lactamase in Non-Pseudomonas Species
A.J. Reid*, I.N. Simpson**, P.B. Harper**, and S.G. B. Amyes*
* Department of Bacteriology, Edinburgh University, Edinburgh, Scotland, UK
** Chemotherapy Department, Glaxo Group Research Ltd., Greenford, UK
This communication reports the first discovery of the Pseudomonas
specific 8~lactamase PSE-4 in two clinical enterobacteria and the
transfer of genetic determinants for this enzyme (Dal 1 and Dal 2)
to other genera by conjugation. In Klebsiella pneumoniae 241, the
Dal 1 gene is carried on a self transmissable plasmid (pUK700) which
is lost upon transfer of Dal 1 into Pseudomonas aeruginosa. In
Enterobacter cloacae 1113, no plasmid carrier for the Dal 2 gene was
found. Dal 1 and Dal 2 express much higher levels of PSE-4
production in P.aeruginosa than in the Enterobacteriaceae. The
isoelectric points, substrate profile and level of expression of the
PSE-4 gene products from Dal 1 and Dal 2 appear to be host modified.
The pseudomonas specific enzymes (PSE) were originally believed to be
mediated by genetic determinants confined to Pseudomonas aeruginosa (1). Recently
the production of PSE-1 and PSE-2 has been reported in the Enterobacteriaceae
(2,3). No similar migration has been observed with PSE-4 even though it is the
most common plasmid-mediated (3-lactamase produced by P■aeruginosa (4).
RESULTS
Two PSE-4 producing isolates, Klebsiella pneumoniae 241 and Enterobacter
cloacae 1113 were discovered during a B-lactamase survey of 228 cephaloridine
resistant strains isolated from hospital patients in Scotland, U.K. Initial
isoelectric focusing (IEF) studies (pH3.5-10.0) indicated that both strains
produced the PSE-4 'Dalgleish' g-lactamase. Closer examination (expanded
pH4.0-6.0 range) revealed minor differences between the newly isolated 'PSE-4'
enzymes and the original Dalgleish enzyme.
Genetic Location of the PSE-4 Determinants
The genetic determinant for PSE-4 B_lactamase in K.pneumoniae 241 (Dal 1)
was freely transferable to Escherichia coli J62-2 and P.aeruginosa FA08.
K.pneumoniae 241 contained two large plasmids - 132 kilobases (kb) and ca 290kb.
As only the 132kb plasmid transferred to E.coli J62-2 it must carry the gene for
PSE-4 production. This plasmid was not seen in the PA08 transconjugants, which
may reflect difficulty found in extracting large intact plasmids from Pseudomonas.
The PSE-4 determinant however, did not transfer from the PA08 host to either
P.aeruginosa or E. coli suggesting that the gene had integrated into the bacterial
chromosome. This hypothesis is supported by loss of some pUK700 genetic markers
which accompanies its transfer into PA08.
The genetic determinant for PSE-4 production in Ent.cloacae 1113 (Dal 2)
was not self-transferable, but following mobilisation with R751 was transferred
to E.coli J62-2 and P.aeruginosa PA08. No plasmids could be distinguished in
Ent.cloacae 1113.
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Expression of PSE-4 g-lactamase
Following transfer to P.aeruginosa both Dal 1 (pUK 700) and Dal 2 mediated
PSE-4 enzymes which were biochemically identical to the Dalgleish PSE-4 enzyme.
Levels of g-lactamase activity were increased over 100 fold in the recipient
(Table 1) which was accompanied by a greater than 20 fold rise in minimum
inhibitory concentration (MIC) of carbenicillin. Following transfer to E.coli
J62-2, Dal 1 and Dal 2 continued to mediate low levels of enzymes biochemically
similar to those produced by the clinical strains; in both cases the carbenicillin
MIC was increased by greater than 1000 fold. In these enterobacterial hosts,





Activity Relative Rates: of Hydrolysis CARB
MIC*
Pi
CARB AMP PENG1 CER
P.aeruginosa Dalgeish 485.0 100 98 102 4 >1000 5.20
K.pneumoniae 241 Dal 1 5.3 100 766+ 936 304 >1000 5.25
E . coli J62-2 Dal 1 5.0 100 128 680 404 >1000 5.25
P.aeruginosa Dal 1 652.0 100 90 107 7 >1000 5.20
Ent.cloacae 1113 Dal 2 6.1 100 161 433 120 32 5.30
E.coli J62-2(R751) Dal 2 6.0 100 102 667 350 >1000 5.30
P.aeruginosa
PA08(R751)Dal 2 697.0 100 75 99 11 >1000 5.20
E.coli J62-2 <1.0 - - - - 1 -
P.aeruginosa PA08 <1.0 — — — — 64 —
CARB-carbenicillin ; AMP-ampicillin ; PENG-penicillin G; CER-cephaloridine.
* nMoles of carbenicillin hydrolysed/minute/mg protein. mg/L
+ Relative rate inflated by presence of chromosomal enzyme.
CONCLUSIONS
This is the first identification of the PSE-4 (3-lactamase in clinical
enterobacteria. In K.pneumoniae 241, the Dal 1 gene is carried on a self
transferable plasmid (pUK700). In Ent.cloacae 1113, no plasmid carrier for the
Dal 2 gene could be found. The PSE-4 determinants both transfer to other genera
and transfer of Dal 1 into P■aeruginosa is followed by loss of the pUK700 plasmid.
Dal 1 and Dal 2 express much higher levels of PSE-4 production in P.aeruginosa
than in the Enterobacteriaceae. Differences observed in pi and specific activity
of PSE-4 in the different strains suggests that the biochemical and biophysical
properties of the PSE-4 enzyme are host dependent.
The PSE-4 g-lactamase is no longer confined to P.aeruginosa and is emerging
as a resistance mechanism in the Enterobacteriaceae.
AJR is supported by a SERC CASE studentship.
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